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Preface
This thesis work is devoted to the study of the structural dynamics of acetyl-
cholinesterase and its interaction with organophosphate nerve agents and reacti-
vators. Intoxication by organophsophates is a major health problem, with about 2
million cases per year in the world, expecially in developing countries, and the cur-
rently available countermeasures are not efficient in protecting against these potent
inhibitors.
In the design of a new family of reactivators, we applied the principles of ratio-
nal drug design. The aim was to capitalize the knowledge of the enzyme and its
structure to improve the currently available reactivators. In particular, we looked
for neutral molecules, capable of passing the blood-brain barrier and restore AChE
activity in the central nervous system, differently from what is currently on the
market. This process led us to develop a first lead molecule, named KM297, and to
improve it through rational optimization to its derivative, JDS207, that conserves
the reactivation properties of the lead molecule, but improves its binding mode in
the active site of the enzyme.
This process has revealed the need for improved knowledge of the dynamics of
the enzyme, in particular in the computational modeling of binding modes. For this
reason, after using traditional docking methods and x-ray crystallography, a large
effort has been devoted to the improvement of the computational characterization
of sidechain rotamers, that have been included in the rational design process.
The manuscript is composed of two main parts. In the first one, chapters 1, 2
and 3, I introduce the main thematics of the work and the experimental method-
ologies. Chapter 1 is devoted to acetylcholinesterase structure and function, with a
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particular focus on its interaction with organophosphates and reactivators. Chapter
2 introduces the thematic of rational drug design, and the implications of protein
structural dynamics in the process. Chapter 3 introduces the main methods used
in the thesis: x-ray crystallography, molecular dynamics simulations and molecular
docking.
The second part, chapters 4 and 5, is focused on the experimental results. Chap-
ter 4 presents all the steps required to go from the design of KM297 to its opti-
mization. Various crystal structures, along with simulation studies, are involved in
the process leading to the design and evaluation of the derivative JDS207. Chapter
5 describes the efforts to develop a new method to include sidechain flexibility in
molecular docking. I will present the main results that range from a qualitative
observation of the sidechain movements in molecular dynamics simulations to the
development of a computer program that generates receptors for docking reproduc-
ing the simulation results.
Finally, the appendix section includes the docking code and the manuscripts
published during the thesis.
Chapter 1
Acetylcholinesterase
1.1 Biological function
Acetylcholinesterase (AChE) is an essential enzyme notably present in the nervous
system of superior eukariotes. In the central nervous system, it is found at cholinergic
synapses, where its role is to hydrolyze the neurotransmitter acetylcholine (ACh)
(Dale, 1914) restoring in this way the excitability of the synapse and allowing the
transmission of the subsequent nervous signal (Silman and Sussman, 2005). Due to
its function, its turnover must be faster than a nerve signal transmission process,
which takes a few milliseconds. For this reason, AChE is one of nature’s fastest
enzymes. Depending on the species considered, AChE can hydrolyze between 1000
and 20000 substrate molecules per second. Its catalytic efficiency has been estimated
to be in the order of 108M−1s−1, in the range of the theoretical limit of diffusion
controlled reaction (between 108M−1s−1 and 109M−1s−1) (Bar-Even et al., 2011).
Therefore it has been suggested that the trafic of substrates and products to and
from the active site should be the limiting factor for the efficiency of the enzyme
(Quinn, 1987).
At neuromuscular junctions (figure 1.1), AChE is present in anchored tetrameric
form. The C-terminal helices of the four monomers interact by binding to a Proline-
Rich Attaching Domain (PRAD) (Massoulié et al., 2005). PRAD peptides are found
in two main proteins. One is a collagenic protein ColQ (Cousin et al., 1996) and the
other is the neuron membranes PRiMA (Proline-Rich Membrane Anchor) (Perrier
et al., 2002).
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Figure 1.1: Schematic representation of a neuromuscular junction. AChE is found in
the synaptic cleft and restores transmission by hydrolyzing neurotransmitter acetyl-
choline (ACh).
Another type of cholinesterase, the butyrylcholinesterase (BChE), is widely present
in eukariotes. It has been characterized by structural and functional studies (Masson
et al., 2009), but its role is still not completely understood.
1.2 Structure and dynamics of AChE
1.2.1 Three dimensional structure of AChE
The first crystals of an AChE were obtained from the electric fish Torpedo californica
(TcAChE) in the late 1980s (Sussman et al., 1988) and the crystal structure was
solved soon after (Sussman et al., 1991). The choice of this organism was motivated
by the fact that its electric organ is formed by a modified muscle containing multiple
neuromuscular junctions, in which a dimeric anchored form of AChE is expressed in
large quantities.
Each of the monomers is folded in an α/β hydrolase fold (Ollis et al., 1992), and
contains 15 α-helices and 11 β-strands, connected by flexible loops. The contact
region between two monomers, made by four helices, is called the 4-helix bundle.
This first AChE structure (Sussman et al., 1991) revealed that the catalytic triad of
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the enzyme, formed by residues Ser200, His440, Glu327 1, is located at the heart of
the enzyme (figure 1.2). The substrate can access the active site through a 20 Å deep
gorge that is less then 5 Å wide at its narrowest point, the so-called bottleneck. A
cluster of aromatic residues, Trp279, Tyr70 and Tyr124, forms a peripheral binding
site at the entrance of the gorge.
Crystallographic structures of complexes between AChE and substrate analogues
revealed how the catalytic machinery is optimized to fit the transition state of the
substrate (ACh). In particular, the structure of TcAChE in complex with a non-
hydrolysable substrate analogue 4-oxo-N,N,N-trimethylpentanaminium (OTMA, fig-
ure 1.3) (Colletier et al., 2006a; Bourne et al., 2006) provides us with the conforma-
tion of the active site in the intermediate state of the hydrolysis reaction.
We can observe (figure 1.2 B) how the OTMA molecule bound to the catalytic
serine interacts with the active site environment, to adopt an optimal position for
hydrolysis. The negative charge of the carbonyl oxygen of the acyl group is stabilized
by a series of hydrogen bonds within the oxy-anion hole, formed by the main chain
NH groups of Gly118, Gly119 and Ala201. The methyl group of the OTMA carbonyl
interacts with the so-called acyl-binding pocket, formed by residues Phe288, Phe290
and Trp233. The limited size of this pocket has an essential role in the substrate
selectivity (Harel et al., 1992).
At the other end of the substrate analog, the most important interaction occurs
between OTMA nitrogen quaternary ammonium and the choline-binding pocket. It
is formed by residues Phe330, Glu199 and Trp84. While the role of the glutamic
acid is uncertain due to controversy regarding its protonation state (Wahlgren et al.,
2011), the main interaction is between the positively charged trimethylammonium
of OTMA and the π electrons of Trp84 and Phe330 (Harel et al., 1993). This
interaction has been calculated to account for about 50% of the interaction energy
between the enzyme and its substrate (Harel et al., 1996). The substrate-binding
mode, as observed from the structure, is optimal to position the ester function in
front of the catalytic serine so is to permit hydrolysis.
The peripheral anionic site (PAS) at the entrance of the gorge (figure 1.2 A)
is responsible for capturing incoming substrate molecules and for orienting them
correctly. Its most important residue was found to be the highly conserved Trp279.
1Residue numbering is from Torpedo californica enzyme in the whole manuscript, unless stated
otherwise.
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Figure 1.2: The 3-dimensional structure of TcAChE (Sussman et al., 1991). The
catalytic triad is shown in red sticks at the core of the enzyme. In this orientation,
the entrance of the active site gorge, whose surface is shown in green, is at the top of
the figure. The red squares show the details of the interaction between the substrate
analogue OTMA (carbons shown in cyan) and the residues in the gorge of TcAChE
(Colletier et al., 2006a). A) The peripheral aromatic site residues, shown in green
at the top of the figure, with a substrate molecule bound in front of Trp279. B)
The catalytic site. Bound to the triad, shown in red, we observe a second substrate
analogue molecule, covalently bound to Ser200. The choline moiety is in cation-π
interaction with Trp84 (blue). The oxygen of OTMA is stabilized in the oxyanion
hole (orange), and the methyl of the acetyl group is nested in the acyl-binding pocket
(purple).
Crystal structures of AChE in complex with high concentrations of substrate, where
a molecule of ACh or acetylthiocholine was found in front of Trp279, confirmed the
role of this residue in binding substrate (Bourne et al., 2006; Colletier et al., 2006a).
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(a) Acetycholine (b) OTMA
Figure 1.3: Neurotransmitter acetylcholine (a) and its non-hydrolyzable analogue
(b) 4-oxo-N,N,N-trimethylpentanaminium (OTMA)
1.2.2 Structural dynamics involved in substrate traffic and
ligand binding
While the access of substrates through the gorge and the general catalytic mech-
anism are well understood, there is still a debate concerning the exit of reaction
products from the active site. Either they can exit through the gorge, or through an
alternative exit, the so called backdoor (Gilson et al., 1994). Crystallographic stud-
ies have shown the presence of the reaction product thiocholine, a choline analogue,
just behind Trp84 (Bartolucci et al., 1999; Colletier et al., 2006b). Mutagenesis
aimed at enlarging the putative backdoor has shown that products can exit through
this route when the gorge entrance is blocked, though this enlargement did not in-
crease the catalytic efficiency of the enzyme when the entrance was free (Kronman
et al., 1994; Faerman et al., 1996; Nachon et al., 2008). It was observed by crystallo-
graphic studies for TcAChE and for BfAChE in complex with an antibody (Sanson
et al., 2011; Bourne et al., 2014), that sidechains of Trp84 and of the related residue
Tyr442 can move to open an exit channel at the bottom of the gorge. The reac-
tion product thiocholine has been observed in MD simulations to leave the active
site through this door (Xu et al., 2010). Molecular dynamics simulation studies
have shown the possibilities for alternative routes to the active site to open (Gilson
et al., 1994; Tai et al., 2001). Even though there is no other direct experimental
evidence of these side doors openings has been observed, the binding of bulky lig-
ands like galanthamine derivatives (Greenblatt et al., 2004), is possible only if these
rearrangements, in particular of the Trp279-Ser291 loop, can occur.
Conformational changes in the gorge environment have been shown to occur
upon ligand binding both by MD simulations and crystallographic structures. The
8 CHAPTER 1. ACETYLCHOLINESTERASE
access of the inhibitor huperzine-A to the active site can only occur through a
rearrangement of the bottleneck region, where the distance between residues Phe330
and Tyr121 goes from 2 to 6 Å during the passage of Hup-A (Xu et al., 2003).
An interesting case is the one concerning the bifunctional inhibitor NF595. This
molecule has been shown to bind to an alternative conformation of the peripheral
site (Colletier et al., 2006b). Molecular dynamics simulations have helped to con-
clude that the molecule binds to a pre existing conformation, rather than through
a mechanism of induced fit (Xu et al., 2008).
Covalent binding of the potent organophosphate cresyl saligenin phosphate in-
duces a conformational change of the acyl-binding pocket (Carletti et al., 2013). In
this case, the conformation assumed by Phe2972 has not been observed in molecular
dynamics simulations of the native form of the enzyme, suggesting that an induced
fit mechanism regulates the interaction of this molecule with the enzyme.
1.2.3 Human AChE crystals
For two decades, the human enzyme was only crystallizable in complex with fasciculin-
2 (FAS-2), a three-fingered toxin that inhibits AChE by binding at the peripheral
site and blocking the access to the gorge. FAS-2 favorizes crystallization of the en-
zyme by participating in crystalline contacts (Harel et al., 1995; Bourne et al., 1995;
Kryger et al., 2000). Structures of hAChE in complex with ligands have been solved
with this method (Nachon et al., 2013). However, opportunities of application of
these crystals have been limited by the occupation of the peripheral site and result-
ing difficulties in the access to the active site. Also, FAS-2 binding was shown to
modify the dynamics of the enzyme (Bui et al., 2006; Bui and McCammon, 2006),
meaning that observation of conformational changes in these crystals would not be
conclusive. A first form of recombinant hAChE, truncated at residue 540, was solved
without fasciculin (Dvir et al., 2010), but crystals diffracted poorly (3.2 Å resolution)
and the access to the active site of one of the monomers was blocked by a symmetry
related copy. Finally, a higher resolution structure (2.0 Å) of another recombinant
form of hAChE truncated at residue 1 and 544 (Cheung et al., 2012), has allowed
soaking of ligands into hAChE, revealing differences in the binding modes of some
molecules, like the anti-Alzheimer molecule donepezil, previously solved in complex
2Mouse AChE numbering, Phe288 in TcAChE
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Figure 1.4: General structure of an organophosphate nerve agent.
with TcAChE (Kryger et al., 2000).
1.3 Organophosphates and their inhibition of AChE
AChE is the target of various potent neurotoxic compounds, including organophos-
phate (OP) compounds. This family of molecules includes both pesticides and chem-
ical warfare nerve agents. While the use of nerve agents is forbidden by international
conventions, organophosphate pesticides are still largely used in the agriculture of
most developing countries. Every year about 3 million intoxications by OP pesticides
are recorded worldwide, including around 280000 fatalities.
The general structure of an OP nerve agent is shown in figure 1.4. A phosphorous
atom forms the core of the molecule, and is bound to four substituents: an oxygen
(or a sulfur) atom, a leaving group (X), an alkoxyle (R1) and another group (R2).
Pesticides were the first molecules of this family to be developed, around the mid
19th century. In the 1930s, Germans synthesized the G-agent series (G stands for
‘german‘). The first was tabun, or GA (1936) followed by sarin (GB, 1937) and
soman (GD, 1944). The other main family of warfare nerve agents, the V agents (V
stands for ‘venomous‘) has been developed by the British, with the synthesis of VX,
which has been followed by a few related molecules, mainly the Russian VX, or VR
and the Chinese VX, or CVX. In general, G agents are more volatile then V agents,
but the latter are more persistent and more toxic, especially through skin contact.
These powerful chemical weapons have only been used on rare occasions. Also, in
1993 , most countries have signed the Chemical Weapons Convention, forbidding the
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Figure 1.5: The main organophosphate agents. Molecules of the G-series: tabun
(GA), sarin (GB), soman (GD), cyclosarin (GF); and lead molecule of the V-series:
VX.
usage of chemical warfare agents. However, we can cite a few cases of terrorist/war
acts using this kind of weapons in the recent years. A famous one is the 1994 Tokyo
metro attack, where sarin was released in a metro station in the capital of Japan,
killing 11 people and intoxicating around 3000. More recently, during the Syrian
civil war, a sarin attack in August 2013 in the suburbs of Damascus has caused
around 1000 deaths, according to American sources 3.
1.3.1 Inhibition mechanism
The catalytic serine of AChE is phosphylated by nucleophilic substitution. In this
mechanism, represented in figure 1.6, the oxygen atom of the catalytic serine attacks
the phosphorous of the OP, from the opposite side of the leaving group, forming a
trigonal bipyramidal transition state. Then, the bond between the phosphorus and
the leaving group breaks, leading to the formation of a tetrahedral serine adduct.
3See for exemple this article from the Washington Post: http://tinyurl.com/ksj2lc2
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Figure 1.6: The inhibition mechanism of AChE by organophosphate nerve agents.
This adduct is a close structural analogue of the transition state of catalysis (figure
1.2).
The catalytic triad is not, however designed to catalyze the hydrolysis of this
adduct. Even if spontaneous dephosphylation by nucleophilic substitution with a
water molecule is possible, it is extremely slow, with timescales spanning from hours
to days.
After inhibition, the enzyme is able to catalyze a secondary reaction, referred to
as ‘aging‘ (Fleisher and Harris, 1965), wich involves the dealkylation of the alkoxyl
group R2. The aged complex is even more stable than the ‘non-aged‘, and dephos-
phylation of the catalytic serine after this stage is virtually impossible (Masson et al.,
2010).
The most probable origin of the stability of the aged adduct, is the formation
of a salt bridge between the imidazolium of the catalytic histidine and the freshly
formed oxyanion group bound to the phosphorus atom.
1.3.2 Three dimensional structures of OP-inhibited AChE
The inhibition mechanism has already been clarified by mutagenesis studies, but its
deeper understanding has been made possible by determining crystal structures of
OPs in complex with AChE from various species (Millard et al., 1999b,a; Ekström
et al., 2006a; Carletti et al., 2008; Sanson et al., 2009). It has been observed, e.g.
that aging of tabun in TcAChE is accompanied by a conformational change of the
histidine of the catalytic triad, figure 1.7. This residue is pushed in a non-native
conformation by the presence of the ethyl group of tabun, and goes back to its
native position after aging, forming a salt bridge with the phosphate group of the
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(a) Non-aged form (b) Aged form
Figure 1.7: Crystallographic snapshots of aging of tabun-inhibited mAChE (pdb
acces code 3dl4 and 3dl7). We can observe that His447 moves from an alternative
conformation forced by the ethoxy substituent of tabun back to its native one,
forming a salt bridge with the oxyanion of the phosphoramidyl group corresponding
to aged tabun (Millard et al., 1999a; Carletti et al., 2008).
inhibited catalytic serine (Millard et al., 1999a). The lack of non-aged structures of
hAChE in complex with OPs, due to the difficulty in performing soaking experiments
with hAChE-FAS crystals, will probably be addressed now that unliganded hAChE
crystals of good quality begin to be available.
1.3.3 Treatment of OP intoxication
The current formulation for treatment of OP intoxication is composed of three types
of drugs, with the goal of addressing the symptoms of AChE inhibition, while also
liberating the enzyme from the presence of the OP: an antimuscarinic (atropine),
and anticonvulsivant (diazepam) and an oxime reactivator of phosphylated AChE.
These drugs are combined into an autoinjector for field treatment. Oximes (figure
1.8) are a class of highly nucleophilic molecules that can make a substitution, thus
breaking the bond between the oxygen of the catalytic serine and the phosphorus
of the OP (Mercey et al., 2012).
The first oxime to be synthetized, about 60 years ago, was the 2-pyridinium al-
doxime methiodide (2-PAM) (Wilson and Ginsburg, 1955). Since then, hundreds of
pyridinium aldoximes have been synthesized. HI-6 (Oldiges and Schoene, 1970) is
considered as the best oxime to date, even if tabun-inhibited AChE is almost com-
pletely resistent. The mechanism of reactivation by an oxime is thought to happen
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Figure 1.8: Structures of the most common oximes.
Figure 1.9: Reactivation mechanism of OP-inhibited AChE by a nucleophile Nu.
according to the following scheme (figure 1.9): the strong nucleophilic oximate at-
tacks the phosphorus atom from the opposite side of the serine to form a reversible
bipyramidal OP-oxime-AChE transition state. The leaving of the OP-oxime adduct
liberates the catalytic serine restoring in this way the activity of the enzyme.
The oxime reaction mechanism has been studied by in vitro assays, simulations
and X-ray crystallography. Crystal structures of AChE in complex with oximes
have shown how they can bind to the enzyme. Most bisquaternary oximes have
been found to bind at the PAS of the enzyme, through cation-π interactions. For
example, one pyridinium group of HI-6 and HLö-7 is bound at the PAS of mAChE
14 CHAPTER 1. ACETYLCHOLINESTERASE
Figure 1.10: General structure of a bifunctional reactivator. It is formed by a group
bearing an oxime function and a peripheral site ligand (PSL), connected by a flexible
linker.
(Ekström et al., 2006b) forming an aromatic stacking involving Trp286 and Tyr1244,
while the stacking of Ortho-7 and obidoxime involves Trp286 and Tyr724. The PAS
tryptophan has to rearrange for stacking to oxime, supporting the hypothesis that
the high level of flexibility of this residue (Xu et al., 2008) is necessary for the binding
of these ligands to the enzyme.
These structural data helped in clarifying the mechanism of reactivation (Ek-
ström et al., 2009) and in pointing out the drawbacks of some oximes. For example
the oxime function of HI-6 is at the closest at more than 9 Å from the phosphorous
atom, implying that the orientation of the oxime group is not optimal for the nu-
cleophilic substitution. Also, 2-PAM has been found to be stacked in front of Trp84
in aged soman-TcAChE with the oxime group forming an hydrogen bond with the
mainchain carbonyl of the catalytic serine (pdb code 2vq6) (Sanson et al., 2009). In
this conformation, reactivation is not possible, the oxime being also at more than 9
Å from the phosphorous atom of the OP.
The development of oximes has greatly taken advantage from the structure of
ternary AChE-OP-oxime complexes. Observation of the binding of bispyridinium
oximes at the peripheral site led to the concept of bifunctional reactivators (figure
1.10), for which one part of the molecule is a specific PAS binder providing affinity to
the enzyme, connected through a carbon linker to an oxime function, that provides
the reactivity of the molecule (Mercey et al., 2011).
Other strategies of protection against OP intoxications involve prophylactic treat-
ments. During the first Gulf war, the US army used pyridostigmine, a carbamate
that inhibits AChE by making a short-lived bond with the catalytic serine, thus
rendering it unable to react with OPs. However, the suspected deleterious side ef-
fects pushed towards the developments of new prophylactic stategies, enzyme-based
4mAChE numbering.
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scavengers being the most promising one. These enzymes can neutralize OPs be-
fore they can inhibit AChE at the synapses and neuromuscular junctions (Nachon
et al., 2013). We distinguish between two kinds of OP scavengers, catalytic and
stoichiometric. Stoichiometric scavengers are molecules that can trap a single OP
molecule. Carboxylesterase (Maxwell and Brecht, 2001; Jackson et al., 2013) and
butyrylcholinesterase (BChE) (Masson et al., 2009), belong to this type. Treatments
based on injections of BChE are now under development, as production costs and
purification efficiencies are improving (Brazzolotto et al., 2012).
Catalytic scavengers, like human paraoxonase (Rochu et al., 2007), phosphotri-
esterase (Griffiths and Tawfik, 2003) or self-reactivable mutants of BChE, have the
ability of hydrolizing OPs and thus neutralizing multiple OP molecules. Therefore,
a significantly lower dose would protect against the same amount of OP. Some mu-
tants of paraoxonase and phosphotriesterase are now efficient enough to offer good
protection and great efforts are devoted to develop safe formulations (Worek et al.,
2014a,b).
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Chapter 2
Drug design and protein flexibility
The process of designing new drugs is a long and tortuous road. At first there is
the need to find a good ligand for a target protein in the organism. Then, this
molecule has to be made into a drug, by improving its pharmacological properties
without loosing affinity and specificity for the target. Finally, it has to pass through
different levels of clinical tests, to assess its efficacity and characterize possible side
effects (Mandal et al., 2009). With the term ’drug design’ we denote the process of
creation of a therapeutic molecule, based on the knowledge of a specific target in
the organism, or in the modification of already known ligands. Definition of ’drug
design’ has been created to put in advance the rational procedure involved in this
process, in opposition to the traditional ’trial and error’ procedure. We should more
precisely talk about ligand design, since this process usually stops at the first step
of the development of a drug, when a good ligand for the target protein is found
and its properties are optimized. Through the manuscript we will keep using the
common expression ’drug design’.
There are two main approaches to drug design: ligand-based or receptor-based
design. In a process of ligand-based design, the focus is made on how to use known
molecules, eventually with modifications, to target receptors related to different dis-
eases. In this thesis we used a receptor-based approach, in which we take advantage
of the knowledge of the structure of a target enzyme to design ligands that specifi-
cally fit inside the active site.
In the past, knowledge of the receptor was limited to its crystallographic struc-
ture. However it is known that protein dynamics can have an impact on the mode
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of interaction with substrates and ligands. After briefly discussing the type of move-
ments involved in the dynamical behavior of proteins, we will describe some methods
to include information about dynamics in the process of designing new ligands.
2.1 Structure based drug design (SBDD)
2.1.1 Definition of structure based drug design
Structure based drug design (SBDD) describes every methodology that uses a known
3-dimensional structure of a target to develop and optimize ligands that would bind
to it. The first drug produced with this method is the anti-glaucoma molecule
Dorzolamide (Greer et al., 1994), which became available on the market in 1995.
Another famous exemple of a rationally designed drug is the tyrosine kinease in-
hibitor Imatinib, approved by the FDA in 2001 and commercialized by Novartis as
Gleevec (Zimmermann, 1996). Even if some molecules created in a drug design pro-
cess made it to the market, this method is still far from being completely efficient:
return on investment is moderate with respect to the previsions made a couple of
decades ago (Brown and Superti-Furga, 2003).
2.1.2 The search for new ligands
Once the target protein is chosen, the search for a ligand begins.
The most common techniques in the discovery of ligands are virtual screening
(Jain, 2004), hight throughput screening (Hertzberg and Pope, 2000) and rational
building (Hartenfeller and Schneider, 2011).
The first two methods consist in the screening, either in vitro or in silico, of large
molecule libraries and of their activity against the chosen target. Virtual screening
techniques use chemical databases, e.g. the ZINC database (Irwin et al., 2012),
which are large libraries of chemical compounds in a standard digital format. All
these compounds are then docked against the target, to find which of them present
the higher affinity.
High throughput screening is conceptually similar but, in this case, activity of
ligands on the target is directly evaluated in vitro, using screening plates. Techno-
logical advances have allowed to screen up to 100,000 ligands per day on a single
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target (Hann and Oprea, 2004). Due to the huge quantity of data generated by both
techniques, data processing has a key role in defining the good hits of the experi-
ments (McInnes, 2007; Jacobsson et al., 2003). Statistical methods exist to combine
in silico and in vitro and increase the accuracy of the screenings (Bajorath, 2002).
If multiple binding sites are present on the target, site-specific hits can eventually
be combined together, to improve their affinity or specificity via a synergistic effect.
This is the case for exemple of AChE and its distinct peripheral and catalytic sites.
Instead of searching for known molecules to fit the binding site of a protein
target, another approach to SBDD consists in building a new ligand de novo, based
on the conformation and the structure of the binding environment (Hartenfeller and
Schneider, 2011). This design process is aimed to adapt the properties of the ligand
to the receptor (Schneider and Fechner, 2005). This kind of design takes advantage
of the structural knowledge of target-inhibitor complexes. These structures can be
a starting point in the design of a ligand by screening for the optimal chemical
functions to bind at a given position in the protein. An example of de novo design
is the combinatory study of human cannabinoid (CB1) receptor inhibitors (Rogers-
Evans et al., 2004). In this work, a series of previously known GPCR inhibitors has
been used to generate fragments that were then combined to design inhibitors for
the CB1.
In our project, we used a mixed approach to develop a family of bifunctional
AChE reactivators. A new reactive oxime molecule has been coupled to a known
ligand for the peripheral site of the enzyme. These results will be presented in
chapter 4.
2.2 Protein structural dynamics
2.2.1 The conformational landscape of proteins
Proteins are in many cases erroneously represented as static, rigid objects. Yet, we
know that many of their functional properties cannot be explained solely by their
crystal structure, which is not a simple photography of a protein, but a temporal
and spatial ensemble average image of all the molecules forming the crystal.
Protein dynamics can be understood in terms of an energy landscape of their
conformations (Frauenfelder et al., 1991). If we consider that a protein can adopt
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Figure 2.1: Simplified representation of the conformational landscape of a protein.
The different heights of energy barriers are translated in the different timescales
at which each of these changes occur. Extracted from Henzler-Wildman and Kern
(2007).
a set of iso-energetic states, it is easier to imagine that it can evolve from one to
another in a dynamic way.
Motions can occur on different time scales (Henzler-Wildman and Kern, 2007),
each corresponding to a specific energetic level in the conformational landscape,
as represented in figure 2.1. The most rapid movements are represented by the
small energy barriers in the conformational landscape. They involve side chain
motions and typically occur on the scale from the picosecond up to the nanosecond.
The slowest movement, with timescales up to the second, correspond to all the
large conformational changes occurring upon folding, interaction with ligands and
rearrangements of subunits of large molecular assemblies.
All the possible movements have been proven to be involved in enzyme function-
ing (Henzler-Wildman et al., 2007), by for example modulating catalysis and access
of substrates to the active site.
2.2. PROTEIN STRUCTURAL DYNAMICS 21
Figure 2.2: Schematic representation of the different techniques available to charac-
terize the structural dynamcis of proteins. The timescales for all atoms MD simula-
tions is constatly increasing, up to the millisecond. Extracted from Henzler-Wildman
and Kern (2007).
2.2.2 Techniques to characterize protein structural dynamics
Different experimental and computational techniques are available to study spatial
and temporal aspects of protein motions. Their respective temporal domains are
represented in figure 2.2. With no intention of being exhaustive, we present here
the most widespread in studying the dynamics at atomic resolution.
Nuclear magnetic resonance (NMR) is a technique that takes advantage of the
resonance frequencies of certain nuclei to both characterize their motions and solve
the structure of a protein. NMR structures are characterized by the fact that data
are reproduced by an ensemble of structures, rather than a single one. This can pro-
vide insight into the dynamic processes regulating protein activity (Marion, 2013).
Kinetic crystallography is a general definition that includes multiple methods
aimed at characterizing the intermediate states of protein ’at work’ by solving their
crystallographic structure (Bourgeois and Royant, 2005; Bourgeois and Weik, 2009).
The common feature of all these methods is the need for synchronization between all
the molecules in the crystals, to get the best snapshot possible for an intermediate
of a reaction. To achieve this synchronization, we can for example recur to caged
compounds, substrate analogs that can be activated through a signal, such as a laser
pulse or an X-ray burn, to achieve a synchronized start of the enzymatic process in
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Figure 2.3: Representation of a single structure in the theory of conformation land-
scape. From Carlson and McCammon (2000).
all the molecules of the crystals (Colletier et al., 2007, 2008). Other techniques used
in kinetic crystallography include substrate diffusion in crystals, variation of data
collection temperature (Weik and Colletier, 2010), pH variation (Nar et al., 1991)
and real time Laue crystallography (Schotte et al., 2003; Bourgeois et al., 2003).
Molecular dynamics simulation is widely used to extract kinetic information on
the properties of a protein, for which the crystallographic 3D structure is known.
Timescales of all atom simulations have constantly increased up to the millisecond,
due to the always larger computational power and to the optimization of massively
parallel integration algorithms (Shaw et al., 2009). More details on MD simulations
can be found in chapter 3.
2.3 Including dynamical information in SBDD
As for enzymatic activity, structural protein dynamics is also involved in the inter-
action with ligands. The description of the conformational ensemble can provide a
sharper understanding of this problem. A single structure, such as a crystallographic
structure, represents only a single point in the entire conformational landscape of
the protein, figure 2.3, and is therefore inadequate to represent the complexity of
protein dynamics and enzymatic catalysis.
For this reason, large efforts have been devoted in the last 20 years to include
dynamic information in SBDD. The increase of available computational power, with
costs always lower, has opened a panoply of opportunities for the development of
new techniques (Carlson and McCammon, 2000; Michel, 2014).
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The most simple approach is the use of multiple structures as a framework for the
design (Totrov and Abagyan, 2008). As explained above, an ensemble of structures
can be obtained with NMR, but this approach is limited to relatively small proteins.
To overcome this limitation, MD simulations have been used to produce an ensem-
ble of structures, extracted from trajectory snapshots (see for example (Pang and
Kozikowski, 1994)). Recently, room temperature crystallographic structures have
also been successfully used to generate multiple receptors for docking and finding
new inhibitors (Fischer et al., 2014).
More sophisticated methods can be included in the general category of soft dock-
ing, which will be described in practical details in the next chapter. We can distin-
guish between traditional flexible docking and more sophisticated techniques. We
consider as a flexible docking experiment the case in which only the sidechains of
chosen residues are free to move. A different case is when the mainchain of the
protein is also given a certain degree of freedom. This is often done by using MD
simulations and extracting multiple snapshots, to find rarely occupied protein con-
formations (Lin et al., 2002).
Including flexibility in drug design has been fundamental in the design of HIV-1
reverse transcriptase inhibitors (Das et al., 2005). In particular, they were designed
to overcome the problem of drug resistance, by targeting multiple conformations
of the target. Crystallographic structures have confirmed that they can bind to at
least two different conformations of the active site (Das et al., 2004).
Another successful example is the HIV integrase inhibitor ISENTRESS, devel-
oped by Merck and approved by the FDA in 2007. This molecule has been designed
following the discovery of a possible binding trench through molecular dynamics
simulations (Schames et al., 2004), which have then been characterized as proper
ligand binding sites by molecular docking techniques.
In chapter 5 of this manuscript we will describe a new method, based on MD
simulations data, to characterize the dynamics of side chains of AChE and include
it in a drug design process.
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Chapter 3
Methods
During this work we recurred to multiple methods to characterize the dynamics of
AChE and its interaction with OP nerve agents and reactivators. In this chapter
we will briefly introduce the following methodologies: X-ray protein crystallography,
molecular docking and molecular dynamics simulations. Materials and methods for
each experiment will be described in subsequent chapters.
3.1 X-ray protein crystallography
X-ray protein crystallography is by far the most widely applied technique to solve
protein structures. The Protein Data Bank (PDB) contains today 104125 structures
1, and almost 90% are obtained by means of X-ray crystallography. The accessibility
of synchrotron radiation facilities around the world has been a great impulse to the
growth of the number of solved structure, along with more user-friendly analysis
software and the increase in computational power. The development of cryo-methods
has also allowed to collect more higher quality data at synchrotron sources.
The bottleneck of protein structure determination is the generation of well diffract-
ing crystals. Automated methods of screening with crystallization robots have made
the process easier, but protein crystallization remains a trial and error procedure.
While recent developments have allowed to solve structures with smaller crystals, it
is usually easier to collect good quality data from large crystals, typically hundreds
of microns of side.
1As of 16th of October 2014
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In the following sections we will introduce the principles of X-ray diffraction by
crystals, then address the issue of obtaining protein crystals and, finally, illustrate
the main methods to solve a protein structure from X-ray diffraction patterns.
3.1.1 Crystal symmetry
A crystal is defined as a solid which has a spatial periodicity. Spatial periodicity
means that it is formed by a regular repetition of the same element over the three
dimensional space. This defines the crystal symmetry, as a set of operations over the
3 dimensions that lead to an identical position. The minimal unit of the crystal is
called the asymmetric unit. It is usually defined by three vectors (a, b, c), describing
its dimensions, and the three angles (α, β, γ) between them. All the possible sym-
metries are classified in 7 lattice systems, and in 14 Bravais lattices. In each of the
lattices, multiple space groups, the total number of possibilities is 230 for crystals of
macro-molecules, can be defined. Each space group has a well defined and unique
symmetry.
3.1.2 Diffraction of X-rays by a crystal
X-ray photons interact with matter, more specifically, with the electron shells of
atoms. The regular arrangement of atoms into a crystal forms planes that, as mir-
rors, have the property to reflect X-rays. This reflection, due to the undulatory
nature of light, can occur only in some well defined directions, where the interfer-
ence between X-rays reflected by adjacent planes is constructive. This mechanism
is described by Bragg’s law (equation 3.1), which defines the condition to have a
constructive interference between waves reflected by different planes of a crystalline
solid. Its derivation is straightforward from a schematic representation of the diffrac-
tion event, figure 3.1.
nλ = 2d sin θ (3.1)
Here n is an integer, λ is the incident wavelength and θ the angle between the
incident wave and the crystal planes. At fixed wavelength, equation 3.1 gives us the
value of the distances between crystalline planes, d, considering that the angle can be
experimentally determined. For a macromolecular crystallography experiment, the
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Figure 3.1: Schematic representation of Bragg’s law.
wavelength is in the order of the Ångström2. As we can deduce from the expression
of Bragg’s law, incident X-rays are diffracted to discrete directions, related to the
different distances between the crystalline planes.
Structure factor
A convenient way to write the Bragg’s law in terms of scattering vectors and unit
cell parameters is the Laue equations, equation 3.2. The Laue equations state that
diffraction only occurs when the scalar product between the diffracted wave vector
S and vectors (a,b,c) of the crystal is an integer


a · S = h
b · S = k
c · S = l
(3.2)
Diffraction by a crystal can be seen as the sum of the individual contributions
of each atom of the system to the scattering of incident radiation. This means that
every scattered amplitude F (hkl) can be defined as the sum of the contributions
of all the atoms in the volume, if we assume that the scattering by each atom is
independent from that of its neighbors. Using the Laue equations, we can derive an
2The wavelength of a 12 keV photon is 1.03 Å
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expression for the diffracted amplitude.
F (hkl) =
N∑
j=1
fje
2pii(hxj+kyj+lzj) (3.3)
Assuming the crystal to be ideally infinite, we can write the sum as an integral
of the electron density over the volume of the crystal:
F (hkl) = V
∫
hkl
ρ(x, y, z)e2pii(hx+ky+lz)dxdydz (3.4)
We can recognize in equation 3.4 the Fourier transform of the electron density of
the crystal, the structure factor F. This gives us a useful relation between measured
quantities (diffracted intensities) and the electron density ρ of the atoms.
Reciprocal space
In order to solve the structure of a protein, we need to relate the (hkl) reflections
observed with the spatial coordinates of the atoms of the protein. To do this,
we have to define a reciprocal space, which can be defined as the wave space, in
opposition to the direct space, which is the space defined by vector distances between
atoms. Direct (a,b,c) and reciprocal (a*,b*,c*) space vectors are mutually related
by equations 3.5. The denominator is the scalar triple product of the three vectors,
which corresponds also to the volume of the unit cell in the direct space.
a∗ =
b× c
a · (b× c)
a =
b∗ × c∗
a∗ · (b∗ × c∗)
b∗ =
c× a
b · (c× a)
b =
c∗ × a∗
b∗ · (c∗ × a∗)
c∗ =
a× b
c · (a× b)
c =
a∗ × b∗
c∗ · (a∗ × b∗)
(3.5)
From this definition we can deduce that the reciprocal space has the same origin
then the direct space, and that if the direct lattice rotates, so does the reciprocal
lattice.
Conditions to obtain diffraction are usefully represented by the Ewald construc-
tion (figure 3.2). This geometric construction arises from combining Bragg’s law
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Figure 3.2: Representation of the Ewald construction. Every time there is an in-
tersection between the Ewald sphere of radius 1/λ and a reciprocal lattice point
contained into the resolution sphere of radius 1/d, there is a constructive condition
for diffraction. Image courtesy J.P. Colletier.
with the Laue conditions. If we build a sphere of radius 1
λ
in the reciprocal space,
we have diffraction every time a vector of the reciprocal space intersects the sphere.
To optimize the number of diffraction spots, during an exposure to X-rays the crystal
is rotated. In this way, more reflections are taken into account per image. Rotating
the crystal also solves the problem that, due to the non ideal alignement of all the
planes inside a crystal, not all the planes respect the Ewald condition at the same
time. This effect, known as mosaicity, leads to the collection of partial reflections,
that are difficult to handle. The reconstruction of the complete reciprocal space
requires the collection of a series of images taken at different degrees of rotation.
We need 360 degrees of rotation, which are reduced to 180 by the basic symmetry
of the reciprocal space. High symmetry space groups allow to collect a complete
dataset with a smaller value for the rotation angle.
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(a) Phase diagram of a protein-precipitantsolution (b) Hanging drop method
Figure 3.3: a: Phase diagram for a protein-precipitant solution. We can observe
how, during a crystallization experiment, the solution moves to the nucleation zone,
where crystals start to appear. The system goes the towards rthe metastable zone,
where crystals can grow in size. b: Schematic representation of a hanging drop
crystallization experiment.
3.1.3 Protein crystals
Crystallogenesis of proteins by the vapor diffusion method
Growing good quality protein crystals is the conditio sine qua non to obtain the
structure of a protein by means of X-ray diffraction. Crystals grow in a particular
phase of a protein solution. If we look at the phase diagram represented in figure
3.3 we can observe a small nucleation region where crystals can start to grow.
Different methods exist to move the solution conditions towards the nucleation
and the metastable region, the most used being the vapor diffusion method. In
this technique, a protein solution is mixed with a buffered solution of precipitant
to form a drop that is placed with a bigger reservoir of the same precipitant in
an hermetic environment. Equilibration of the drop and reservoir through vapor
diffusion leads to a slow concentration of precipitant and protein and eventually to
the growth of small protein crystals in the drop, i.e. the nucleation process. By
this phenomenon, the concentration of protein available in the solution decreases,
resulting in the movement towards the metastable zone. This region of the phase
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diagram is favorable forfurther crystal growth. A common setup to perform vapor
diffusion is the hanging drop method,figure 3.3 b, where a drop of protein solution
(typical volume is in the order of 1 µl) is deposed on a glass slide with the same
ammount of precipitant solution. The slide is then used to close a crystallization pit,
containing around 1 ml of the precipitant solution. The slide is sealed with grease.
This creates an isolated atmosphere where vapor diffusion can take place.
3.1.4 Crystallographic data collection at synchrotron radia-
tion sources
Once the crystals have been produced, they are exposed to an X-ray beam and
diffraction patterns are recorded that can be integrated to determine the structure
factors.
Synchrotrons
In a synchrotron, a beam of electrons is accelerated by a series of injectors and
boosters up to energies of a few GeV and then stored on a circular accumulation ring.
Electrons are kept into a pseudo-circular trajectory by a series of dipolar bending
magnets (BM). For a phenomenon known as synchrotron radiation, electrons will
lose energy by emitting X-rays in the direction of the tangent of the curve they
are turning. Energy loss is then compensated by radiofrequency cavities, that are
designed to keep the electron kinetic energy constant over a turn of the machine.
The inconveniece is that a BM X-ray beam has a large energy spectrum and a large
spatial dispersion.
Modern synchrotrons, usually referred to as third generation synchrotrons, use,
along with bending magnets, another method of generation of X-rays called insertion
device (ID). In an ID beamline, electrons are brought to oscillation by a series of
consecutive permanent magnets of opposite polarization, called undulators. The
spectrum of the emitted X-rays is narrower and the power is a couple of orders of
magnitude higher than that of a BM.
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X-ray detectors for protein crystallography
Electronic detectors of X-rays have been a major improvement in the history of
crystallography. Before, we needed to collect diffraction patterns on photographic
paper and then manually process the data.
In the last years, the most widely used detector was the charge-coupled device
(CCD) detector. In a CCD detector, X-rays are initially converted into visible light
by interaction with a scintillating material such for exemple Gd2O2S:Tb. Visible
light is then brought to a CCD device through an optic fiber and is translated
into an electric signal. The rise of high flux beamlines has made CCD too slow,
so they are currently being replaced by faster photon counting detectors, such as
the Pilatustm (Henrich et al., 2009). These detectors directly count X-ray photons,
without the need for a scintillator, that increases enormously the noise into the
signal by spreading a spot over multiple adjacent pixels. Contrary to CCD detectors,
photon counting detectors have a short readout time, in the order of 10ms and can
be read continuously.
Radiation damage and cryo-cooling
The incident beam interacts in multiple ways with the proteins in the crystal (Murray
et al., 2005). To be more precise, only 2% of the incident beam actually interact with
the crystal, while about 98% of the photons simply pass through it. At the energies
used in a synchrotron crystallography experiment, in the order of 12 keV, only 8% of
the interacting photons are diffracted. Most of the interaction, accounting for about
84% of the interacting photons, comes from photoelectric effect. The liberated
photo-electron is highly energetic, and can lead to hundreds of secondary ionization
events, leading to the formation of radical species (Garman, 2010). The effects of
this series of events can be classified as specific and global radiation damage.
Global radiation damage, accounts for the general loss in diffraction quality of
the crystal, which is reflected in the loss of intensity of diffraction spots and in the
increase of Wilson B factors and mosaicity.
X-rays can also cause specific damage to the protein. It has been observed that
some chemical groups, like disulfide bonds and carboxylic groups of glutamates and
aspartates, are more sensitive than others to radiation damage (Weik et al., 2000;
Ravelli and McSweeney, 2000; Burmeister, 2000).
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The simplest way to mitigate the effects of radiation damage in protein crystals
is cryo-cooling. This method, developed in the 90’s, consists in collecting data at
cryogenic temperature, usually 100 K, instead of room temperature. Crystals are
cryo-cooled by mounting them in a loop (Teng, 1990) and then submerging them
into liquid nitrogen. Data collection is then performed at the synchrotron beam line
under a flux of nitrogen gas at a temperature of 100 K. At this low temperature,
radiation damage is reduced by a factor of about 100 compared to room temperature,
due to the reduced mobility of radical species. For example, the only radical that can
still move in amorphous ice at 110 K are electrons, while OH radicals are immobilized
(Garman, 2010).
During the cooling process, crystals have to be protected from the effects of this
rapid drop of their temperature. In fact, the water of the crystallization solution
forms crystalline ice that both dominates diffraction at high resolution and damages
crystals, reducing their diffraction quality. For this reason, a cryo-protection is re-
quired. It consists in soaking the crystal in a liquor that includes some additive that
prevents the formation of crystalline ice. The most used cryoprotectant is glycerol,
but other substances, such as small PEG molecules, have also this characteristic.
The choice of a good cryoprotectant can dramatically change the diffraction power
of a crystal and is thus a key step in obtaining good data (Juers and Matthews,
2004).
3.1.5 Data processing
Diffraction data sets consist in a series of images, each of them characterized by its
signal intensity and by two coordinates. By processing of the data we mean all the
treatment required to find the diffraction spots in this images and then translate
them into a 3 dimensional diffraction pattern, that can later be used to generate
electron density maps with an operation of Fourier transform. We will describe
here the three main steps during a data processing pipeline. Each of the most used
software, typically XDS (Kabsch, 2010) and MOSFLM (Leslie, 2006), performs them
in different ways.
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Indexing
The first step in data processing is the indexing, meaning giving each single diffrac-
tion peak a Miller index (hkl). Each spacegroup is characterized by specific sym-
metry of the diffraction patterns, along with missing reflections. A few images are
needed to properly index the reflections. From a practical point of view, indexing
software usually rank possible space groups with a certain penalty score. The good
solution is then chosen as the one with the lowest penalty score and the highest
symmetry.
Integration
After assigning a unique Miller index to each spot, in the integration step the am-
plitude of each reflection is determined. In particular, integration software sums the
amplitude of each peak over adjacent pixels of the detector, distinguishing them from
the background noise. Software like XDS also take into account crystal absorption
and incident beam divergence effects.
Scaling
Even if theory states that symmetry-related spots must have the same amplitude
(Friedel’s law), this is not always the case after integration. Changes in beam
intensity during data collection, crystal anisotropy and diffraction quality loss due
to global radiation damage can cause this kind of problem. For this reason, a scaling
step is needed. It consists in compensating the differences in amplitude between
these reflections. The scaled amplitudes can then be used to compute the Fourier
transform and reconstruct the protein structure.
3.1.6 The phase problem
As mentioned before, to obtain the electron densities we need calculate the inverse
Fourier transform of the structure factor F(hkl). This requires the knowledge of
diffracted amplitudes and phases. Now, we know that a detector measures intensi-
ties, rather than amplitudes. Amplitudes F are related to measured intensities I by
the simple relation 3.6
I = |F |2 (3.6)
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So we can see that the phase is not directly measurable, being |eiφ|2 = 1. A number
of methods have been developed to solve this problem, which is central in crystallog-
raphy. Since phase information is lost by measuring intensities instead of amplitudes,
a function, named Patterson function was defined. It is defined as the autoconvolu-
tion of the observed structure factors, and its peaks are related to the interatomic
distances.
Isomorphous replacement methods (Green et al., 1954) consist in binding to the
protein ligands with a high diffraction power, typically heavy atoms. Considering
the number of different heavy atom complexes, we can distinguish between MIR
(Multiple Isomorphous Replacement) and SIR (Single Isomorphous Replacement).
The phasing is based on calculating the differences between the structure factors for
the native and the derivative crystals. The heavy atom sites will then be easy to
find on a Patterson map. The information on their position will then be used to
phase the derivative crystal and, then, knowing their contribution to the structure
factors, the native crystal.
Another family of methods is based on the use of anomalous scatterer (Hen-
drickson, 1991), i.e. atoms that absorb and fluoresce at a certain wavelength. These
methods, based on the number of wavewlengths used in the experiments, are called
MAD (Multiple Anomalous Dispersion) and SAD (Single Anomalous Dispersion).
The role of the anomalous scatterers is to introduce a difference between centrosym-
metric reflections, that will not obey any more the Friedel’s law. This information is
then used to retrieve the phases for the dataset. Anomalous diffusion is dependent
on the X-ray wavelength, and for this reason it requires to collect multiple datasets
at different energies.
The method of molecular replacement is based on obtaining initial phases from
known analogues of the protein of interest, or at least of a part of it. In this work, all
the crystallographic structures were solved by the molecular replacement method,
using the program Phaser (McCoy et al., 2007). Molecular replacement is based
on confronting the measured Patterson function with one other calculated from a
protein on known structure, which should be similar to the one we are looking for.
The method consists then in calculating the rotation and translation of the map
that maximizes the superposition between the two Patterson functions (Rossmann
and Blow, 1962). Phases are then retrieved from this initial model. The initial guess
is usually good enough if there is at least a sequence identity of 25% between the
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replacement model and the protein of interest.
3.1.7 Structure refinement and validation
Once the initial phase guess is obtained, we can compute an electron density map, in
which we can fit a first model of our protein. Since the first electron density is based
on the MR homologous, the model needs then to be refined in order to calculate
new phases and improve the final electron density map.
This is usually an iterative process, where the protein atoms are fitted into the
electron density and then the improved model is used to calculate the new phases
to improve the density. Various refinement techniques exists, and they usually differ
by how the model is modified. To asses if a model improves the structure or not,
we usually consider the variation of the R-factor defined in 3.7, where Fo is the
measured structure factor and Fc is the structure factor calculated from the model
for the same reflection.
R =
∑
reflections |Fo − Fc|∑
reflections |Fo|
(3.7)
Another widely used criterion is the R-free (Brünger, 1992), defined as the R-
factor, but considering only a subset of randomly chosen reflections, usually between
5% and 10% of the total number of reflections, which are then not included in the
refinement. This value reduces the model bias implicitly included in the R factor.
3.2 Molecular dynamics simulations
Proteins are not static objects. They are animated by internal dynamics, which is
fundamental for their functioning. The picture we get from crystallographic struc-
tures represents simply the most stable conformations of the protein, at a temper-
ature, 100 K, which is far below the domain of biology. The approach of molecular
dynamics simulation consists in solving the equation of motion (EOM) for each atom
of the protein and of the solvent at room temperature (300 K), taking the crystallo-
graphic structure as a starting point. In this paragraph I will introduce the equation
of motion of bound atoms in the most general way, and then show how we can use
force fields to solve it in the case of protein simulations.
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3.2.1 The equation of motion (EOM) of atoms in a protein
An atom, submitted to a force, moves following Newton’s equation
F = m
∂2x
∂t2
(3.8)
This equation stands for only one atom. Depending on the kind of dependency the
force has on the other variables, especially the spatial coordinates, it has an analytic
solution.
A multibody problem, especially in the case where forces are dependent on the
relative position of the atoms, is more complex and has in general no analytical
solution. The most common strategy is to calculate a numerical, approximated
solution. Most numeric integration algorithms work by calculating the value of the
force at each time t, and use it to calculate the coordinates and velocities at the
time t + ∆t If we make the assumption that the force stays constant between the
time steps, which is equivalent to say that we are integrating time over steps ∆t
that are small enough, the equation of motion of each atom can be integrated using
for example the Verlet algorithm.
x(t+∆t) = x(t) + v(t)∆t+
F (t)
2m
∆t2
v(t+∆t) = v(t) +
F (t) + F (t+∆t)
2m
∆t2 (3.9)
This particular algorithm is interesting because it is the time reversible form of the
most classical Euler integrator
x(t+∆t) = x(t) + v(t)∆t+
F (t)
2m
∆t2
v(t+∆t) = v(t) +
F (t)
m
∆t2 (3.10)
It is easy to observe that, to use this kind of approach, we simply have to
calculate the parameter F (t) at each time step and for each atom. But we need to
consider that F (t) in reality depends on the relative positions and velocities, being
therefore F (x(t), v(t)). This implies that the exact form of the force term is too
heavy, depending, in a system of N atoms, on 6N parameters at least. For this
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reason, approximate forms of the force, called force field, have been developed.
3.2.2 Force field parameters to integrate the EOM
A force field is a set of parameters that defines the forces that an atom of a particular
kind, is subjected to. Considering that the force is the derivative of the potential
along the spatial directions,
F = −
∂V
∂xi
(3.11)
the force field defines the potential rather than the force itself. The general form of
a force field, equation 3.12, includes multiple parameters for the different kinds of
forces acting on an atom in a protein.
V =
bonds∑
ij
1
2
kij(rij − r
eq
ij )
2
+
angles∑
ijk
1
2
kij(θijk − θ
eq
ijk)
2
+
dihedrals∑
ijkl
kφ,ijkl(1 + cos(nφijkl − φ0))
+
∑
i>j
[
qiqj
ǫrij
+
Aij
R12ij
−
Bij
R6ij
]
(3.12)
We assume here that the potential is defined as the sum of multiple, independent
terms. The first three terms in the forcefield account for bonded interactions. Their
name is due to the fact that these terms contain bond lengths, angles and dihedrals
for bound atoms. This set of contributions describes movements such as vibrations of
chemical bonds around their equilibrium position, angles and dihedral angles modi-
fications and improper parameters, accounting for groups that can have movements
other than the ones listed above. The last line of the force field includes the long
range interaction, or non-bonded parameters. The main contribution to this term
comes from electrostatic potential and van der Waals interaction. They are usually
taken into account as a Lennard-Jones potential.
The general definition described above is valid for all of the force fields commonly
used, but each of them uses different functional forms. In particular, equation 3.12
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is based on the Amber force field functional form (Cornell et al., 1995). Practically,
the force field contains, for each atom type, equilibrium values of bond, angle and
dihedral angle and the constants for its functional form. Other common force fields
like CHARMM (Brooks et al., 2009) or GROMOS, use a different functional form,
as well as a different definition of parameters.
3.2.3 Solvent models
Proteins in a living system are in contact with water. To take this into account
during MD simulations we include the protein into a solvation box. Ideally, we
should use an infinite environment to calculate properties of the system without
any bias, but this is computationally unfeasible. The use of a box with periodic
boundary conditions overcomes this problem.
Multiple models of water have been developed during the years, to try to repro-
duce solvent properties in the most accurate way. They are divided in two main
categories: implicit and explicit water models.
Implicit models consider the solvent as a continuous medium. They use a func-
tional approach to calculate as a numerical value the influence of the environment on
each atom, in particular the contribution of water to the free energy of the system.
The two principal models are in this case the Poisson-Boltzmann and the Gener-
alized Born (GB) model, which is a linear approximation of the first one. Both of
these models are implemented in molecular dynamics software, like Gromacs, and
the GB model is by far the most used one.
In the explicit solvent approach, we characterize each single water molecule
within the system. This increases enormously the amount of atoms for which sim-
ulation is carried out, but also allows to describe more precisely the interactions
between the protein and solvent. Different explicit water models have been de-
veloped over the years. The most simple are the three site models SPC, TIP3P
(Jorgensen et al., 1983) and SPC-E (Berendsen et al., 1987), all of which describe
water by its three atomic sites H-O-H. Bond parameter and partial charges on wa-
ter atoms are slightly different in these three models. Four site models, such as the
common TIP4P (Jorgensen et al., 1983) include a fourth dummy atom, whose role
is to adjust the electrostatic potential around the molecule.
The chosen water model can influence the final output of a simulation, both
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concerning bulk solvent properties and protein dynamics (van der Spoel et al., 1998;
Tarek and Tobias, 2000). Using more accurate explicit models should be preferred,
but their computational cost is heavy. In any case, the access to massively parallel
computational resources should make the explicit solvent possible for any length of
simulation.
3.3 Molecular docking
One aim of structural biology is to participate in the design of new drugs. To achieve
this goal, techniques of molecular docking, i.e. a large spectrum of methodologies
to predict the interactions between molecules are of great help. (Sousa et al., 2013).
In the framework of this thesis work, we are interested in the interaction between
proteins and ligands.
3.3.1 Principles
In a docking experiment, we look for the best conformation, or binding mode, of a
ligand inside a target protein, which is called the receptor. The docking program
will look for candidate binding modes using different algorithms, which explore
the conformational space of the ligand-receptor system and extracts various poses,
usually hundreds or thousands. These poses are then scored using a function, which
is typical for each program and is probably the most important feature of a docking
pipeline. Finally, all the poses are ranked by their scoring, to extract the most
probable one, which should also describe the optimal binding mode for the ligand
within the receptor.
3.3.2 Docking algorithms
The algorithms used by docking programs follow different methods (Lengauer and
Rarey, 1996), depending on the required exhaustiveness and on the use of compu-
tational resources.
The method of shape complementarity consists in a calculation of the affinity
between the ligand and the protein based on the mutual interaction between their
surfaces. In particular, this approach looks at the interaction between the calculated
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electrostatic fields of the two partners. This docking method is the simplest one,
but has lower accuracy and is also less suited to give flexibility to the ligand, and
even less to use a flexible receptor.
The second, most complex method is the simulation. It consists in simulating
the binding process by calculating the mutual interaction between the atoms of the
receptor and the ligand. For its functioning, it is almost costless to take flexibility
into account with this method. The main drawback is the computational cost of
exploring a larger energy landscape. But modern optimized algorithms and the
always increasing computing power have made simulation docking a routine.
Finally, two of the most commonly used programs, GOLD (Jones et al., 1997)
and AutoDock (Goodsell et al., 1996), use a genetic algorithm. The method in
this case is to evolve a random initial conformation, usually for both the ligand
and the receptor, trying to optimize some variable. This method leads to the most
exhaustive exploration of the energy landscape of the complex.
3.3.3 Scoring function
Scoring functions (Jain, 2006) have the role to rank the number of docking poses
generated by the search algorithm. To perform this task, a scoring function needs to
handle the 3-dimensional structure of a protein, to analyze the receptor, the shape
of the ligand, and the binding mode between the two. The methods used to score
docking poses fall in three main families.
Force fields can be used, as in molecular dynamics simulations, to estimate the
affinity between protein and ligand. The use of force fields provides a direct estima-
tion of the binding energy, because of their ability to calculate forces between atom
pairs of ligand and receptors. Using force fields, we can also calculate the energy
contribution due to internal strains both within ligand and receptor, that could give
a hint on the relative probability to find them in a particular conformation. Fi-
nally they can also be used to calculate desolvation energy using the same models
of implicit solvent of molecular dynamics simulations.
Empirical scoring functions are simpler, and they work by counting the number
of interactions between molecules (Böhm, 1998). Some interactions add points to
the final score, like the number of possible hydrogen bonds in every pose, or the
hydrophobic/hydrophilic interactions between ligand and receptor. When the ligand
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is considered as being flexible, a penalty score will be given also to each mobile
rotamer that is fixed in a non-optimal conformation.
Knowledge-based functions, or statistical potentials, are the last type of scoring
functions (Muegge and Martin, 1999; Muegge, 2006). They start from the observa-
tion of most occurring interactions in large databases, such as the PDB, to derive a
potential of mean force, which describes each interaction of interest.
3.3.4 Flexible docking
Docking programs usually try to dock a series of conformations of a ligand, for which
the rotamers are modified, into the binding site of a rigid receptor. This assumption
is however too stringent, and a few methods exist to take intrinsic receptor flexibility
into account. The large number of degrees of freedom of receptors is rapidly too
computationally heavy, so the flexibility of the receptor is reduced to that of a few
amino acids of the predicted binding site. Even in this case, to speed up calculations,
approximate and faster methods are needed. The most common method consists in
using rotamer libraries, that the program will explore to generate a large amount of
conformations for the receptor.
Flexible receptors can also be derived from experimental techniques. NMR en-
sembles are an example of protein structure ensembles that have successfully been
used as flexible receptors in docking (Totrov and Abagyan, 2008). More recently,
hidden conformations in crystallographic structures have also been used to generate
multiple docking receptors with different conformations (Fischer et al., 2014).
Other methods rely on molecular dynamics simulations to generate receptors, by
extracting snapshots from a simulation (Wong et al., 2005). But this requires the
production of lengthy and computationally consuming simulations. Recent develop-
ment of faster graphic processor-based simulation algorithms, along with the use of
implicit solvent models has partially solved this issue, but it is still uncommon to
use MD snapshots as docking receptors.
Chapter 4
Optimization of KM297, a neutral AChE
reactivator
The main goal of this thesis work was to participate in the design of bifuncitonal
reactivators of OP-inhibited AChE. To this end, we investigated the structural dy-
namics of AChE during ligand binding and solved structures of native and OP
inhibited AChE in complex with the newly designed reactivators. A bifunctional re-
activator (figure 4.1), is a molecule featuring an oxime and a PAS ligand, connected
by a flexible linker, usually formed by carbon atoms.
Starting from a previously known PAS binding molecule, we designed a series of
bifunctional reactivators, that were then screened in vitro to find a lead molecule
(section 4.1), with the best reactivation capability. This lead was characterized by
flexible docking, to analyze its possible binding modes, and molecular dynamics,
to define an optimal linker length (sections 4.2 and 4.3). By solving the crystal
structure of TcAChE, both in its native form and inhibited by an OP, in complex
Figure 4.1: Schematic representation of a bifunctional reactivator. An oxime func-
tion is connected to a PAS ligand (PSL) through a flexible linker.
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with our lead molecule we found that the chosen PAS ligand could also bind in the
active site (section 4.4). Therefore we modified the lead, in order to force it to bind
exclusively at the PAS. The family of modified derivatives designed to this end was
also characterized by flexible docking and by solution of the crystal structures of
their complexes with AChE (section 4.5).
All the crystallographic structures were solved using TcAChE, but since our
reactivators are aiming at reactivating AChE in humans, human AChE would be a
more appropriate choice. We managed to obtain crystals of recombinant hAChE in
the absence of fasciculin (section 4.6), but their diffraction quality was lower than
that of TcAChE crystals.
4.1 Design, synthesis and in vitro evaluation of the
reactivator KM297
In the development of an efficient bifunctional reactivator, knowledge of the structure
of the enzyme and of the binding modes of its ligands is fundamental. Not only
can ligands bind to the main conformation of the enzyme, determined by X-ray
crystallography, but also to alternative conformations of binding sites, as introduced
in chapters 1 and 2. Rearrangements of the PAS region upon ligand binding to
AChE were observed in crystallographic structures (Bourne et al., 2004; Colletier
et al., 2006b; Rydberg et al., 2006).
Tetrahydroacridine (tacrine), known to bind at the active site of AChE (Harel
et al., 1993), has also been incorporated into bifunctional inhibitors (Harel et al.,
2000; Bourne et al., 2010a). The crystal structures of AChE in complex with ligands
bearing a bis-tacrine function (Rydberg et al., 2006; Colletier et al., 2006b) revealed
that tacrine can also bind to an alternative conformation of the PAS Trp279 in
TcAChE (figure 4.2). The ability to bind at the PAS is a key feature for a bifunc-
tional reactivator, and we decided to exploit it.
A series of molecules, all featuring a tacrine moiety as a PAS ligand, was syn-
thesized by the joint effort of our collaborators at the Université de Strasbourg and
Université de Rouen. These molecules were tested in vitro and we found that KM297
(figure 4.3), featuring a 3-hydroxy-2-pyridine aldoxime as reactivating function and
a linker length of 4 carbons, was the most efficient in the in vitro reactivation tests
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Figure 4.2: Crystal structure of TcAChE in complex with the bis-tacrine inhibitor
NF595 shown in cyan (PDB acces code 2cek) superposed to the structure of native
TcAChE (PDB acces code 1ea5), shown in green. We can observe the rotation of
the PAS residue Trp279 around the χ1 angle, to allow the binding of the inhibitor.
Figure 4.3: Lead molecule KM297.
(Kliachyna et al., 2014).
In vitro results showed that KM297 can reactivate VX-inhibited hAChE more
efficiently than any available reactivator, with also a good efficiency against tabun
and paraoxon. Its bimolecular reactivation constant (table 4.1) against VX is twice
that of obidoxime and about 3 fold that of HI-6, the best reactivator available so far.
Against tabun and paraoxon, for which HI-6 has no measurable reactivation capacity,
KM297 is respectively 20 and 1.5 fold more efficient than obidoxime. Reactivation
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Reactivator VX Tabun Paraoxon
2-PAM 0.28 nd nd
HI-6 9 nd nd
Obidoxime 11 0.16 20
KM297 22 3 31
Table 4.1: Comparison of the bimolecular reactivation constants of different reacti-
vators for hAChE inhibited by VX, tabun and paraoxon. All values are expressed
in mM−1min−1.
efficiency tests, not reported here, have also shown that the homologue with a 5
carbon linker has a lower in vitro reactivation power than KM297, with its 4 carbon
linker.
Due to its high efficiency in reactivating several OP inhibited hAChE, KM297
was chosen as the lead molecule of this family.
4.2 Flexible docking of KM297 into hAChE-VX
We performed flexible docking experiments of the reactivator KM297 to the non-
aged form of VX-inhibited hAChE. These experiments were aimed at verifying that
KM297 could bind to OP-inhibited hAChE, and the choice of flexible docking was
due to the fact that tacrine can bind to alternative conformations of the PAS,
as observed by X-ray crystallography for NF595 (Colletier et al., 2006b). Finally,
docked conformations can help in elucidating the mechanism of reactivation, and
were used as a starting point to perform molecular dynamics simulations of the
complex hAChE-VX-KM297. The choice of VX was made due to the necessity to
characterize in detail how KM297 can reactivate so well hAChE inhibited by this
particular OP, and also because VX is considered the most dangerous of the OPs,
due to its high toxicity and persistence.
4.2.1 Material and methods
Calculations were performed using AutoDock Vina (Trott and Olson, 2010). The
receptor was prepared by superposition of native hAChE crystal structure (Cheung
et al. (2012) PDB acces code 4ey4), and VX-inhibited non aged mouse AChE (PDB
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acces code 2y2u). The active site of the inhibited mouse enzyme was used as a
reference to model the receptor active site in the human enzyme. The choice of
mAChE as a template is justified by the identity of the residues within the gorge of
mAChE and hAChE.
We used as flexible residues the closest to the supposed position of the ligand
into the enzyme, Tyr721, Asp74, Trp86, Tyr124, Ser125, Trp286, Tyr337, Phe338,
Tyr341, along with the ethyl group of the non-aged VX. These residues were provided
as a list to the MGL AutoDockTools (Morris et al., 2009) script that generates
flexible receptors from a PDB file.
Ligands were designed and optimized by processing their SMILES string (Weininger,
1988) with phenix.eLBOW (Moriarty et al., 2009). This program optimized the lig-
and’s partial charges and protonation state, writing the output to a PDB file, which
was then pre processed with the appropriate script from the AutoDockTools set.
The procedure has been automated with bash scripts to screen ligands with differ-
ent characteristics simultaneously. Docking experiments were performed following
the Vina docking protocol.
A parallelepipedal docking box of about 17200 Å3, smaller than the recommended
upper limit of 27000 Å3, was centered at the middle of the gorge, at the level of
the bottleneck residues, so as to consider the whole gorge volume as the docking
region and include all the side chains of the flexible residues listed above. We chose
to generate nine output conformers, that were then observed qualitatively using
molecular graphics programs like PyMOL (Schrödinger, 2010).
4.2.2 Ligand scoring and conformational analysis
Vina scores obtained for the best 9 conformers of ligand KM297 are shown in table
4.2. As stated by the Vina documentation, we can conclude that KM297, having an
estimated affinity in the sub-nanomolar range, is a very good ligand for the enzyme.
Unfortunately, this calculated affinity values did not allow to properly discriminate
between docked conformations, due to the fact that they are all of the same order
of magnitude. A more detailed observation of the output structures is required in
this case.
The interest in performing flexible docking experiments lies in the possibility
1hAChE numbering.
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Conformation Affinity(kcal/mol) Affinity(Mol)
1 -11.7 3.36E-10
2 -11.4 5.88E-10
3 -11.3 7.09E-10
4 -11.3 7.09E-10
5 -11.2 8.53E-10
6 -11.2 8.53E-10
7 -11.1 1.03E-09
8 -11.1 1.03E-09
9 -10.9 1.49E-09
Table 4.2: Affinities for the nine best conformers of KM297 docked into non-aged
hAChE-VX complex.
of finding affinities for alternative conformations of the enzyme. In particular, we
wanted to verify that our working hypothesis of binding to a non-native conforma-
tion of the tryptophan at the PAS was supported by the calculations. Among the
nine output conformations, six presented the enzyme in its native conformation,
while three featured a conformational rearrangement of the PAS. Number 4 was
particularly interesting, because it features an aromatic stacking between Trp2862
and Tyr72, similar to the crystal structure of the TcAChE-NF595 complex (PDB
acces code 2cek). As we can observe in the insert of figure 4.4, Trp286 also rotates
by about 90 degrees around the χ1 angle from its native conformation, but in the
opposite direction that in the 2cek structure, thus laying in the same plane. This
generates a very similar binding mode for the tacrine moiety in the two conforma-
tions, also due to the fact that the very stable residue Tyr72 (Tyr70 in TcAChE)
is not observed to move, neither in the crystal structure nor in the docking results,
being therefore parallel to Trp286. The only difference arising from the opposite
rotation is that the tacrine moiety is flipped so that its double ring faces each aro-
matic residues and forms the appropriate aromatic stacking. The flexible docking
tests confirmed our hypothesis of tacrine moiety of KM297 binds at the PAS of
VX-inhibited AChE, and in particular to a non-native conformation of Trp286.
2hAChE numbering.
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Figure 4.4: Docked conformation number four of KM297 within the gorge of VX-
inhibited hAChE. We can observe the tacrine moiety at the PAS stacked in between
Tyr72 and Trp286 in an alternative conformation. In the insert we show a super-
position of the conformation of Trp286 in our output (grey) and the one observed
for Trp279 in the crystal structure of the TcAChE-NF595 complex (cyan). We ob-
serve that they rotate in two opposite directions, but lay in the same plane for the
aromatic stacking of the tacrine moiety.
4.3 Simulation of hAChE-VX-KM297
We simulated a hAChE-VX-KM297 complex observed from docking experiments to
get useful information for ligand optimization. In particular, we determined that the
observed binding mode was effective for stabilizing the ligand and we characterized
the influence of the carbon linker length on the distance between the oxime oxygen
and the OP phosphorus. This process required several steps, from the calculation of
force field parameters for the modified catalytic serine to the analysis of reactivation
conditions in MD simulations. In this section we will discuss the details and results
of this set of simulations.
4.3.1 Calculation of force field parameters for OP-inhibited
AChE
As explained in Chapter 3, we need force field parameters describing each residue
if we want to perform molecular dynamics simulations. Force fields are capable of
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handling all principal native 20 amino-acids, and there are simple methods to include
small ligand molecules in the simulation system. However, OPs bind covalently to
the catalytic serine of AChE, creating a new phosphylated residue, which needs to
be defined in the force field. For this reason, we calculated force field parameters for
phosphylserines resulting from the reaction with the most common organophosphate
nerve agents. Inhibited-serine models were extracted from the PDB, since there are
a few structures of non-aged AChE displaying the conformations of OPs bound to
the catalytic serine. The phosphylated serine of interest was capped by methylamine
at the C-terminus and acetyl group at the N-terminus and minimized using Chimera
(Pettersen et al., 2004). Two main chain conformations of the capped residue, the
α-helix and β-sheet, were taken into account for the RESP (Restrained ElectroStatic
Potential) charges (Cornell et al., 1995) calculation for the system using the REDS-2
server (Vanquelef et al., 2011). Following the instruction of the server maintainer,
calculations were performed using Gaussian09 with fixed side chain angles and using
all the options compatible with the parm99 force field set. After obtaining the
partial charges of the residues, they were included into the Amber99sb force field,
with the proper form of the bonded and non-bonded parameters for each atom.
The missing parameters were actually defined into the General Amber Force Field
(GAFF) (Wang et al., 2004), wich was created for the purpose of describing small
organic molecules compatible with force fields of the Amber family. GAFF contained
all the bond lengths, angles and dihedral constant for the non-standard serine-OP
conjugates, such as the dihedral angle C-N-P-O in the serine-tabun adduct.
In order to verify the validity of our parameter set, it was tested by running
molecular dynamics simulations of inhibited AChE. We first modified the Amber99sb
force field description files to include our newly defined residues. Then, the catalytic
serine of native human AChE was modified accordingly, as well as the conformation
of His447, in order to match the conformational changes observed in the struc-
tures of mAChE or TcAChE, when available. All calculations were performed using
Gromacs4.5 (Hess et al., 2008) and the experimental protocol described in section
(4.3.2). The dynamics of the system was then simulated for 5 ns to verify the stabil-
ity of the constructed residue. Having a force field description for the VX-inhibited
serine means that we can simulate how KM297 binds to AChE inhibited by VX.
4.3. SIMULATION OF HACHE-VX-KM297 51
Figure 4.5: General structures of molecules of the KM family. The number of carbon
atoms in the linker (n) was varied between two and five.
4.3.2 Optimization of the ligand linker length
We involved molecular dynamics simulations in the optimization process of KM297
to improve our knowledge of the reactivation mechanism. The goal was to better
understand the mechanism of interaction between the oxime and the inhibited en-
zyme. We decided to simulate several KM297 derivatives (figure 4.5), differing in the
carbon linker length, to observe how this parameter influences the distance between
the oxime oxygen and the phosphor of VX. The evolution of this distance along the
simulation was considered as being directly related to the reactivation properties of
the molecule.
Methods
The model structure of the non-aged hAChE-VX complex in the conformation re-
sulting from flexible docking was simulated using the amber99sb force field, with
the VX parameters calculated as described above. The constructed protein model
was included in a cubic box of 10×10×10 nm3, with periodic boundary conditions.
The KM-ligand topology was prepared using acpype (Sousa da Silva and Vranken,
2012; Wang et al., 2006), to be included in the simulation system. The ligand in
docked conformation number 4 was added to the system, which was then solvated in
simple point charge water. After charge equilibration with the appropriate number
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Figure 4.6: RMSD of bifunctional KM reactivators within the gorge of VX-inhibited
hAChE calculated from a 5 ns MD simulation. The four molecules have linker
lengths of 2, 3, 4 and 5 carbons respectively.
of counter ions, the energy was minimized. The temperature was kept at 300 K by
coupling to a Berendsen thermostat at 300 K with a coupling time of τT = 0.1 ps
(Berendsen et al., 1984). Pressure was maintained at 1 bar by coupling to a Berend-
sen barostat with compressibility of 4.5× 10−5 bar and τP = 1.0 ps. Bond lengths
were restrained with the LINCS method (Hess et al., 1997) and the electrostatic in-
teractions were calculated using the particle-mesh Ewald algorithm (Essmann et al.,
1995; Darden et al., 1993). The dynamics of the system was then simulated for
5 ns and output coordinates were stored every picosecond. Stability of the ligand
conformation was checked by calculating its RMSD with the program g_rmsd, fit-
ting at each timestep the positions of protein Cα. Distances were monitored with
the program g_distance, defining the OP phosphor atom and the oxime oxygen as
two separated groups. Data were then processed and plotted using python modules
matplotlib and Numpy.
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Results and discussion
The RMSD of the ligand position within the enzyme was calculated, after having
aligned at each MD simulation step the protein Cα positions. The alignment of
the protein backbone Cα atoms means that the RMSD value we are calculating is
directly proportional to the movement of the ligand within the gorge of the enzyme.
Results showed that all of the ligands remain near their initial position during the
simulation (figure 4.6), because the average RMSD for each of the molecules is of
the order of 2 Å. This means that tacrine, the PAS ligand moiety of the bifunctional
reactivator, is adapted to stabilize KM297 and its analogues in the docked confor-
mation. The molecule with a 4-carbon linker produced a steep variation of RMSD
after 2 ns, but visual observation of the trajectory revealed that it was due to a
movement of the oxime moiety, and that the PAS ligand remained in its initial po-
sition all along the simulation. The stability of the PAS conformation also confirms
that the distance between the VX phosphor atom and the oxime oxygen is a good
parameter for investigating the movements of the linker and the oxime within the
gorge of the enzyme.
After measuring the distances at each 1 ps step of the simulations, we plotted
their distributions in a histogram with bins of 1 Å (figure 4.7). Average distances
reported for each molecule in table 4.3 are smaller for the 4 and 5 carbon linker
molecules. It is straightforward to conclude that the two longer linkers better fit the
spatial dimension of the gorge, and are, therefore, more efficient than the shorter
ones in positioning the oxime near the OP.
The reactivation event is a chemical process that can occur only if the two atoms
get close enough. The minimal distance between phosphor and oxygen observed
during the simulation trajectory is, therefore, a direct indicator of a possible reac-
tivation event in our set of simulations and it was used to discriminate which of
the linkers was the most appropriate. The 4-carbon linker molecule is the one that
brings the oxime group closest to the phosphor atom, with a minimum distance of
3.5 Å, which is also close to the limit achievable in an MD simulation (the sum of
the van der Waals radii of oxygen and phosphorus is 1.8 Å+1.5 Å=3.3 Å).
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Figure 4.7: Distribution of the distances between the oxime oxygen and phosphor
atom of VX calculated from a 5 ns molecular dynamics simulation for KM297 analogs
with several linker lengths. We can observe how the distribution for the 4-carbon
linker molecule is the only one showing a sharp peak at a shortest distance. It is
also the data set where the closest distance, between 3 and 4 Å, is reached more
often than in the other.
Carbon linker length Average distance(Å)
2 8.82
3 7.58
4 6.15
5 6.33
Table 4.3: Average distances between the oxime oxygen and the phosphor atom of
VX for different carbon linker lengths. Four and 5 carbon linkers have the lowest
value, which is presumably more favorable to the reactivation reaction.
4.4 X-ray crystallography
A series of crystallographic experiments was performed with the aim of structurally
characterizing the interactions between AChE and the reactivators of the KM family.
Using hAChE for structural studies would have been ideal. Unfortunately, the form
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of hAChE available in our laboratory (untruncated recombinant form) crystallizes
only in the presence of FAS-2, an inhibitor that occupies the PAS and blocks the
access to the gorge. The presence of FAS-2 is therefore an obstacle for ligand soaking
experiments. Since good quality crystals of truncated recombinant hAChE (Cheung
et al., 2012) were not yet available to us, we decided to proceed using TcAChE.
TcAChE yields well diffracting crystals. Also, the crystal packing leaves the
PAS and gorge freely accessible, making it possible for ligands to enter the active
site during soaking experiments. For these reasons, AChE from this species is a
common choice for performing crystallographic experiments. The main goal of this
structural study was to obtain a crystallographic structure of ternary TcAChE-OP-
reactivator complexes, in order to determine, from a structural point of view, how
our reactivators interact with the non-aged form of the AChE-OP complex. We
chose tabun instead of VX as a nerve agent for these crystallographic experiments.
The reason for this choice is that a tabun-inhibited hAChE is reactivated about 10
times slower by KM297 than VX- or paraoxon-inhibited hAChE, as observed in vitro
(Kliachyna et al., 2014). Thus, the probability that reactivation may occur inside
the crystalline enzyme during the soaking time is reduced, and the ternary complex
should accumulate and be easier to observe. Slow aging of tabun-AChE was also a
favorable consideration. Since we do not know how the crystal environment would
affect reactivation constants of KM297, a slow aging OP allows us to soak ligands
for several hours, without significant aging. We first solved the structure of the non
aged TcAChE-tabun complex, and used it later as the starting structure for the
refinement of the ternary complexe.
4.4.1 Material and methods
TcAChE was provided by Prof. I. Silman’s laboratory at the Weizmann Institute
of Science (Israel). It is purified from the electric organs of Torpedo californica fish
according to the protocol presented in Sussman et al. (1988). The crystallization
condition used in the experiment work at 4◦C, so all the manipulations have been
performed in a cold room. Crystallization experiments were done using the hanging
drop method with drops of 1 µl of precipitant and 1 µl of protein, at a concentration
between 10 and 15 mg/ml. TcAChE is known to crystallize in 36% PEG200, 150
mM MES pH 5.6. In any case, the percentage of PEG200 was refined by screen-
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ing for each new purification batch. We generally obtain crystals for concentrations
spanning from 30 to 40% PEG200. They usually grew in 2-10 days and can be found
in three different crystal forms. The two most commonly obtained are trigonal3 and
orthorhombic-14 ones. The first appear as cubes of a few hundred micrometers in
dimension, and diffract up to 1.8Å while the latter grow in the form of multiple,
superposed plates and they diffract to about 2 Å. The latter needed to be separated
before flash-cooling, in order to reduce the chances of hitting multiple crystals when
collecting a data set. A third crystal form is also orthorhombic5, but its diffrac-
tion quality is significantly lower (2.4 Å resolution). The active site gorge is not
accessible, being closed by a symmetry-related molecule.
Crystal soaking
Crystal soakings were performed by fishing a crystal and putting it into a drop of the
mother liquor, containing the ligand we want to study in a concentration depending
on its solubility and its affinity.
To study OPs and their surrogates, TcAChE crystals were soaked in a 2 µl
drop of the mother liquor containing 0.5 mM of OP. The concentration and volume
both allow manipulating only small amounts of the toxic OP, while also minimizing
the quantity of isopropanol, in which the OP is stored, in the soaking conditions.
We performed experiments mainly with sarin, VX and tabun, with soaking times
spanning from 5 minutes to 10 days, depending on the need to trap either the non-
aged or the aged form. Half time of aging in solution is 3 hours for sarin, 27 hours for
tabun and 36 hours for VX. For tabun, complete aging in solution requires soaking
times larger than 48 hours. The pH of soaking (5.6) lower than at physiological
conditions and spontaneous hydrolysis of the organophosphate in the crystallization
conditions suggested reducing the soaking time to a few minutes to trap the structure
of the non-aged complex. In any case, due to the very high bimolecular reaction
rates, inhibition in crystallo is mainly rate-limited by the diffusion of the ligand into
the solvent channels.
The soaking of neutral reactivators presents more difficulties. Due to their lack
of permanent charge, these molecules are weakly soluble in water (a few hundred
3Space group 152 (P3121) , 112 112 138 Å, 90◦ 90◦ 120◦
4Space Group 19 (P212121), 91 107 151 Å, 90◦ 90◦ 90◦
5Space Group 19 (P212121), 80 112 164 Å, 90◦ 90◦ 90◦
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µM). We managed to solubilize KM297 and its homologs at a concentration of 20
mM in 100% dimethylsulfoxide (DMSO) at room temperature. DMSO deteriorates
crystal quality, so we needed to screen for optimal soaking conditions in the presence
of this solvent. Our optimized conditions were found by testing dilutions between
1 and 20% of DMSO and collecting diffraction data sets on soaked crystals. We
obtained the best results by mixing 5µl of reactivator-DMSO solution with 95µl of
mother liquor, to obtain a final concentration of 1 mM reactivator with 5% DMSO.
Crystals were soaked in these conditions for a time spanning between 2 minutes and
2 days.
For non-aged ternary complexes, crystals were at first soaked for a few hours
with tabun, according to the protocol described above. Then they were fished again
and soaked for 2-20 minutes into a second solution, containing mother liquor and 1
mM of reactivator and 0.5 mM tabun, with 5% DMSO and 5% isopropanol. The aim
of adding tabun is to re-inhibit the enzyme that was eventually reactivated inside
the crystals.
Ligand co-crystallization
An alternative to soaking for solving structures of proteins in complex with ligands
is the co-crystallization method. It consists in growing crystals in a drop of mother
liquor containing the ligand. In this way, the ligand ideally binds to the enzyme
before crystallization actually occurs.
We performed co-crystallization experiments of TcAChE in complex with the
reactivators KM297 and its homolog molecule JDS207. Following the crystallization
protocol described above, hanging drops were prepared with 1 − 1.5 µl of protein
at a concentration of 10 to 15 mg/ml and the same volume of precipitant solution
containing 1 mM of reactivator and 5% DMSO.
Data collection and processing
Owing to the cryo-protectantxs power of PEG200 at concentrations higher than
20%, TcAChE crystals can be cryo-cooled without any additional cryoprotectant.
Diffraction data were collected at the ESRF, at the MX beam lines ID14-4, ID23 and
ID29. Each diffraction image is collected by rotating the crystal during exposure.
In our case, we collected either with an oscillation range of 1◦ per image, or using
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Figure 4.8: Nerve agent tabun (GA)
the fine slicing collection method, in which images are collected with an oscillation
range of 0.1◦ instead of 1◦. For the orthorhombic space group, images should be
collected over at least 90◦ of rotation, in order to obtain a complete data set. The
higher symmetry of the trigonal space group requires, in theory, only 60◦. Usually
more images than the minimum required by the theory are collected, to maximize
the chances of obtaining a complete data set. These days, synchrotron beam lines
offer an automatic data processing routine that was used to quickly inspect data
sets and check the presence of ligands in the structures. Along with using auto-
processing results, most data sets were also reprocessed by us using XDS (Kabsch,
2010). Knowing the crystal form, we processed directly in the proper space group.
Once the reflection data set was scaled and truncated at a proper resolution using
the AIMLESS-POINTLESS pipeline in CCP4, the native TcAChE monomer (PDB
acces code 1EA5) was used as the initial model to perform molecular replacement
for trigonal crystals. The native TcAChE dimer (PDB acces code 1w75) was used
for the orthorhombic crystals. Molecular replacement was done using Phaser (Mc-
Coy et al., 2007). Finally, refinement was performed with either PHENIX (Adams
et al., 2010) or REFMAC (Murshudov et al., 2011). Coot (Emsley et al., 2010) was
employed to observe and manipulate the models.
4.4. X-RAY CRYSTALLOGRAPHY 59
Data
Resolution range (Å) 45.74 - 2.2 (2.28 - 2.2)
Space group P 31 2 1
Unit cell (a,b,c (Å); α, β, γ, (◦)) 111.8 111.8 137.2 90 90 120
Total reflections 274775 (27951)
Unique reflections 50213 (5024)
Multiplicity 5.5 (5.6)
Completeness (%) 98.84 (98.55)
Mean I/sigma(I) 13.7 (2.20)
CC 1/2 0.999 (0.918)
Refinement
R-work (%) 17.5 (32.7)
R-free (%) 21.6 (33.7)
RMS bond lengths (Å) 0.008
RMS bond angles (◦) 1.08
Atoms in asymmetric unit 4784
Ramachandran favored (%) 96
Ramachandran outliers (%) 0.19
Average B-factor (Å2) 42.00
Table 4.4: Refinement and data statistics for TcAChE-tabun conjugate. Values in
parenthesis correspond to the highest resolution shell.
4.4.2 Crystallographic structure determination of the non-
aged TcAChE-tabun conjugate.
Of all the OP nerve agent-AChE conjugates, AChE-tabun is the most resistant to re-
activation, while having a relatively long half-life in the non-aged form (27 h, Worek
et al. (2004)). It was thus the OP of choice as a starting point in the crystallographic
study of reactivators because of its low reactivability by oximes, which means that
we don’t expect reactivation of tabun-inhibited enzyme to happen within the crys-
tal. Along with this, aging time longer than the soaking experiment, ensures that
no significant aging occurs over the experiment time scale. The structure of the
non-aged AChE-tabun was solved with mouse AChE(Carletti et al., 2008), but the
TcAChE-tabun structure remained unsolved.
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Data collection and processing
Trigonal TcAChE crystals were soaked for 5 minutes in a solution containing 36%
PEG200, 100 mM MES pH 5.6, 0.5 mM tabun and 1% isopropanol. Data were
collected on the ID14-4 beam line at the ESRF. We collected 90 images with os-
cillation range of 1◦ per image at a temperature of 100 K. Data were processed
with XDS (Kabsch, 2010) using the trigonal space group unit cell parameters and
were truncated using XSCALE at a resolution of 2.2 Å. Complete statistics for data
processing and refinement are shown in table 4.4.
Structure refinement
Refinement was performed using phenix.refine (Adams et al., 2010). Atom posi-
tions were refined, along with individual atomic B-factors. Restraints for the tabun
substituent were calculated with phenix.eLBOW (Moriarty et al., 2009), and the
length and angles for the binding to the catalytic serine were obtained from the
output of quantum mechanical calculations previously used for the force field pa-
rameter calculation (section 4.3.1), performed on the REDS server (Vanquelef et al.,
2011). Water molecules were added, using the automatic water search in Coot (Em-
sley et al., 2010) and a comparison with the ones observed in the high resolution
native TcAChE structure 1ea5. Water molecules were then validated with MolPro-
bity (Chen et al., 2010). After several cycles of restrained refinement and manual
reconstruction in Coot, refinement statistics, converged (table 4.4).
Structure analysis
After molecular replacement, a strong signal at about 11σ was present in the Fo-Fc
electron density map in front of the catalytic serine. This signal is the key signature
of the presence of the organophospate within the structure, as it is in agreement with
the presence of a phosphorus atom at covalent bonding distance from the Ser200-
OG atom. The tabun moiety was subsequently modeled in the active site as shown
in figure 4.9. The electron density map around the position of the ethyl group of
tabun is not clearly defined in the non-aged TcAChE-tabun complex (figure 4.9 a).
Considering that aging of tabun involves the loss of this group, the structure has
also been refined in the aged form. However, a peak appeared in the Fo-Fc electron
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(a) non-aged complex (b) aged complex
Figure 4.9: Electron density map of the catalytic serine inhibited by tabun either
in (a) non-aged and (b) aged form. Blue mesh represents the 2Fo-Fc map at 1σ
level and green and red mesh the Fo-Fc map at +3 and -3 σ respectively. The
poor definition of the 2Fo-Fc map around the ethyl group in the non-aged model
could suggest either partial aging of the complex. Refinement of the aged model (b)
presents a peak in the Fo-Fc map, at the position of the ethyl group.
density map at the position of the C08 carbon atom of the ethyl leaving group (fig-
ure 4.9 b) suggesting that the non-aged form is the most occupied in the crystal.
It was observed, for mAChE and hAChE (Carletti et al., 2008) that aging, along
with the dealkylation of the ethyl group, involves a conformational change in the
position of the catalytic histidine, that returns to its native conformation. The cat-
alytic histidine could not be modeled in its native conformation, even when refining
the aged form of the TcAChE-tabun complex, thus supporting the hypothesis of
the complex being non-aged, if aging procedes similarly in mAChE and TcAChE.
Comparison with the structure of the non-aged mAChE-tabun complex (figure 4.10
c) shows that catalytic histidine assumes the same conformation in the presence of
tabun.
Tabun interacts with the environment of the active site (figure 4.10 a) by forming
four hydrogen bonds. The first three are between the O2 atom of tabun and the
oxyanion hole residues Gly118-Gly119 and Ala201, similarly to what was observed
for substrate analog OTMA (Chapter 1, Colletier et al. (2006a)). The other oxygen
atom in tabun (O6) also forms a hydrogen bond with the catalytic triad residue
His440, which is, as already anticipated, observed in a non-native conformation. We
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can appreciate the amplitude of this conformational change in the superposition of
the non-aged TcAChE-tabun conjugate and the native TcAChE structure (figure
4.10 b). The side chain of His440 rotates 90◦ around the χ1 angle, while the backbone
atoms are shifted away from the catalytic Ser200 (1 Å for Cα). The orientation of
the dimethyl-amine substituent seems to be different from the one observed in non-
aged mAChE-tabun conjugate, (PDB acces code 3dl4; Carletti et al. (2008); figure
4.10 c). But in our case, the resolution permitted to fit the two methyls in a unique
conformation, while the lower resolution of mAChE crystals (2.5 Å) made it more
difficult to unequivocally model this moiety.
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(a) Interactions tabun-AChE (b) Native and tabun inhibited TcAChE
(c) Inhibited TcAChE and mAChE
Figure 4.10: a: Polar contacts between tabun and the residues in the TcAChE
gorge. The main interaction is through hydrogen bond between Tabun O2 atom
and the oxy-anion hole residues Gly118-119 and Ala201. These bonds stabilize the
substrate in native enzyme. There is also another hydrogen bond between tabun
O6 and the His440 NE2 atom. This interaction pushes His440 in a non-native
conformation. Distances are expressed in Å. b: Superposition of native (PDB acces
code 1ea5, cyan) and inhibited by tabun (green) structures of TcAChE, featuring an
alternative conformation of His440. c: Superposition of non aged tabun-TcAChE
(green) and tabun-mAChE (yellow,(Carletti et al., 2008) ). We can observe how the
dimethyl-amine is oriented in two different ways in the enzyme from the two species,
while the position of the leaving group is the same.
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4.4.3 Crystallographic structure determination of the TcAChE-
KM297 complex
With the aim of structurally characterizing the interactions between KM297 and
AChE, we solved the structure of TcAChE-KM297 complex. In vitro inhibition
tests have already shown that it has a good affinity for the enzyme (IC50=1.4 µM),
which is positive for soaking tests. However, due to the low solubility of KM297 in
aqueous solution, a big effort was devoted to finding the proper soaking conditions
for formation of the complex. Data were collected at the ESRF for about 50 crystals
during different experiments6 to finally obtain a first structure.
Data collection and processing
Soakings trials revealed that the DMSO concentration in the soaking solutions must
not be higher than 15%. Above this threshold, crystals either dissolved during the
soaking procedure, or lost their diffraction quality. Due to the difficulties to grow
trigonal crystals, all the soaking tests were performed with orthorhombic-1 plates.
At lower DMSO percentages, between 5% and 10%, a few reflections were observed
up to the known resolution limit for this kind of crystal (around 2.0 Å). TcAChE
orthorhombic-1 crystals were soaked for 24 hours in a solution containing 36% PEG,
100 mM MES pH 5.6, 1 mM KM297, 5% DMSO. A complete data set of 240 images,
with an oscillation range of 0.5◦ per image was collected at a temperature of 100 K
on the beam line ID 14-4 at the ESRF.
Automatically processed data were truncated at a resolution of 2.6 Å (com-
plete statistics for data processing and refinement are reported in table 4.5). After
performing molecular replacement with a TcAChE dimer model (PDB access code
1w75), the electron density map could be observed to check for the ligand.
Structure refinement
Refinement was performed using phenix.refine. Atom positions were refined, along
with atom individual B-factors, in several cycles of refinement and manual re-
construction using Coot. Restraints for the ligand KM297 were calculated with
phenix.eLBOW. Water molecules were added, using the automatic water search
6Thanks to the IBS BAG experiment
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Data
Resolution range (Å) 45.91 - 2.63 (2.724 - 2.63)
Space group P 21 21 21
Unit cell (a,b,c (Å); α, β, γ, (◦)) 91.3 106.2 150.5 90 90 90
Total reflections 214755 (21464)
Unique reflections 43964 (4317)
Multiplicity 4.9 (5.0)
Completeness (%) 99.49 (99.40)
Mean I/sigma(I) 9.22 (1.88)
CC1/2 0.992 (0.739)
Refinement
R-work (%) 19.0 (28.2)
R-free (%) 26.5 (37.2)
RMS bond lengths (Å) 0.009
RMS bond angles (◦) 1.20
Atoms in asymmetric unit 9139
Ramachandran favored (%) 94
Ramachandran outliers (%) 0.28
Average B-factor (Å2) 35.00
Table 4.5: Data and refinement statistics for TcAChE-KM297 complex. Values in
parenthesis refer to the highest resolution shell.
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(a) CAS (b) PAS
Figure 4.11: 2Fo-Fc electron density maps at 1 σ level (blue mesh) and Fo-Fc at
+3 and -3 σ level (green and red red mesh respectively) for KM297 in he gorge
of TcAChE. Panels show the ligand at CAS (a), with the position of the catalytic
serine shown in red, and PAS (b) of TcAChE.
in Coot and were compared with the ones observed in the high resolution native
TcAChE structure 1w75. MolProbity tools were used to validate the structure.
Structure analysis
A first inspection of the structure suggested the possible presence of a KM297
molecule bound at the active site. This observation was also corroborated by a
conformational modification of the Phe330 side chain. A more detailed analysis of
the electron density map was performed using the program phenix.ligand, to look
for other possible KM297 molecules bound to the enzyme. We were able to find, in
each of the two protein monomers in the asymmetric unit, two molecules of KM297,
located in the gorge of the enzyme. Both of them have a well defined tacrine moi-
ety, while the electron density map of the linker is less clearly defined (figure 4.11).
The molecule in the CAS has also a poor electron density around the oxime moiety,
especially the oxime C=N-O function. This can be either due to a higher mobility
of this part of the molecule, or to a partial hydrolysis of the oxime, which could be
less stable at pH 5.8 of the crystallographic conditions than at pH 7.
We can observe in figure 4.12 how KM297 is bound to the peripheral and active
sites of the enzyme. Binding to the PAS is fundamental for a bifunctional reactivator.
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Figure 4.12: Binding of two KM297 molecules in the gorge of TcAChE. We can
observe that the presence of a KM297 molecule in the active site prevents the oxime
function of the molecule at the PAS to enter into the gorge as originally designed
for the reactivation reaction.
This observation supports, therefore, the choice of tacrine as a PAS binding moiety
for KM297. However, no conformational rearrangement of the PAS residues was
necessary to accommodate the ligand, as the orientation of Trp279 is the same as
observed in the native enzyme.
One should note that the orientation of the pyridine aldoxime of the KM297
molecule bound at the PAS is not suitable for reactivation. Instead of going down
into the gorge the oxime is stacked to the tacrine moiety, with the carbon linker
forming a U-turn. In this conformation the oxime moiety forms an hydrogen bond
with the main chain carbonyl of Tyr334. A decisive contribution to the stabilization
of the oxime in this conformation at the PAS is the presence of residue Gln185
from a symmetry related enzyme in the crystal, whose side chain lies parallel to
the pyridine aldoxime at 3.6 Å (figure 4.13). This distance is proper to the packing
of orthorhombic-1 crystals. Trigonal crystals are arranged differently, thus soaking
in this crystal form should not be affected by the vicinity of the symmetry-related
enzyme. However, this experiment was not performed, due to the difficulty to grow
trigonal TcAChE crystals. No KM297 molecule was found at the PAS of crystals
grown in presence of KM297.
As suggested from a first observation of the electron density, the second molecule
bound to the enzyme is oriented upside-down in the CAS, with the tacrine moiety
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Figure 4.13: Interactions between KM297 and the PAS region of TcAChE. We
can observe the aromatic stacking between the tacrine moiety and Trp279, and the
hydrogen bonds with Tyr334 and Gly335. In magenta we show the residue Gln185
from a symmetry related enzyme in the crystal, whose amide group could interact
with the pyridine π−system. Distances are expressed in Å.
sandwiched between Trp84 and Phe330 and the carbon linker pointing towards the
PAS. The position of the tacrine moiety in the active site is analogous to what is
observed both in the structure of the TcAChE-tacrine complex (PDB acces code
1acj) and also in similar molecules featuring a tacrine moiety, such as A8 and NF595
(PDB acces codes 1odc and 2cek, respectively).
It should be noted that the oxime function does not lie in the plane of the
pyridine but appears to be slightly twisted. This observation indicates that the
oxime function is not necessarily conjugated to the pyridine π-system when bound
to the enzyme. It also justifiesthe fact that we did not impose any constraint of
coplanarity for the oxime and pyridine during docking and MD simulations.
In figure 4.14, we show a superimposition of the TcAChE-KM297 structure and
TcAChE-NF595 structure (PDB acces code 2cek). The tacrine moiety of the KM297
bound in front of Trp84 superimposes remarkably well to that of the NF595 molecule.
The situation is different at the PAS, where both tacrine moieties do not superim-
pose. This can be explained by the fact that the PAS residue Trp279 stays in its
native conformation and does not rotate as in the NF595 structure. For this reason,
the planes of both tacrine moieties lay perpendicular one to each other.
The structure of this complex provide us with good conditions to perform soaking
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(a) (b)
Figure 4.14: Superimposition of the KM297 and NF595 (PDB acces code 2cek)
TcAChE complexes. The tacrine moiety of KM297 observed in the active site adopts
the same conformation as that of NF595, while the tacrine moieties at the PAS are
not superimposable. In particular, we don’t observe the conformational change of
the side chain of Trp279. Panels a and b are rotated by 45 degrees around the
vertical axis.
KM297 so as to obtain the ternary complex conjugate.
4.4.4 Crystallographic structure determination of non-aged
TcAChE-NEDPA-KM297 complex
With the aim of obtaining the structure of KM297 in the putative conformation as-
sumed during reactivation of inhibited AChE, we solved the structure of the ternary
complex TcAChE-NEDPA-KM297. Due to the difficulty to access OP nerve agents,
and more generally to avoid manipulating these dangerous molecules, the following
experiments were performed using OP surrogates that are orders of magnitude less
toxic than the actual chemical warfare agents, yet produce the same conjugate of
the inhibited serine. In particular, we used the tabun surrogate 4-nitrophenyl ethyl
dimethylphosphoramidate (NEDPA; Meek et al. (2012)), synthesized by the group
of Prof. P.Y. Renard from the University of Rouen (figure 4.15).
The reduced toxicity is obtained by replacing the cyanide group of the leaving
group of tabun, by a p-nitrophenol group. This substitution has two effects: it
reduces the accessibility of the molecule to the active site and makes it non-volatile,
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Figure 4.15: Tabun surrogate NEDPA. Cyanide, the leaving group of tabun, is
replaced by paranitrophenol.
allowing a safer manipulation. Also, such of surrogates are not submitted to the
chemical warfare convention and can be manipulated in any laboratory. In vitro
tests performed in the laboratory7 have shown that this surrogate inhibits AChE
740-fold slower than tabun (ki = 1.0±0.1104 M−1min−1vs 7.4±0.2107 M−1min−1).
As we will show below, it produces the same adduct as tabun on the catalytic serine,
and is therefore strictly equivalent to tabun for crystallographic and reactivation
studies.
Data collection and processing
Orthorhombic-1 TcAChE crystals were in a first step soaked in a solution containing
36% PEG200, 100 mMMES pH 5.8, 0.1 mMNEDPA and 1% isopropanol for 4 hours.
Then the were soaked again for 10 minutes in 36% PEG200, 100 mM MES pH 5.8,
0.1 mM NEDPA and 1% isopropanol, 5% DMSO and 1 mM KM297. A complete
data set was collected on beam line ID23-1 at the ESRF. We collected with the fine
slicing method, 1270 images with a rotation angle of 0.1◦ per image at 100 K. Data
were processed with XDS, using the orthorhombic-1 unit cell parameters. Using
AIMLESS (Evans and Murshudov, 2013), we truncated them at a resolution of 2.9
Å. Molecular replacement was performed using a TcAChE dimer (PDB entry 1w75).
7M.T. Froment, personal communication
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Data
Resolution range (Å) 58.14 - 2.9 (3.004 - 2.9)
Space group P 21 21 21
Unit cell (a,b,c (Å); α, β, γ, (◦)) 91.5 106.4 150.5 90 90 90
Total reflections 150232 (15096)
Unique reflections 32837 (3215)
Multiplicity 4.6 (4.7)
Completeness (%) 98.71 (99.14)
Mean I/sigma(I) 9.20 (2.3)
CC1/2 0.99 (0.85)
Refinement
R-work (%) 18.5 (25.4)
R-free (%) 26.1 (33.2)
RMSD bond lengths (Å) 0.009
RMSD bond angles (◦) 1.20
Atoms in asymmetric unit 8777
Ramachandran favored (%) 92
Ramachandran outliers (%) 0.47
Average B-factor (Å2) 39.50
Table 4.6: Data collection and refinement statistics for TcAChE-NEDPA-KM297
complex. Values in parenthesis are relative to the highest resolution shell.
Structure refinement
Refinement was performed using phenix.refine. Atom positions were refined, along
with atom individual B-factors. Restraints for the tabun substituent and for KM297
were calculated with phenix.eLBOW. Bond length and angles for the covalent bond
between tabun and the catalytic serine were obtained from the model used in the cal-
culations of force field parameters presented above (section 4.3.1). Water molecules
were added, using the automatic water search in Coot and a comparison with the
ones observed in the high resolution native TcAChE structure 1ea5. Statistics for
the refined structure can be found in table 4.6.
Structure analysis
As for the TcAChE-tabun complex, the presence of the OP in the active site was
indicated by a high positive peak in the Fo-Fc map after molecular replacement. We
managed to model the OP correctly in both monomers, in particular in monomer
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(a) Inhibited serine and tabun surrogate (b) PAS
Figure 4.16: a: 2Fo-Fc electron density map at 1 σ level (blue mesh) of Ser200
modified by the tabun surrogate NEDPA from monomer B of TcAChE. Differently
from the non-aged TcAChE-tabun complex, the ethyl group of NEDPA is well
defined in the maps; b: 2Fo-Fc electron density map at 1 σ level (blue mesh) and
Fo-Fc map at +3 σ and -3 σ (green and red mesh respectively) of KM297 at the
PAS of NEDPA-inhibited TcAChE. As for the complex with native TcAChE, the
KM297 molecule at the PAS is folded and the oxime does not enter the gorge.
B, where the electron density of the ethoxy substituent was well defined compared
to that in monomer A (figure 4.16 a). Aging of the adduct can be dismissed, given
that His440 was found in a single conformation, corresponding to that observed
in the non-aged form of the mAChE-tabun complex. We found electron density
corresponding to a reactivator molecule in monomer A, close to Trp279 (figure 4.16-
b). The tacrine moiety could be modeled in this density in a conformation identical
to that binding at the PAS in the structure of TcAChE-KM297 discussed above. The
pyridine aldoxime part of the molecule is similarly folded to stack on the aromatic
part of the tacrine.
The important result is that the reactivator molecule did not bind in the active
site as in native TcAChE (figure 4.17). At a more detailed level of observation,
we can conclude that the ethyl group of non-aged tabun would overlap with the
tacrine moiety of the molecule located in the active site of the TcAChE-KM297
complex. For this reason the reactivator can not bind deep into the active site gorge
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Figure 4.17: Position of KM297 in the gorge of NEDPA-inhibited TcAChE.
of the inhibited enzyme. At the PAS, KM297 is stabilized by a hydrogen bond with
Tyr334 and by the vicinity of symmetry related Gln185, whose influence on the
binding mode was discussed above. If we compare the surface of the gorge with the
one observed in the complex with native enzyme (figure 4.12), we can conclude that
the presence of the tabun surrogate, together with the non-native conformation of
the catalytic histidine between the native and tabun-inhibited structure, reduces the
accessible volume of the active site. This confirms our hypothesis that the ligand
binds only at the PAS in the non-aged form of the enzyme inhibited by an OP.
The oxime function does not point down into the gorge Thus, this structure does
not represent the functional state of the ternary complex. Nevertheless we have a
direct confirmation that our strategy of targeting the PAS ligand of the OP-inhibited
enzyme with a reactivator was correct.
Some electron density is found in the gorge, spanning from Trp84 to Tyr334.
Such density has already been observed in many TcAChE structures, but no con-
sensus was found on its origin. It was possible to model it as a small PEG molecule,
triethylene glycol, which is present in the mother liquor.
We demonstrated, through docking and crystallographic studies that binding of
the tacrine moiety at the PAS can occur. In this mode, simulation showed that the
4-carbon linker of KM297 is the most suited to span the gorge and bring the oxime
close to the OP-inhibited serine. Yet, we could not confirm the action mode of
the reactivator by crystallographic study, because of an artifact induced by crystal
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Figure 4.18: A derivative of KM297, featuring a chlorine substituent at position 7
on the tacrine moiety of the molecule, generating a steric hindrance, which should
prevent binding within the active site of the enzyme.
packing. This could be assessed by performing soakings in another crystal form, i.e.
the trigonal one, featuring a different crystal packing that the orthorhombic-1 form.
However, we did not manage to grow enough crystals in this form to perform the
experiments. Still we can suggest some chemical modifications to our lead molecule,
in order to maintain its reactivation properties, while limiting its binding to the
active site of the uninhibited enzyme.
4.5 Lead optimization: the JDS family
The high affinity of KM297 for the native enzyme (IC 50=0.25 ± 0.05 µM against
hAChE) can be potentially a drawback in the design of a highly efficient reactivator.
An ideal reactivator should have a high affinity for the inhibited enzyme, and a low
affinity for the native enzyme, to avoid inhibition of AChE and subsequent secondary
effects within the nervous systems . Based on the structure of the TcAChE-KM297
complex, we designed a new family of molecules, carrying a chlorine atom at the
position 7 of the tacrine moiety (figure 4.18). The role of this substituent is to
decrease the affinity for the active site by creating a steric clash between the ligand
and the environment of the gorge, while maintaining the affinity for the PAS.
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Figure 4.19: A family of nine chlorinated derivatives of KM297. They all bear a
chlorine atom at position 7 of the tacrine group. Carbon linker lengths span from 3
to 5 atoms and saturated cycle sizes from 5 to 7 carbons.
4.5.1 Docking of chlorinated derivatives of KM297
We used our docking protocol to screen nine possible modifications of KM297 (figure
4.19) in order to asses the influence of the presence of chlorine, of the size of the
saturated ring and of the linker length (3, 4 or 5 carbon atoms), on the binding to
native and inhibited AChE. As predicted, calculated affinities (table 4.7) are good for
all of the compounds, the tacrine moiety of the reactivator interacting with the PAS
tryptophan. The docking score is particularly good for molecule number 1, featuring
a 4 carbon linker and a 6-carbon saturated cycle similarly to KM297. Julien de Sousa
from the University of Strasbourg then synthesized this molecule, named JDS207
hereafter. It was studied in more detail by flexible docking, crystallography and in
vitro reactivation tests.
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Molecule Binding energy (kcal/mol)
1 -13.1
2 -12.6
3 -11.6
4 -12.5
5 -11.7
6 -10.3
7 -11.6
8 -11.9
9 -13.0
Table 4.7: Docking scores of the KM derivative series in non-aged hAChE-VX.
Molecule number 1, featuring a 4 carbon linker and a 6-carbon saturated cycle is
the one with the best score in docking experiments.
4.5.2 Docking of JDS207
JDS207 (figure 4.19-1), the chlorinated analog that has the best affinity for the non-
aged form of hAChE-VX complex in docking experiments. We decided to examine
its docked conformations in more detail, also because, from the set of nine suggested
modifications, it is structurally closest to the lead molecule KM297. Docking results
reported in table 4.8 show that it has a calculated affinity lower than KM297 for
the non-aged hAChE-VX complex (-13.1 kcal M−1 vs -11.7 kcal M−1 for KM297).
However, docking to the native form of hAChE lead to the conclusion that KM297
is more affine than JDS207 for the native enzyme (-12.4 kcal M−1 for JDS207 vs -
13.3 kcal M−1 for KM297). This observation is also corroborated by in vitro affinity
measurements that show the IC50 of KM297 is 10 times higher than JDS207 for
native hAChE.
Structural observation of the binding modes to both the native and VX-inhibited
form of hAChE shows that none of the output conformations has a tacrine in the
active site, but they all feature binding at the PAS. None of the outputs features the
same rotation of Trp286 (Trp279 in TcAChE) as for KM297, but the lowest energy
solution has an analogous stacking of the tacrine between Trp286 and Tyr124. This
difference in stacking modes seems to be due to the presence of the chlorine sub-
stituent. This atom would lead to multiple clashes with the residue of the PAS region
if we try to model it in the docked conformation of KM297 previously discussed.
4.5. LEAD OPTIMIZATION: THE JDS FAMILY 77
Conformation Binding energy hAChE-VX (kcal/mol) Binding energy hAChE(kcal/mol)
1 -13.1 -12.4
2 -13.1 -11.7
3 -12.8 -11.5
4 -12.7 -11.4
5 -12.6 -11.2
6 -12.0 -10.9
7 -11.6 -10.8
8 -11.1 -10.5
9 -11.1 -10.4
Table 4.8: Docking scores for the 9 output conformers of JDS207 in non-aged
hAChE-VX and native hAChE.
4.5.3 Crystallographic structure determination of TcAChE-
JDS207 complex
Data collection and processing
TcAChE orthorhombic-1 crystals were soaked at 4◦C for 15 minutes in mother liquor
(36% PEG200, 100 mM MES pH 5.8) plus1 mM JDS207 and 5% DMSO. 180 images
with oscillation range of 1◦ per image were collected on the ID29 beam line at the
ESRF at a temperature of 100 K. Data, processed with XDS, were truncated with
AIMLESS at a resolution of 2.9 Å. Molecular replacement was performed using the
TcAChE dimer, PDB entry 1w75, as a template. Complete statistics are reported
in table 4.9.
Structure refinement
Refinement was performed using phenix.refine. Atom positions were refined, along
with atom individual B-factors. Restraints for the ligand JDS207 were calculated us-
ing phenix.eLBOW. Water molecules were added, using the automatic water search
in Coot and a comparison with the ones observed in the high resolution native
TcAChE structure 1ea5. After several refinement cycles and manual reconstruction
in Coot, refinement statistics converged (table 4.9).
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Data
Resolution range (Å) 46.3 - 2.9 (3.0 - 2.9)
Space group P 21 21 21
Unit cell (a,b,c (Å); α, β, γ, (◦)) 91.8 107.2 150.4 90 90 90
Total reflections 212283 (21557)
Unique reflections 33562 (3300)
Multiplicity 6.3 (6.5)
Completeness (%) 99.9 (99.9)
Mean I/sigma(I) 10.1 (2.9)
CC1/2 0.99 (0.90)
Refinement
R-work(%) 19.4 (27.2)
R-free (%) 26.6 (31.5 )
RMSD bond lengths (Å) 0.097
RMSD bond angles (◦) 2.28
Atoms in asymmetric unit 9051
Ramachandran favored (%) 92
Ramachandran outliers (%) 0.19
Average B (Å2) 32.5
Table 4.9: Data and refinement statistics for TcAChE-JDS207 complex. Values
between parenthesis refer to the highest resolution shell.
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(a) (b)
Figure 4.20: 2Fo-Fc electron density map of JDS207 bound at the peripheral site of
TcAChE, represented at 1 σ level by the blue mesh. Green and red meshes show
the Fo-Fc electron density map at +3 σ and -3 σ level respectively. JDS207 is folded
on itself with the tacrine moiety in between the aromatic ring of Trp279 and that
of the pyridine aldoxime. Monomers A and B present the molecule in two different
orientations, as shown in panels a and b, respectively.
Structure analysis
The electron density map showed the presence of a tacrine moiety at the PAS, stack-
ing in front of Trp279, which is again found in its native conformation (figure 4.20).
Orienting JDS207 is easier than KM297, due to the presence of the chlorine atom,
which is clearly defined, being the strongest peak in the electron density map. As
for the structure of TcAChE-KM297 described above, the pyridine aldoxime part is
stacked against the tacrine part, forming a triple aromatic stacking at the PAS. Also
in this case, the presence of the residue Gln185 from a symmetry related enzyme of
the crystal seems to help in the stabilization of this conformation (figure 4.21), along
with a hydrogen bond with Tyr334. To overcome this bias, soaking with a trigonal
crystal was performed, but the ligand was not observable in the electron density
map. The electron density for the linker is better defined in monomer B than in the
case of KM297, which helps in fitting the ligand in the proper orientation. There
is no electron density for the linker in monomer A. This allowed us to model the
reactivator in an alternative orientation, with the NH group of the tacrine pointing
towards the outside of the gorge.
In contrast to what was observed in the TcAChE-KM297 structure (figure 4.12),
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(a) (b)
Figure 4.21: Position of the JDS207 molecules in the gorge of TcAChE. Monomers
A and B feature two different orientation, with the one in a seeming more prone to
reactivation.
there is no sign of the presence of the reactivator in the active site of the enzyme
(figure 4.21). A small electron density peak in front of Trp84 is not different from
what is also generally observed in crystals of native TcAChE, and could be related
to the presence of a low-weight PEG molecule from the mother liquor solution.
4.6 Structure determination of native hAChE
The vast majority of the crystallographic structures of AChE were obtained, over
the last two decades, either from TcAChE or mouse AChE. Only a small subset is
from hAChE. Also until 2010, the only known way to obtain good-quality crystals of
the human enzyme was to crystallize the complex with the snake toxin fasciculine-2.
This toxin has the inconvenience of occupying the PAS and restraining access to
the active site gorge. Efforts were made to produce crystals of native hAChE using
truncated forms of the enzyme (Cheung et al., 2012; Dvir et al., 2010). Cheung’s
hAChE, which was truncated at the N-terminus position 1 and C-terminus position
544 yielded the best crystals to date, allowing to solve structures at 2.1 Åresolution.
In the meantime, and as described in the following, we also managed to obtain
crystals of hAChE truncated at residue 544, thus cutting the long C-terminal helix,
and solved a structure of this form of hAChE.
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(a) Condition 1 (b) Condition 2 (c) Condition 3
Figure 4.22: Hits from crystallization screening. Condition 1: 100 mM Bicine pH 9,
20% PEG 6000; Condition 2: 50 mM Hepes pH 7, 1.6 M Li2SO4, 50 mM MgSO4;
Condition 3: 0.1 M trisodiumcitrate pH 5.6, 0.1 M Li2SO4, 12% PEG6000
4.6.1 Enzyme production
Frozen CHO-K1 cells previously transfected with a pGS-hAChE-L544Stop vector
carrying the glutamine synthetase gene marker, and stably expressing variant L544Stop
hAChE, were thawed and cultured in UltracultureTM medium (Lonza, Belgium)
containing 50µM methionine sulphoximine (MSX) for selection pressure. The cells
were expanded in flasks before being transferred to roller-bottles for enzyme produc-
tion. The culture medium, 1/3 Ultraculture (Ozyme) and 2/3 Ham’s F12 (Dutscher),
containing the secreted enzyme, was changed every 3-4 days. Our form of enzyme
does not contain His tag and was purified to homogeneity as described in Carletti
et al. (2008). Shortly, protein was precipitated from the media by ammonium sul-
fate. After dialysis, the enzyme contained in the pellets was purified on a sepharose-
4B/procainamide affinity column then a monoQ anion-exchange chromatography
column. Fractions containing high hAChE activity were pooled, buffer was ex-
changed to match that used in Cheung et al. (2012) (10 mM HEPES pH 7.0 and 10
mM NaCl), and the enzyme was finally concentrated to 12-16 mg/mL.
4.6.2 Crystallogenesis
Crystallization conditions were at first screened with the Hampton screens 1-6 at the
EMBL high throughput crystallization laboratory (HTXLab) in Grenoble. After two
months of monitoring the plates, we found crystals in three conditions (figure 4.22).
We tried to reproduce them in hanging drop 24 wells plates, but only condition
number 2 yielded crystals. Screening the concentrations of Li2SO4 and MgSO4, we
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Figure 4.23: Crystals of hAChE-L544Stop from optimized conditions (100 mM
Hepes pH7, 1.7M Li2SO4, 60 mM MgSO4) Scale bar correspond to 100 µm.
managed to grow bigger crystals of about 100 µm in their longest dimension in large
numbers (figure 4.23). Optimized conditions are 100 mM Hepes pH 7, 1.7 M Li2SO4,
60 mM MgSO4. These crystals were cryo-protected with mother liquor containing
18% glycerol and flash-cooled in liquid nitrogen to be taken to the synchrotron beam
lines.
4.6.3 Data collection and processing
We collected data from several crystals obtained in the optimized condition number
2 on the beam line ID23-1 at the ESRF, at a temperature of 100 K. Due to the high
concentration of Li2SO4, about half the collected data sets presented large noise
from powder diffraction of salt micro-crystals. It was possible for iMOSFLM (Battye
et al., 2011) to automatically index them in P6 group with unit cell parameters of
211, 211, 115 Å, 90◦ 90◦ 120◦ similar to that reported by Dvir et al. (2010) for the
L544Stop variant expressed in Drosophila cells. A total of 120 images was collected,
with an oscillation range of 1◦ per image. Data were successfully processed with XDS
with the P6 space group unit cell parameters and integrating 80 images yielded a
complete data set. Using AIMLESS-POINTLESS in CCP4, we found that the actual
space group was P61, and that the data set was truncated at a resolution of 3.4 Å.
Matthews coefficient calculation suggests that the most probable asymmetric unit
composition is of 4 monomers, but after molecular replacement, only one dimer of
AChE was found. This yields a solvent content in the crystals of 75%. The low
protein content of this crystal form may be the cause of the low diffraction power
(Kantardjieff and Rupp, 2003). For this reason, our efforts are still devoted to the
reproduction of the screening hits number 1 and 3.
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Data
Resolution range (Å) 49.0 - 3.4 (3.5 - 3.4)
Space group P 61
Unit cell (a,b,c (Å); α, β, γ, (◦)) 210.9 210.9 116.3 90 90 120
Total reflections 288467 (29202)
Unique reflections 40653 (4058)
Multiplicity 7.1 (7.2)
Completeness (%) 100.00 (99.98)
Mean I/sigma(I) 10.9 (2.0)
CC1/2 0.995 (0.664)
Refinement
R-work(%) 17.3 (30.4)
R-free (%) 21.0 (34.5)
RMSD bond lengths (Å) 0.010
RMSD bond angles (◦) 1.35
Ramachandran favored (%) 83
Ramachandran outliers (%) 4.1
Clashscore 12.4
Average B-factor 94.6
Table 4.10: Data collection and refinement statistics for hAChE-L544 stop. Values
between parenthesis refer to the highest resolution shell.
4.6.4 Structure refinement
Refinement was performed using phenix.refine. Atom positions were refined, along
with atom individual B-factors. Water molecules were added, using the automatic
water search in Coot and a comparison withe the ones observed in the high reso-
lution native hAChE structure 4ey4. The flexible loop 492-498, not present in the
replacement model, has been reconstructed with the fit_loop utility in Coot and
adjusted into the electron density map by real space refinement. After several re-
finement cycles and manual reconstruction in Coot, refinement statistics (table 4.10)
converged and provided us with interpretable structures.
4.6.5 Structural analysis
As observed in orthorhombic crystals of TcAChE, and also for hAChE (Dvir et al.,
2010), an asymmetric unit contains a dimer of the enzyme. The two monomers
interact through the 4-helix bundle. The truncation of the C-terminal helix before
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Figure 4.24: A dimer of hAChE
residue 544 rigidifies the helix and favorizes packing of the enzymes in the crystals.
Crystal packing is analogous to that observed in the structure of Dvir et al.
(2010). In this arrangement of molecules, the gorge of monomer A is blocked by the
presence of the symmetry related enzyme in the crystal. In particular, the flexible
loop 492-498, which is for instance not observed for monomer B by Cheung et al.
(2012), is visible in our case and participates in crystal contact, by being trapped
at the entrance of the gorge of monomer A of the symmetry related molecule, with
Arg493 interacting with Trp286 and Tyr72 (figure 4.25).
Clear electron density corresponding to sugars are observed for the two monomers
in front of Asn350 and for monomer B close to Asn265, two known sites of glycosyla-
tion and was modeled with NAG molecules. The electron density map corresponding
to these sites for monomer A was too weak to be modeled with a particular sugar.
During the refinement process, a strong positive peak at 6 σ level in the Fo-Fc
electron density map suggested that some ligand could be situated in front of the
catalytic serine in both of the two monomers. We modeled an acetate group in this
density, covalently bound to the catalytic serine. Its presence, already presented
in a structure of native mAChE (PDB acces code 2xud, (Bourne et al., 2010b)),
is able to explain the electron density and to slightly improve the statistics of the
refinement.
Another unknown density is present along the gorge, spanning from the PAS to
the level of Trp86. This is reminiscent of the density usually modeled as a PEG
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Figure 4.25: Crystal contact between two hAChE molecules. We can observe the
flexible loop 490-495 of chain B, in red, interacting with the PAS of chain A, in
green.
molecule in TcAChE structures, except than no PEG was present, neither in the
crystallization conditions, nor in the cryo-protecting solution. We decided to model
it with a series of dummy atoms.
4.7 Conclusions
In this chapter we have shown the process leading from the rational design of a
neutral reactivator, KM297, to the optimization of its derivatives, in particular
JDS207. This process has involved docking studies, molecular dynamics simulations
and x-ray crystallography. The molecule KM297 and all its potential derivatives
were patented by our collaboration (Kliachyna et al., 2013).
We managed to observe through flexible docking that KM297 can bind at the
PAS of VX-inhibited AChE, both to its native state and to alternative conformations
of Trp286, analogous to the one observed for AChE inhibitors NF595 (PDB acces
code 2cek), A8B (PDB acces code 1odc) and TZ5 (PDB acces code 1Q83).
Molecular dynamics simulations confirmed that tacrine is a PAS ligand adapted
for the design of bifunctional reactivators, due to the stability of KM297 within the
enzyme. Measuring the distance between the oxygen atom of pyridine-aldoxime and
the VX phosphor atom along the simulation, we were able to conclude that a 4
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carbon linker has the optimal length to promote reactivation.
We managed to solve multiple crystal structures, in order to characterize the
interactions between our reactivators and TcAChE, both native and inhibited by an
OP. KM297 has two binding sites in native TcAChE, one at the peripheral site and
the other into the active site. Only binding at the PAS, although biased by a crystal
artifact, can lead to reactivation, but this requires that the gorge is not occupied by
another ligand. In our structures, the presence of another KM297 molecule bound
at the active site makes impossible to observe the oxime moiety of the KM297 at
the PAS reaching the catalytic triad.
Solving the structure of non-aged TcAChE-tabun has allowed us to show that
the presence of tabun induces a reorientation of the catalytic histidine in TcAChE,
also reducing the accessible volume in the active site.
We deduce that, as already shown by docking studies, KM297 cannot bind within
the active site of the inhibited enzyme, but only at the PAS. This was confirmed
by solving the structure of the ternary complex TcAChE-NEDPA-KM297. NEDPA
is a tabun surrogate that leads to the same adduct on the catalytic serine, but is
less dangerous to manipulate. In the ternary complex, KM297 was observed to bind
only at the PAS, but again the oxime could not enter the gorge, again due to a
packing artifact.
Without a structure of the ternary complex with the reactivator in the proper
position, we decided that the first optimization to make on the molecule was to force
binding only at the PAS. The family of JDS molecules was designed from KM297
by adding a chlorine substituent on the tacrine moiety. Docking studies have shown
that this modification is effective, and this was also confirmed by the crystallographic
structure of the TcAChE-JDS207 complex, where the ligand is only found at the
PAS of the native enzyme.
All the crystallographic structures of TcAChE in complex with the reactivators
KM297 and JDS207 presented in this chapter were obtained by soaking orthorhombic-
1 crystals. As mentioned above, the reactivator conformation is affected by the pres-
ence of a symmetry related enzyme, creating a crystallographic artifact in TcAChE-
reactivator complex structures. In order to overcome this bias, we could either
perform co-crystallization or soakings in trigonal crystal of TcAChE, this space
group being characterized by a different contact between symmetry related enzymes
in the PAS region. However, the presence of the ligand was not observed at the
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PAS in TcAChE crystals grown in the presence of KM297, and we didn’t manage
to obtain crystals in the presence of JDS207. Trigonal crystals, which grow in the
same conditions as the orthorhombic-1 ones, were not obtained in our crystallization
experiments, and we did not succeed in performing micro-seeding from old crystals
of this form.
Both KM297 and JDS207 were tested in vitro to know their reactivation con-
stants against OPs and IC50 for native hAChE. They both present a good reacti-
vation capability for VX-inhibited hAChE, with a reactivation constant kr2 = 22
mM−1min−1 for KM297 and kr2 = 13 mM−1min−1. As a comparison, HI-6, the best
molecule on the market today, has a kr2 = 9 mM−1min−1 against VX. JDS207 has
an IC50 for hAChE (IC50 = 2.33 ± 0.18 µM) 10 times higher then that of KM297
(IC50 = 0.25 ± 0.02 µM). As discussed, a lower affinity for the native enzyme is a
positive point in the design of a reactivator, so JDS207 appears to be a promising
optimization of our lead KM297.
The efforts in crystallizing human AChE were focused on the mutant hAChE544stop,
that was found to crystallize in three different conditions. Crystals grow in Li2SO4
similar to those obtained by Dvir et al. (2010). These crystals couldn’t be used for
soaking of our reactivators, due to the inaccessibility of the active site of one of the
two monomers and to the difficulties of solubilizing hydrophobic molecules in high
salt concentrations. The high solvent content of these crystals (75% with respect
to an average of 43% in the PDB) is a limiting factor. For this reason, it will be
important in the future to reproduce the other screening hits and verify if they can
lead to better diffracting crystals like the ones obtained by Cheung et al. (2012).
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Chapter 5
Building a flexible docking receptor library
The utility of structural dynamics in drug design is introduced in chapter 2. While in
chapter 4 we presented a practical case of rational drug design targeting alternative
conformation of a specific residue, an in-depth characterization of the conforma-
tions accessible to side chain is needed for more general cases. In this chapter we
will present how information from molecular dynamics simulations can be used to
design a library of conformers. Simulations were ran both on the human AChE
and on TcAChE, for which many X-ray structures already exist. In this chapter we
will discuss about simulation of native hAChE and TcAChE. Comparing different
simulation strategies, one long simulation versus a combination of multiple shorter
simulations, we will argue that combining multiple short simulations is preferable
for sample the populations of side chains rotamers. With the multiple simulations
approach, we compared the dynamics of key residues in the gorge of TcAChE and
hAChE, revealing differences in their dynamical behavior. Flexible docking meth-
ods are usually not specific to the dynamics of the receptor, but are rather based
on statistical properties of a particular amino acid. We developed a method that
takes advantage of MD simulations to generate a receptor library that reflects the
motions proper to specific residues of AChE.
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5.1 Simulations of native AChE
5.1.1 Material and methods
The simulations presented in this chapter were performed using as a starting model
either the native TcAChE monomer (PDB acces code 1ea5) or the native hAChE
monomer (PDB acces code 4ey4) as a starting model. The simulation methodology
is exactly the same for the two enzymes for the sake of comparison. Protein models
was inserted in a cubic box of 10× 10× 10 nm3, with periodic boundary conditions
and solvated in simple point charge waters (SPC-E). After charge equilibration with
the appropriate number of counter ions, the energy was minimized. The temperature
was kept at 300 K by coupling to a Berendsen thermostat at using with a coupling
time of τT = 0.1 ps (Berendsen et al., 1984). Pressure was maintained at 1 bar by
coupling to a Berendsen barostat with compressibility of 4.5×10−5 bar and τP = 1.0
ps. Bond lengths were restrained with the LINCS method (Hess et al., 1997) and the
electrostatic interactions were calculated using the particle-mesh Ewald algorithm
(Essmann et al., 1995; Darden et al., 1993). Output coordinates were written every
10 ps. Using this methodology, a set of 20 trajectories of 20ns were produced for
both TcAChE and hAChE. Initial velocities differed in all simulations, owing to the
use of a different random seed. For both TcAChE and hAChE, we also ran a 200 ns
trajectory using the same protocol as described above. Simulations were performed
using GROMACS and the GROMOS56 force field.
Dihedral angles for the side chains of all residues in the protein were calculated
with the same time resolution using the program g_chi and the -rama option. Con-
formations of residues like tyrosine and phenylalanine are identical when rotating
by 180◦ around χ2. This has to taken into account when comparing dihedral sam-
pling. For comparison of the sampling between the long and the multiple short
trajectories, every crystallographic structure of TcAChE available in the PDB was
downloaded and assembled into an multi-state PDB file. This file format can be
processed with the same tools used for the calculation of dihedral angles from MD
simulation trajectories.
Figures were produced using Python and matplotlib (Hunter, 2007).
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(a) 200 ns, His440 (b) 10× 20 ns, His440
(c) 200 ns, Glu199 (d) 10× 20 ns, Glu199
Figure 5.1: Dihedral angles for side chains of TcAChE residues His440 and Glu199,
calculated from a 200 ns MD simulation (a, c) and 10×20 ns simulations (b, d). The
heat map represents the density of points on the plane, and white dots correspond
to the conformations of the crystallographic structures of TcAChE , both native
and in presence of ligands, in the PDB. Native structure is indicated by the green
star.
5.1.2 Sampling of side chain conformations in one long versus
multiple short simulations
We compared the sampling of side chain dihedral angles in one long simulation
(200 ns) versus a combination of multiple shorter ones (10 × 20 ns). Evaluation
of sampling efficiency was based on the inspection of (χ1, χ2) plots calculated for
different amino acids in the gorge of TcAChE. The choice of TcAChE over hAChE
was led by the fact that there are 79 TcAChE structures in the PDB as of April
92 CHAPTER 5. BUILDING A FLEXIBLE DOCKING RECEPTOR LIBRARY
2014, and 9 hAChE structures devoid of FAS-2. Comparison with crystal structures
would therefore be more meaningful for TcAChE. We chose a set of amino acids that
occupy key regions in the gorge of TcAChE, and which were observed previously to
have different degrees of flexibility. We chose the active site residues His440, Trp84
and Glu199, the peripheral site Trp279, the bottleneck residue Phe330, and Tyr442,
a residue involved in the dynamics of the backdoor region (Sanson et al., 2011).
Comparison was made between two data sets of 20000 (χ1, χ2) points each. One
is calculated from a 200 ns simulation (‘long‘ data set) and the second from a set
of 10 different 20 ns simulations (‘short‘ data set), randomly chosen from the 20
trajectories we produced. To complete the analysis, sampling has been compared
to all the 79 crystallographic structures of TcAChE available in April 2014 in the
PDB. Results are shown in figures 5.1, 5.2, 5.3, where the heatmap represents the
simulation results and the white dots correspond to the conformations found in the
different crystal structures.
We can observe that almost all the white dots are found over occupied regions of
the heatmap both for long and short simulations. The most striking exceptions are
the two conformers of His440 (χ1, χ2)=(100,90) and (χ1, χ2)=(120,95), which are
only rarely found in the 10×20ns simulations set and never in the 200 ns simulation
(figure 5.1). This particular conformational state is found in PDB structures 1vxr
and 1gqr. In the first, it is induced by the presence of nerve agent VX at the
active site that, as discussed above for tabun, features a conformational change
of the catalytic histidine, induced by the presence of the OP. In the second, the
conformational change is induced by the presence of rivastigmine in the acitve site
(Bar-On et al., 2002).
Given the equivalency of the two simulation methods for reproducing conforma-
tional side chain eterogeneity in known crystal structures, we can now investigate
how they perform in terms of sampling of the whole conformation space for each
residue. Two characteristics are compared: the number of observable conformations
and the separation between them. The general trend we observe is that using many
short simulations we can find more and better separated occupied regions in the
(χ1, χ2) plane.
Histidine 440 and glutamate 199 His440 was found to display more conforma-
tions in the multiple short simulations dataset, as compared to the long one (figure
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5.1 a-b). Based on occupancies, the first of these two conformers (300,300) appears
the most probable. As mentioned already, the coverage by simulations of confor-
mations observed in crystallographic structures is roughly equivalent in the short
and long datasets. The short data set is however less biased by initial velocities,
allowing to single out false positives in the long dataset. For example, the transition
from peak (200,50) to peak (200,250) is not a proper local minimum of energy, but
only due to a slow rotation rate in the 200 ns simulation. Concerning Glu199 (figure
5.1 c-d) is less straightforward. Its conformations are better separated in the long
simulation data set, and the recovering of the different areas is different between the
two simulations sets, contrarly to what is observed for all the other residues.
Tryptophan 84 and 279 An interesting feature is observed for the active site
residue Trp84 in figure 5.2 a-b. In the long simulation, only two rotamers are ob-
served, while in the many short simulation data set at least five major conformations
appear. Movements of this residues were observed in MD simulations to be related
to the flexibility of the Ω loop, requiring timescales longer than the 20 ns of the
simulation. The high flexibility of this residue in MD simulations was already ob-
served by Xu et al. (2008), and has been ascribed to the influence of crystal packing
on the mobility of the Ω loop region. In the many short simulations approach the
different velocities seeds accelerate this evolution by sampling different regions of
the conformational space one at the time.
The case for the peripheral site Trp279, in figure 5.2 c-d, known to be one of
the most flexible residues in the enzyme is different. In this case, the long and
short simulations cover approximatively the same conformational space, with the
exception of the (50,100) region for 10 × 20. The many short simulation approach
in this case allows more precise separation the various conformations, that appear
less broadend in the (χ1, χ2) plots.
Phenylalanine 330 and tyrosine 442 Phenylalanine and tyrosine demand a
more careful observation. As mentioned above, we have to consider that their con-
formations are identical if rotated by 180 degrees around their χ2 angle. We show an
example in figure 5.3, where we compare dihedral angles for Phe330, the bottleneck
residue and Tyr442, a residue involved in the opening of the backdoor. In both
cases, no major differences were observed, between the 200 ns and the 10 × 20 ns
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(a) 200 ns, Trp84 (b) 10× 20 ns, Trp84
(c) 200 ns, Trp279 (d) 10× 20 ns, Trp279
Figure 5.2: Dihedral angles for side chains of TcAChE residues Trp84 and Trp279,
calculated from a 200 ns MD simulation (a, c) and 10×20 ns simulations (b, d). The
heat map represents the density of points on the plane, and white dots correspond
to the conformations of the crystallographic structures of TcAChE , both native
and in presence of ligands, in the PDB. Native structure is indicated by the green
star.
simulations, the region at peak (300,300) found in the 200 ns simulation for Tyr442
being identical to the one at (300,100) in the 10x20 ns simulation. The two meth-
ods of sampling account equivalently for the crystallographic conformations and the
same regions are covered by the heatmap.
This qualitative analysis confirmed that the method of combining multiple short
simulations is more adapted than a single long simulation to reproduce the confor-
mational heterogeneity of amino acid side chains.
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(a) 200 ns, Phe330 (b) 10× 20 ns, Phe330
(c) 200 ns, Tyr442 (d) 10× 20 ns, Tyr442
Figure 5.3: Dihedral angles for side chains of TcAChE residues Phe330 andTyr442,
calculated from a 200 ns MD simulation (a, c) and 10×20 ns simulations (b, d). The
heat map represents the density of points on the plane, and white dots correspond
to the conformations of the crystallographic structures of TcAChE , both native
and in presence of ligands, in the PDB. Native structure is indicated by the green
star.
5.1.3 Convergence of the multiple short simulations method
After observing qualitatively that the approach of combining multiple different short
simulations is more appropriate to sample side chain conformers, we investigated if
the sum of short trajectories converges, or if adding more trajectories systematically
and significantly improves the coverage of the conformational space. We developed
an iterative method to evaluate the evolution of the surface of (χ1, χ2) plots as
a function of the number N of trajectories used to generate the observed dihedral
angle distribution. We consider the quantity I (equation 5.1), defined as the relative
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increase in the occupied surface SN of the (χ1, χ2) when adding a new trajectory to
the data set.
I =
SN+1 − SN
SN
(5.1)
The Python functions reported below (listing 5.1) were used for this analysis.
The first function, named countOnes, is used to calculate how many pixels are
occupied, i.e different from 0, in a (χ1, χ2) plot, thus determining the surfaces SN .
The second one, ControlSurface, iteratively combines the 20 trajectories in random
order, measuring the surfaces SN and SN+1 calculated from N and N+1 trajectories.
If the increment I calculated with the two surface values is greater than a chosen
threshold, the new trajectory is accepted as useful for additional sampling. For the
next iteration, the program will considerN = N+1, and continue the analysis. After
20 iterations, the final value of Ntot, representing the number of useful trajectories,
is stored. The same test is performed multiple times choosing the trajectories in
random order, to ensure that the result is not dependent on the order in which
trajectories were summed. Finally, the average Ntot obtained from the repetitions
of the test is printed for each residue, along with the average value of the surface
SNtot .
def countOnes (H) :
b = 0
for x in H:
for y in x :
i f y == 1 :
b+=1
return b
def Contro lSur face ( f i l ename ) :
for s t a r t in head :
print s t a r t
modX,modY = np . l oadtx t ( f i l ename+sta r t , u s e c o l s =(0 ,1) , unpack=
True )
B, xmod , ymod = np . histogram2d (modX,modY, b ins =(360 ,360) , normed
= False )
model = [ "a" , "b" , "c" , "d" , "e" , " f " , "g" , "h" , " i " , " j " , "k" , " l " , "m" , "n
" , "o" , "p" , "q" , " r " , " s " , " t " ]
model . remove ( s t a r t )
counter = 1
for s in range (0 , 19 ) :
ind = random . cho i c e (model )
model . remove ( ind )
x , y = np . l oadtx t ( f i l ename+ind , u s e c o l s =(0 ,1) , unpack=True )
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H, xed , yed = np . histogram2d (x , y , b ins =(360 ,360) , normed =
False )
BinH = H > 0
BinB = B > 0
CompareH = BinH∗ I
CompareB = BinB∗ I
Result = CompareH − CompareB
thre sho ld = countOnes (B) ∗ f loat ( c u t o f f ) /100
B +=H
i f countOnes ( Result ) > thre sho ld :
counter += 1
counter s . append ( counter )
s u r f a c e . append ( countOnes (BinB) )
return (np . average ( counter s ) , np . average ( s u r f a c e ) )
Listing 5.1: Python code for the surface convergence test
The output of the test is represented in figure 5.4. Each point represents, for
a single residue1, and the average surface S occupied on its (χ1, χ2) plot as a
function of the average number of trajectories which passed the convergence test.
15 trajectories would be accepted with a threshold of 1% (panel A) and 12 if we
chose a threshold of 2% (panel B). The sum of 10 trajectories satisfies a threshold
condition between 2% and 5%, i.e. a situation between panels B and C. A rough
estimate indicates that a single conformational island accounts for 5% of the total
surface. The choice of 10x20 ns simulations2 thus fully samples the conformational
space of each residue3. Interestingly, the number of trajectories required to converge
does not depend on the residue considered, but only on the chosen threshold.
1We analyzed the convergence of the sampling for the aromatic residues in the gorge: Tyr70,
Trp84, Phe120, Tyr121, Trp233, Trp279, Phe288, Phe290, Phe330, Phe331, Trp432, Tyr442
2Used to compare with a 200 ns simulation
3This conclusion stands for residues with dihedral orders up to 2 up to χ2, but has to be
demonstrated for higher dihedral orders
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Figure 5.4: Results the convergence test for the many short simulations method.
Each panel represents the results for a different threshold value. Each dot represents,
for a single residue, the average surface covered for a residue as a function of the
average number of trajectories required to obtain it. We can see that the cutoff
choice provides similar results, independently from the kind of residues used.
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(a) TcAChE-Phe330 (b) hAChE-Tyr337
Figure 5.5: Dihedral angles for Phe330 (TcAChE) and Tyr337 (hAChE) as assessed
in 10x20 ns MD simulations. The heat map represents the occurrence of each dihe-
dral pair in logarithmic scale.
5.1.4 Comparison of human and Torpedo californica AChE
dynamics
The comparison between human and Torpedo californica AChE is fundamental to
determine if, using TcAChE as a model for drug design, we eventually miss some
fundamental conformational or dynamical differences that could influence the de-
sign of molecules targeting hAChE. It is important to remember that the gorge
environment in the two species is very similar, with the only difference being residue
Phe330 in TcAChE that replaces Tyr337 in the human enzyme. This difference
could account for subtle alteration of ligand binding modes, observed for example
by Cheung et al. (2012) for donepezyl. They observe that the nitrogen of the piperi-
dine of donepezyl in hAChE interacts with Tyr337 through an hydrogen bond with
a water molecule. In TcAChE, this interaction occurs with Tyr121, on the opposite
side of the bottleneck, leading to a different orientation of the piperidine in the two
species. We decided to observe whether or not this different binding mode could be
due to a difference in side chains dynamics. The analysis is based on the comparison
of 10× 20ns simulations for both hAChE and TcAChE.
At first, a clear difference is observed (figure 5.5), as expected, for the flexi-
bility of Phe330 in TcAChE with respect to Try337 in hAChE. Conformations of
Phe330 accessed in silico are more numerous and broadened than those of Tyr337.
Also, Tyr337 does not assume a χ1 > 200 in contrast to Phe330. The size of each
100CHAPTER 5. BUILDING A FLEXIBLE DOCKING RECEPTOR LIBRARY
(a) TcAChE-Trp279 (b) hAChE-Trp286
Figure 5.6: Dihedral angles for Trp279 (TcAChE) and hAChE Trp286 (hAChE) as
assessed in 10x20 ns MD simulations. The heat map represents the occurrence of
each dihedral pair in logarithmic scale.
conformational island provides an idea of the stability of this particular dihedral con-
formation: the smaller the area, the more rigid the conformation. We can explain
this difference by observing that the phenoxyl group of Tyr337 forms a hydrogen
bond with the phenoxyl of its neighbor Tyr124. An analogous tyrosine is found also
in TcAChE (Tyr121) but in the absence of a hydroxyl group for Phe330, no hydro-
gen bond can be formed, leaving thus more freedom to Phe330, which can explore
a larger conformational space.
As discussed above, one of the most flexible residues in AChE is the peripheral
site tryptophan. Observing the results for Trp279 in TcAChE and Trp286 in hAChE
simulations (figure 5.6) we can see that they assume the same 5 main conformations,
but their relative distribution is different. A sixth conformation is observed only for
Trp279 at (50, 270). Trp279 tends to be found more frequently in its native crystal-
lographic position (χ1, χ2)=(300,90), represented on the heatmap by a star, while
the most probable position for Trp286 is found at (χ1, χ2)=(180, 90). Also, the two
conformational islands at the top of the plots (χ2 > 200) appear more populated
for TcAChE than for hAChE. As discussed in the previous chapter, the reactivators
we developed (KM297 and JDS207) target an alternative conformation of the pe-
ripheral site tryptophan, which was observed in crystallography only for TcAChE.
This difference in the flexibility of the residue in the two species, as observed in MD
simulations, has to be taken into account carefully in the design process.
Another fundamental residue for the functioning of the enzyme is Trp84 (Trp86
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(a) TcAChE-Trp84 (b) hAChE-Trp86
Figure 5.7: Dihedral angles for Trp84 (TcAChE) and Trp86 (hAChE) as assessed in
10x20 ns MD simulations. The heat map represents the occurrence of each dihedral
pair in logarithmic scale.
in hAChE), which is involved in the stabilization of the substrate and in the traffic
of reaction products. We can observe in figure 5.7 that Trp86 in hAChE remains in
its native conformation. Even if its χ2 angle can span a bit more than 100 degrees,
its χ1 angle is fixed in its initial position. On the other hand, Trp84 in TcAChE can
move around its χ1 angle, assuming five main conformations, the most interesting
being the one at (χ1, χ2)=(50,70) and corresponding to a configuration in which the
backdoor channel is completely open, as observed in MD simulations (Xu et al., 2010;
Sanson et al., 2011). The different dynamics of the active site tryptophan between
hAChE and TcAChE in particular is intriguing. No major structural differences are
present in this region of the enzyme between the two species, but the hydrogen bond
between Trp86 and Tyr449 appears to be more stable in hAChE than in TcAChE.
There maybe some backbone movements of the Ω-loop that could differ between the
two species, leading to different dynamics on the short 20 ns timescale.
We can conclude that hAChE and TcAChE present key dynamical differences
in residues which are fundamental for ligand binding and trafic in the gorge, like
Trp84, Trp279 and Phe3304. Their different behavior has to be taken into account
when designing ligands targeting hAChE.
4Trp86, Trp286 and Tyr337 respectively in hAChE
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5.2 Generation of receptors library
Once we verified that the ensemble of 10 short trajectories is suitable for model-
ing side chain dynamics, we searched for a method to produce a receptor library
for flexible docking, based on the dihedral angles distributions calculated from the
simulations. At first, we looked for methods to find the most probable rotamers
for a set of residues of interest. These rotamers have then been used to generate
the docking receptors. Attention has been paid to possible clashes that could arise
between neighboring residues from this generation method and to the role of water
molecules in the process.
We have chosen to work with TcAChE instead of hAChE for a first validation
of the method. Even if we have shown that the two species have important dynam-
ical differences, the choice of TcAChE is justified by the fact that more structures
are available in the PDB, so that the validation of our results with the available
structures can be more conclusive.
5.2.1 Extraction of the most probable side chain conforma-
tions from MD simulation trajectories
Data sets from 10 × 20 ns trajectories are stored by Gromacs to a file containing
(χ1, χ2) pairs on each line. They are easy to be processed with a Python code, in
particular by creating Numpy N-dimensional arrays, with N being the maximum
dihedral order for each residue. We tested two methods for extracting the most
probable conformations for the residues chosen to be flexible in the subsequent
docking phase.
The first method is restricted to N=2, because the usage of image processing
consumes too much computational resources for arrays of more than 2 dimensions.
At first, we populate a 2-dimensional histogram with the different (χ1, χ2) pairs for
each residue. We chose a bin size of 3◦. We consider that this choice of binning is
fine enough. For example, for a tyrosine rotating by an angle of 3◦ around its χ1
angle, the oxygen of the phenol group moves by 0.3 Å only. Once the histogram
is filled, we apply a Gaussian filter to smothen the peaks and finally search for
the position of local maxima with a photographic filter from the SCikit-NDImage
module (van der Walt et al., 2014). An example of the output of this function is
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Figure 5.8: Peak coordinates for TcAChE residue Trp279, as found from our code.
Red dots represent the coordinates of all the maxima found by the program. For
each circle, only the coordinates of the highest peak are considered.
shown in figure 5.8 for the peripheral site residue Trp279. The program then simply
writes the coordinates of each of the maxima to a file that can be passed as an input
to the receptor generation program.
The second method is easier and therefore less heavy. It is also not limited to
residues with only two dihedral. At first we generate a normalized N-dimensional
array containing the distribution of observed χN angles. A normalized array can be
considered as a probability distribution P (χ1, χ2) for the occurrence of a (χ1, χ2) pair
during the MD simulations. We then generate random pairs following this distri-
bution by using a rejection sampling algorithm. Figure 5.9 shows an example of
100 random points generated following the simulated dihedral angles distribution of
Trp279.
def randomHist ( pdf ) :
normPdf=pdf /pdf .sum( ) #normal ize
check = False
while check==False :
ch i1= np . random . rand int (0 , 120)
ch i2= np . random . rand int (0 , 120)
z = np . random . uniform (0 , 1 )
i f z<normPdf [ chi1 , ch i2 ] :
check = True
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Figure 5.9: Results for the rejection sampling method, applied to TcAChE residue
Trp279. 100 green dots are generated following the heat map as a distribution of
probability.
return 3∗ chi1 , 3∗ ch i2
Listing 5.2: Python code for the rejection sampling method.
The function randomHist (listing 5.2) for the two-dimensional case, generates a
random (χ1, χ2) pair using the array as a distribution of probability.
5.2.2 Modification of TcAChE structure to generate recep-
tors
Two codes, described in detail in appendix A, were developed to modify the side
chains of TcAChE residues according to dihedral pairs obtained with either the
peak finder or the rejection sampling method. Both of them are able to produce
receptor structures, but while the peak finder implies a combinatory approach to
the problem, which means the number of receptors grows exponentially with the
number of residues included5, the rejection sampling allows the user to chose the
number of output structures. The rejection sampling method is faster and more
easily adaptable, especially to the case of side chains with dihedral order larger than
5Nreceptors =
n∏
i=1
Xi where Xi is the number of possible peaks per residue.
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2. We produced, using the rejection sampling method, 300 structures and performed
a first validation of the methodology. Results for some ligands are reported below
(section 5.4).
5.3 Validation of the method: docking routines
Once we verified that the method for the production of the library is reliable, a
docking routine has been created to use the library conformers as a set of receptors
and validate the approach. The validation consisted in evaluating the capability,
for our method,to reproduce the crystallographic structures of the TcAChE-ligand
complexes present on the PDB, in particular the complexes in which ligand bind-
ing occurs to an alternative conformation of the enzyme. For this first validation,
we chose to generate 300 receptors with the rejection sampling method, consider-
ing as flexible residues whose side chain conformation are heterogeneous in crystal
structures: Trp86, Trp279, Phe288, Phe330, and His440.
Our method of receptor generation is completely independent from the choice of
the docking program, and the adoption of AutoDock Vina lays in its large popularity
between the users and in the simplicity of its usage. It has also been observed that
the scoring function of Vina is the most appropriate to describe docking in the gorge
of AChE6.
First, we used receptors generated by our method to screen for ligands of which
the structure in complex with ACHE was known. After downloading the component
definition files of each of these ligands in mmCIF format, we processed them using
phenix.elbow to generate a file in the proper PDB. The ligand pdb files were then
processed with the script prepare_ligand4.py from the AutoDockTools set, to create
a pdbqt ligand that can be provided to AutoDock Vina as input.
A configuration file for docking experiment was created through the AutoDock
plugin for PyMOL. The docking box was centered at the middle of the active site
gorge and its dimension was chosen so that the box includes every conformer of the
flexible residues.
The program performs a single docking experiment of each of the ligands against
each one of the receptors. A single flexible docking experiment is in this case trans-
6W. Song and Y. Xu, unpublished
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Figure 5.10: Molecules used fot validation
formed in a series of a few hundreds rigid dockings, one for each receptor in the
library. Outputs are saved to a single folder, bearing the ligand name, and that
contains all of the output log files and structures of the docking experiments.
5.4 Validation of the method: analysis of the results
The raw output of the docking routine consists in a series of separated ligand struc-
ture files, each of them having a code name referring to the specific receptor they
were docked to. The first operation performed in the analysis is to sort them follow-
ing their docking binding energy. A text file containing the affinities and the name
of each structure is created and serves as a reference for the analysis process.
In order to simplify the analysis of the outputs, each of the solutions, ranked
from the highest binding energy to the lowest, are combined in a multistate pdb file
containing the ligand within the corresponding receptor, which can later be observed
with molecular graphics programs. The analysis routine also calculates the binding
energy distributions of the solutions and their RMSD with respect to the lowest
energy solution, which are then useful for interpretation of the results. We report
here the analysis of three molecules (figure 5.10) that led to representative results:
the bifuncitonal inhibitor NF595 (Savini et al., 2003), the reactivator HI-6 (Oldiges
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Figure 5.11: Docking results for the bifunctional inhibitor NF595 within 300
TcAChE structures generated with the rejection sampling method. We observe
how the resulting conformation presents two main spatial arrangements, with the
same docking binding energy.
and Schoene, 1970) and the natural inhibitor Huperzine-B (Liu et al., 1986).
5.4.1 Quantitative analysis of docking solutions
For the analysis process, the solution presenting the lowest binding energy is chosen
as a reference. This reference solution is used to calculate ligand RMSD, a value
that is probably the most simple description of conformational differences between
the docking solutions. The ranked solutions for each ligand are represented on a
cartesian plane, as a function of their binding energy and their RMSD from the best
solution. We also calculated the distributions of binding energies and ligand RMSD
in order to have a quantitative evaluation of the homogeneity of docked solutions.
These data were used to generate a scatter plot, in which they can be clustered
in families, and two histograms, containing the normalized number of solutions per
value of RMSD and binding energy.
The first concerns the bifunctional inhibitor NF595 (figure 5.11). We can observe
that the ligand takes two different major spatial conformations, which share the
same range of binding energy value. The fact that the two conformations account
for half of the solutions is easily related to the similarity of the two extremities of the
molecule that can be docked upside-down without significant change in the binding
energy.
A smaller, non flexible ligand is the AChE inhibitor Huperzine-B (HUB, figure
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Figure 5.12: Docking results for Huperzine-B within 300 TcAChE structures gener-
ated with the rejection sampling method. 50% of the solutions have an RMSD from
the lowest energy solution of less than 1 Å, meaning that the binding site and the
orientation of this molecule are not modified by the conformational changes of the
side chains of most of the chosen flexible residues.
5.12). In this case, the binding conformation of the ligand is better defined than
for NF595, as can be deduced from the fact that around 50% of the solutions have
an RMSD lower than 1 Å with respect to the lowest energy one. This means that,
even if the conformation of the receptor changes, the molecule binds with a large
probability at the same place and mostly in the same orientation.
A third case is the reactivator HI-6, which also features two similar moieties and
has a more flexible structure than Huperzine-B. These two characteristics can help
in interpreting the results of figure 5.13. In fact, the RMSD values are widely spread
without any particularly favorable orientation, while the binding energy values for
this molecule fall within a narrow window. We can say that the flexible structure
of the ligand, along with the aromatic nature of its pyridiniums rings, that can
interact with most of the residues of the gorge wall, helps in always finding a proper
orientation inside the gorge with a reasonably low binding energy.
5.4.2 Structural analysis of docking solutions
The goal of generating multiple receptor structures was to improve flexible docking
procedures for ligands for which a conformational change in the gorge was revealed in
the crystal structure of the complex. This structural validation is only preliminery,
since it has beeen carried on only for a few molecules. In particular, we would need
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Figure 5.13: Docking results for the reactivator HI-6 within 300 TcAChE structures
generated with the rejection sampling method. Solutions present a uniform spatial
dispersion, while the calculated binding energy is the same for all of them.
(a) Solution cluster A (b) Solution cluster B
Figure 5.14: Representative conformations for the two solution clusters for NF595.
They are very similar, but the docked molecule is found in two opposite orientations,
with the sulfur atom either at the PAS or at the bottom of the gorge. Images are
in the same orientation.
to compare our output also with AutoDock Vina flexible docking results, and not
only with the available crystal structures.
For NF595, we obtained two main conformational clusters of the docked solutions
(figure 5.11). In the two panels if figure 5.14, containing a representative solution for
each of the clusters, we can see that the RMSD separation between the two families is
due to the upside-down orientation of the ligand, with either the tetrahydroacridine
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bearing the sulfur atom at the PAS of the enzyme or in the CAS. If we compare
the two structures, we can observe that the tetrahydroacridine at the active site is
always in aromatic stacking in between Trp84 and Phe330. The one at the peripheral
site is also found in aromatic stacking with Trp279. The relative similarity in the
conformation of the solutions conforts the reliability of the method in finding binding
modes for this type of ligand.
We can compare the solution from one of the clusters with the crystallographic
structure of the complex TcAChE-NF595 (pdb code 2cek). The superimposition
of the docking output and the crystallographic structure is shown in figure 5.15.
The main features of the binding mode at the active site are well reproduced by
the docking solution, in particular the orientation of Phe330, found in an alterna-
tive conformation, and Trp84, which correctly maintains its native orientation. The
tacrine appears to be correctly sandwiched between these two residues, leading to
a correct orientation of the unsaturated cycle. At the peripheral site, however, the
docking results cannot be superimposed to the crystallographic structure. The con-
formation of the ligand is different, because the different displacement of Trp279 in
the receptor with respect to the alternative conformation observed in the crystal-
lographic structure prevents the formation of a double aromatic stacking involving
Trp279 and Tyr70. The conformation of Trp279 observed in the crystallographic
structure is also present in the library, but to reproduce the aromatic sandwich, we
would need an exact parallelism between the peripheral site tryptophan and Tyr70.
However, a divergence of 3 degrees from the crystallographic position, due to the
binning used for the dihedral generation, would be enough to avoid a perfect paral-
lelism between Trp279 and Tyr70. This problem could probably be avoided by an
accurate minimization of the docking solutions, which has not been included in our
experimental procedure for the sake of reducing computational time.
Analysis of binding modes of HI-6 (not shown) has shown that this reactivator
is docked in the active site, rather than assuming the position observed in crystal
structure, half way through the gorge. The AChE inhibitor Donepezyl correctly
binds with its active site moiety, but again the peripheral site part of the moelcule
is not in the same orientation than in the crystallographic structure.
None of the analysed structures was comparable with the crystal structure. A
comparison including Vina flexible docking results would be necessary, in order to
asses the utility of our receptors generation method.
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(a) (b)
Figure 5.15: Comparison between docking solution from cluster A and crystal struc-
ture 2cek (Colletier et al., 2006b). The docked ligand is in orange, flexible receptor
residues in green and the crystallographic structure in cyan (ligand) and magenta
(residues). While the two structures present the same binding mode in the active
site, between Phe330 and Trp84, they differ in the conformation of both the ligand
and Trp279 at the peripheral site. Panels (a) and (b) are rotated by 20 degrees
around the vertical axis.
Figure 5.16: Conserved waters in the gorge of TcAChE (Koellner et al., 2000)
included in the docking receptors library.
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5.4.3 The role of water molecules
The results described in the previous section were obtained without any water
molecules in the gorge of AChE. We know, however, that some of these molecules
are highly conserved (Koellner et al., 2000) and actively participate in ligand bind-
ing, so we include them in the initial model for receptor generation. The docking
procedure was the same as reported before and data were processed in the same
way.
As observed above, there was no clear definition of a favored conformer for HI-6
in the set of receptors (figure 5.13). The presence of water molecules inside the
active site, while not improving the binding energy score, restrict the orientation
of the ligand, leading to a single conformer accounting for more than 80% of the
solutions (figure 5.17). While having an impact on the statistical distribution of
solutions, the presence of water molecules did not improve the prediction of crystal
structures, since again we could not reproduce them for any of the ligands.
5.5 Conclusions
The comparison between the sampling of side chain conformers in one long or many
short simulations has shown that the strategy of producing 10 trajectories of 20 ns
each is appropriate to completely explore the space of (χ1, χ2) orientation for each
residue.
This strategy of simulating the dynamics of the enzyme was used to compare
the conformational heterogeneity of some key residues in the gorge of hAChE and
TcAChE, and to produce a library of receptors for flexible docking.
The comparison of side chain conformational heterogeneity obtained from MD
simulation for hAChE and TcAChE has shown that the human enzyme has a re-
duced conformational heterogeneity with respect to the torpedo one both at the
peripheral site and in the active site. The striking difference of the dynamics of
Trp84 (TcAChE) and Trp86 (hAChE) suggests some different behavior concern-
ing the traffic of reaction products. The peripheral site tryptophan of hAChE, on
the other hand, presents the same set of conformations, only with different relative
occurrence during the MD simulations.
The production of receptor libraries was tested with two methods, a combination
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(a) No waters
(b) Waters
Figure 5.17: Docking results compared for HI-6 within 300 TcAChE structures
generated with the rejection sampling method, with and without conserved water
molecules in the receptor. The presence of water molecules leads to the exclusion of
some conformational regions for the ligand, as observable from the sharper distri-
bution of RMSD values.
of peaks conformers and a rejection sampling method. The combination of peaks has
some major drawbacks. It is computationally intensive, not adapted to be ported to
dihedral orders higher than 2 and does not consider the fact that a conformation is
not sharply defined, but can be broadened over a large region in the (χ1, χ2) plot.
For this lack of intrinsic flexibility, when checking for clashes a lot of conformations
are excluded and lost in the final sampling. The rejection sampling method works
differently. It can handle a large number of residues, with no limitation in dihedral
order. Using all the information in the simulation data sets, rather than only the
peaks in the dihedral distributions, helps in accounting for the spreading and relative
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population of different conformers.
A docking method was implemented to test the efficiency of this new approach
of sampling side chains conformers. Screening all the receptors in our library with
a standard rigid docking procedure, it requires the same computational time as a
standard flexible docking experiment with AutoDock Vina.
The analysis of docking results shows that ligand docking scores (binding en-
ergy) and conformational variability logically depends on the size and the degree
of flexibility of each ligand. Small rigid molecules are more univocally docked than
large, highly flexible ones. Calculated affinities can help in discriminating between
molecules whose binding depends or not on a specific conformation of the side chains
in the gorge. The comparison of the docking solution with crystallographic struc-
ture remains of limited success. We were not able to fully reproduce the binding of
molecules like NF595, as discussed above in the results section. Other molecules,
not presented in the manuscript like A8 (Rydberg et al., 2006) or ortho-7 (Hörnberg
et al., 2010), binding in cristallo to the same alternative conformation of Trp279
as NF595, could also not be docked properly at the peripheral site. Even in cases
where the receptor conformation was present in our library, docking procedure failed
in properly positioning the ligand inside it. This discrepancy does not appear to be
due to the lack of water molecules in the original test. Including conserved waters
into the calculation didn’t allow to better reproduce the crystallographic structures,
but helped in restricting the number of solutions for some flexible ligands, like HI-6
as discussed above. As discussed for Trp84 in TcAChE, the difference in binding
mode observed in docking and crystallography could also arise from the fact that
the observed crystallographic structure, affected by the crystal packing, might not
represent the predominant conformation of the protein in solution, that might be
better sampled by MD simulations.
We cannot conclude on the real efficiency of our docking method. Yet we believe
that it is a clear improvement over methods using a single conformation of the
enzyme or limited conformations found in crystal structures. The problem with our
method is that the final receptor is rigid and that only the ligand can adapt to
the receptor during the docking, which could lead to imperfect minimization of the
energy of the system. A possible evolution of the methodology would be to use the
approach of sampling side chains through MD simulation as a method to generate
the initial poses directly inside the docking code. A genetic algorithm could then be
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able to evolve both the ligand orientation and the angles of the side chains within
the conformational space identified in the MD simulation.
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Chapter 6
General conclusions and perspectives
We presented two main research projects in this manuscript. The first one, con-
cerning the design and evaluation of bifunctional neutral reactivators, has allowed
producing a first lead molecule, KM297, and an optimized derivative, JDS207. This
process involved docking studies, molecular dynamics simulations and X-ray crys-
tallography. The second one, concerning computational sampling of side chains con-
formations, aimed at producing a receptor library for flexible docking on TcAChE.
Results concerning the efficiency of the docking method were not conclusive, but the
process allowed us to provide insight into the structural dynamics of hAChE and
TcAChE, and on the method for taking account this flexibility in the modeling.
6.1 Design and optimization of KM297
The design of KM297, chosing tacrine as the peripheral site binder has been followed
by its successful synthesis(Kliachyna et al., 2014). The reactivation capability of
KM297 has been tested in vitro and was proven to be more efficient than 2-PAM
(the standard reference in literature) and HI-6, the last generation molecule to reach
the market. Flexible docking studies of KM297 on human AChE have comforted
the design hypothesis of binding to an alternative conformation of the peripheral
site, targeting in particular aromatic stacking of the tacrine moiety between Trp286
and Tyr72. The complex hAChE-KM297 showed a conformation analogous to that
observed with the bis-tacrine inhibitor NF595, which was the initial model used for
the design of KM297.
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Molecular dynamics simulations demonstrated the binding stability of tacrine
at the peripheral site in the docked conformation. Analysis of the distance during
simulation between the oxime and the phosphorous atom of an OP, VX in this
case, has been used to determine an optimal linker length between tacrine and the
reactivion function. A 4-carbon linker appears to be most appropriate to correctly
position the oxime for reactivation, supported by in vitro tests, which showed that
reactivation by KM297 is better than KM175, the analogue with a 5-carbon linker
length.
We solved structures of KM297 in complex with both native and tabun-inhibited
TcAChE. The complex TcAChE-KM297 has allowed to observetwo possible binding
sites for the reactivator in the native enzyme, one at the peripheral site and another
in the active site, with the oxime pointing towards the peripheral site. By contrast,
when the catalytic serine was phosphylated by NEDPA, a surrogate forming the
same conjugate as tabun, KM297 could not enter the active site. In this structure,
only one molecule of KM297 has been observed in the gorge, bound at the peripheral
site.
A series of new derivatives has been subsequently designed, to prevent binding
within the active site. In particular, introducing a chlorine substituent at position 7
of the tacrine moiety has emerged as a chemically simple and structurally efficient
solution. According to molecular docking, the presence of the chlorine in this par-
ticular position should create a steric clash preventing binding of the tacrine moiety
in front of Trp84. The chlorinated derivative of KM297, named JDS207, has been
synthesized and studied in detail. X-ray crystallography confirmed that JDS207
binds only at the peripheral site.
KM297 and JDS207 can be compared for their in vitro reactivation and inhibition
properties. They both present good reactivation capability fo VX-inhibited hAChE,
with a reactivation constant of kr2 = 22mM
−1min−1 for KM297 and of kr2 =
13mM−1min−1 for JDS207. As a comparison HI-6, the last molecule to reach the
market, has a kr2 = 9mM
−1min−1. The IC50 of JDS207 for hAChE, (2.33 ± 0.18
µM) is 10 times larger than that of KM297 (0.25 ± 0.02 µM). The chlorination
of the tacrine moiety thus decreased the global affinity of the molecule for non-
inhibited AChE by limiting binding to peripheral site. Yet, it is not clear at this
point if inhibition of the non-inhibited enzyme by a reactivator is a bad property
for a reactivator. This should be determined during in vivo experimentation.
6.2. SIDE CHAINS DYNAMICS AND FLEXIBLE DOCKING 119
Computational studies are all based on models of hAChE, while the crystallo-
graphic structures presented were obtained with TcAChE. Yet, there could be a
serious bias between TcAChE and hAChE structures due to non conserved residues
across species (Cheung et al., 2012). For the sake of uniformity, we tried to obtain
hAChE crystals that would allow solving the structure of hAChE complexes. We
obtained crystals in conditions similar to those obtained by (Dvir et al., 2010). But
these crystals could not be used for soaking of our reactivators, due to the high salt
concentrations found in the crystallization conditions, in which KM297 and JDS207
precipitate.
6.2 Side chains dynamics and flexible docking
We assessed two simulation strategies with the aim of improving the characterization
of side chains mobility in the gorge of AChE and build an optimal conformational
library. Comparing one long (200 ns) with many combined short (10x20 ns) simula-
tions, we concludes that both approaches are adequate to reproduce the conforma-
tional diversity observed in crystal structures. Yet, the multiple short simulations
approach is more suitable to obtain more and better defined conformational islands
as represented on plots of the (χ1, χ2) angles that characterize each conformation.
Therefore, we chose this latter approach (10x20 ns simulations) to compare the
dynamic behavior of some key residues in the gorge of TcAChE and hAChE. We were
able to show that the conformational variability is reduced in the human enzyme with
respect to the torpedo enzyme. For the aim of designing reactivators, the similarity
of the PAS sampling between the two species was encouraging. In particular, we
observed that the PAS tryptophan assumes the same conformations in both enzymes,
though with different occurrence rates.
We developed two methods to generate a library of docking receptors from the
dihedral data sets generated from simulations. Combining the various peak coor-
dinates has not proven to be efficient, even if is conceptually easier. At first, it is
complicated to extend this approach to dihedral angles of order larger than 2. Also,
all the information included in the spread of (χ1, χ2) regions is lost by considering
only one point per conformational island. Eventually, exclusion of clashes related to
sub-optimal relative position of dihedrals can lead to the loss of an entire conformer.
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Including less strict cutoff criteria and minimizing the output structures does not
appear as a valid option.
Therefore, we tested a rejection sampling method, in which only one specific
dihedral pair, rather than the whole conformational island, is excluded in case of a
clash. This approach has the advantage of taking into account the relative occurrence
of the different conformations, so that the most probable ones recur more often in
the receptor library.
Once the receptor is prepared, we implemented an automated procedure to dock
a set of ligands into them and verify the efficiency of the side chain sampling. Dock-
ing results show that ligand docking scores (binding energy) and conformational
variability logically depend on the size and the degree of flexibility of each ligand.
Small rigid molecules are more univocally docked than large, highly flexible ones.
For a given molecule the docked conformation is most often different from the
crystallographic structure of the complex suggesting that some key features are
missing in the receptor library. For example we could not reproduce the double
aromatic stacking of the tacrine moiety of NF595 at the peripheral site of AChE
despite the proper receptor conformation, with the rotation of Trp279, is present
in the receptors library. This implies that the limiting factor lays in the docking
procedure rather than the receptor library itself.
Adding conserved crystallographic water molecules helps in disambiguating dock-
ing results for highly affine and flexible molecules, such as HI-6, but this does not
help in reproducing the crystallographic structures.
6.3 Perspectives
We have shown how the structure-based development of reactivators allowed us to
obtain efficient molecules. In this work we presented molecules based on a tacrine
PAS ligand, but many additional PAS ligands have been tested and will be. In par-
ticular, we will target the synthesis of molecules that enhance Blood-Brain-Barrier
crossing like sugars and/or allow to better solubilization in aqueous medium. A
better solubility will be of great advantage for in vivo experiments. Until now,
preliminary surviving tests in a mouse model have not been conclusive, since the
amount of KM297 we could inject to a mouse is limited by the solubility of the
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compound 1. Galenic formulation must be explored to improve the bioavailability
of the molecules, for example by making chlorhydrate salts of them.
Crystallographic results have all been obtained with TcAChE, rather than hAChE.
As we have shown, the binding modes of ligands within the two enzymes can differ,
due to the different dynamics and composition of the active site gorge. Ideally we
will work exclusively with hAChE, and our effort to obtain well diffracting crystal,
such as the ones by (Cheung et al., 2012), are still ongoing. We managed to ob-
tain some crystals in the same space group, but they diffracted only up to 3.2 Å.
Optimized crystallization conditions along with a wider screen of cryo protecting
solutions, should allow us to push this limit farther, towards the current resolu-
tions of TcAChE crystals, i.e close to the 2 Å-limit. The current production rate of
the hAChE-544stop mutant in CHO cells will yield sufficient amount of enzyme to
perform exhaustive crystallization screening tests.
The docking pipeline has proven not to be adapted to take advantage of the
improved specificity for side chain conformer generation. Probably the best way to
benefit from this approach should be to include it directly into the docking program.
Each conformation generated this way will then be used to produce an initial pose
for the ligand that current docking algorithms are able to optimize in order to find a
properly docked conformation for both the ligand and the enzyme. This big effort,
however, goes beyond the scope of this thesis.
1G. Calas, unpublished results
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Chapter 7
Resumé de la thèse en français
7.1 Introduction
7.1.1 L’acetylcholinesterase
L’acétylcholinestérase (AChE) est une des enzymes des plus rapides de la nature.
Elle intervient dans la transmission du signal nerveux, en hydrolysant le neurotrans-
metteur acétylcholine (ACh) dans les synapses et jonctions neuromusculaires. Son
efficacité catalytique est proche de la limite théorique imposée par la vitesse de diffu-
sion des substrats et produits. Sa structure tridimensionnelle a initialement surpris
par le fait que le site actif se trouve enfoui au fond d’une gorge étroite et profonde.
Mais cette particularité génère un environnement optimal pour favoriser l’hydrolyse
du substrat par la triade catalytique.
En raison de ce rôle, l’AChE est la cible de différentes familles de toxiques, no-
tamment les neurotoxiques organophosphorés (OP). Cette large famille de molécules
comprend des pesticides, comme le paraoxon, et des toxiques de guerre, comme le
sarin, qui est redevenu d’actualité lors de la guerre civile syrienne. Les OPs inhibent
l’AChE en formant une liaison covalente avec la sérine catalytique, et l’empêchent
donc de jouer son rôle de nucléophile dans l’activité d’hydrolyse de l’ACh. Les con-
séquences physiologiques de cette inhibition sont mortelles pour l’homme. L’activité
catalytique de l’enzyme peut être restaurée en utilisant les oximes, une classe de
puissant nucléophiles qui sont capables de libérer la serine catalytique en déplaçant
l’OP. Cependant, après une durée variable suivant la nature de l’OP, les complexes
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AChE-OP subissent une réaction secondaire dit de vieillissement, après laquelle la
réactivation par une oxime n’est plus possible.
Les études structurales des complexes AChE-OP-oxime ont montré que le po-
sitionnement l’oxime dans la structure n’est pas optimal pour la réactivation de
l’enzyme inhibée par les toxiques organophosphorés. Nos travaux ont eu pour ob-
jectif de concevoir des oximes plus efficaces en adoptant la stratégie des réactivateurs
bifonctionnels: la partie réactivatrice est connectée à un ligand connu pour se fixer
au site périphérique de l’AChE.
L’étude des réactivateurs bifonctionnels a été le coeur de ce travail de thèse, et
les résultats sont détaillés dans ce manuscrit.
7.1.2 Conception de médicaments et dynamique des proteines
La conception raisonnée des médicaments est un processus basé sur la connaissance
de la structure des protéines cibles, qui permet de créer des molécules qui auront
une action sur ces mêmes cibles. Plusieurs techniques existent, la plupart desquelles
utilisent de larges ressources de calcul. Ces techniques présentent le défaut de reposer
sur un nombre limité de structures cibles et donc de souvent négliger la nature
dynamique des protéines.
Les protéines sont des macromolécules, qui existent dans plusieurs états confor-
mationnels à un instant donné. Cette description, dite du paysage conformationnel,
nous permet de comprendre que chaque protéine peut être considérée comme un
objet dynamique, qui à l’équilibre peut passer d’un état conformationnel à un autre,
avec des échelles temporelles allant de la picoseconde jusqu’à la seconde.
Pour cette raison, un large nombre de techniques existe pour caractériser la
dynamique structurale des protéines à une résolution atomique. Toutes ces informa-
tions, obtenues notamment par cristallographie au rayons X, résonance magnétique
nucléaire ou simulations par dynamique moléculaire, sont utilisées dans les travaux
de conception de médicaments.
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7.2 Resultats
7.2.1 Conception et optimisation d’un oxime bifonctionel
Dans le cadre de nos projets, plusieurs molécules ont été synthétises. Parmi elles,
la molécule KM297, composée d’une tacrine comme ligand du site périphérique de
l’AChE et d’une 2-hydroxypyridine aldoxime comme fonction réactivatrice, a donné
les meilleur résultats dans les tests in vitro. Pour cette raison, elle a été l’objet
des études structurales plus détaillées, pour identifier quel type de modification
pourrait l’améliorer. La caractérisation par des méthodes computationelles a permis
de montrer que la longueur du linker de carbones de la molécule KM297 était la
meilleure pour bien positionner l’oxime dans le site actif de l’AChE inhibée par le
VX. La structure cristallographique du complexe TcAChE-KM297 illustre que la
molécule présente deux sites de fixation dans la gorge de l’enzyme non inhibée. Le
premier site de fixation est à l’entrée de la gorge au niveau du site périphérique.
Mais la présence du partenaire symétrique dans le cristal impose une conformation
qui empêche la pénétration de la partie réactivatrice dans la gorge. La deuxième
molécule se trouve avec la partie tacrine positionnée dans le site actif, en interaction
avec le Trp84.
L’observation de la structure de ce complexe nous a permis de concevoir et
synthétiser un dérivé de KM297 ne se liant qu’au site périphérique de l’AChE, le
JDS207. La molécule JDS207 présente en position 7 de la tacrine un atome de chlore,
qui devrait créer un encombrement stérique lorsque la molécule se lie au fond du
site actif par interaction avec Trp84. Cette hypothèse a été d’abord confirmée par
docking moléculaire avant d’être validée expérimentalement par cristallographie. Les
deux méthodes ont permis de mettre en évidence que le seul mode de fixation pour
le JDS207 est au niveau du site périphérique, en interaction directe avec le résidu
Trp279.
Toutes les structures cristallographiques présentées dans ce manuscrit ont été
obtenues avec l’enzyme de Torpedo californica. Pour avoir des résultats plus ap-
plicables à l’homme, nous avons concentré nos efforts sur l’obtention de cristaux
de l’AChE humaine. Les cristaux obtenus jusqu’à présent diffractent à trop faible
résolution (3.2 Å) pour révéler le niveau de détail nécessaire à la conception de nou-
velles molécules. De plus, le site actif est bloqué pour une molécule d’enzyme sur
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deux en raison du type d’empilement cristallin. Ils se sont donc montrés inadaptés
pour les études structurales de complexes AChE-réactivateurs. Mais les efforts se
poursuivent pour obtenir des cristaux de qualité suffisante.
7.2.2 Developement d’un outil pour le docking flexible
L’étude en dynamique moléculaire des chaînes latérales des résidus aromatiques
localisés dans la gorge de la TcAChE nous a permis de montrer que la méthode
la plus appropriée pour couvrir au mieux l’espace conformationnel est de combiner
plusieurs trajectoires courtes, chacune avec des vitesses initiales différentes. Une
étude plus détaillée nous a permis de montrer que 10 trajectoires était suffisantes
pour efficacement échantillonner l’espace conformationnel de ces chaînes latérales.
Cette technique nous a d’abord permis de montrer que les chaînes latérales des
résidus de la gorge ont une dynamique différente entre l’hAChE et la TcAChE. Cette
remarque est importante, car la plupart des informations structurales obtenues à ce
jour sont sur la TcAChE. Le mode de liaison des molécules dans les deux enzymes
peut donc significativement varier en raison de cette hétérogénéité dynamique et
conformationnelle.
Une bibliothèque de récepteurs couvrant l’ensemble de l’espace conformation-
nel des résidus du site actif a ensuite été générée à partir des données produites
par les calculs de dynamique moléculaire. La bibliothèque a été testée avec tous
les ligands de AChE pour lesquels une structure cristallographique du complexe
TcAChE/ligand est connue. Les résultats ont montré une claire dépendance de
l’énergie de liaison estimée à la conformation de chaque récepteur. Toutefois, nous
n’avons pas réussi à reproduire la structure cristallographique observée, du moins à
l’aide du logiciel utilisé pour exploiter la bibliothèque. La présence ou non, lors du
docking, des molécules d’eau très conservées dans les différentes structures cristallo-
graphiques de l’AChE n’a pas permis non plus de retrouver les complexes observés
dans les structures cristallographiques. Mais leur présence permet de réduire le nom-
bre de conformations pour un ligand donné et aide donc à mieux isoler la meilleure
conformation prédite par docking.
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7.3 Conclusions generales
En conclusion de ce travail, nous avons conçu des réactivateurs bifonctionnels avec un
noyau tacrine comme ligand périphérique de l’AChE qui sont supérieures en terme
d’activité in vitro à l’activité des molécules actuellement en commerce. Leur solubil-
ité limitée en milieu acqueux sous leur formulation actuelle est toutefois un problème,
et elle sera adressée dans la continuité de ces travaux. Deux pistes sont envisagés:
1) la conception de nouvelles molécules avec des ligands du PAS monochargés à base
quinolinium, sachant que la présence d’une seule charge pourrait être suffisante pour
permettre le passage de la barrière hémato-encéphalique 2) la formulation des ligands
sous forme de sel de chlorhydrate ou mésylate, pour optimiser leur biodisponibil-
ité. L’utilisation de l’enzyme TcAChE est sans doute un facteur biaisant dans les
études structurales. Pour cette raison, nous avons travaillé à l’obtention de cristaux
d’hAChE similaires à ceux obtenus par (Cheung et al., 2012) à partir d’une forme
d’hAChE tronquée au résidu 544. À ce jour, nous avons obtenu des cristaux iden-
tiques mais ne diffractant pas au delà de 3.2 Å, encore loin des 2 Å espérés. Les
efforts poursuivent à l’aide d’une forme moléculaire strictement identique à celle
utilisée par Cheung et al.
Malgré l’utilisation orginale de notre bibliothèque conformationnelle, notre méth-
ode de docking n’a pas permis de reproduire de manière fiable les complexes observés
dans les structures cristallographiques lorsqu’ils sont accompagnés de changements
conformationnels. On observe, par contre, une très nette dépendance de l’énergie
de liaison estimée vis-à-vis des différentes conformations du récepteur, ce qui prouve
l’intérêt de la bibliothèque pour ne passer à côté d’une conformation pour laquelle
le ligand a des interactions préférentielles. Une méthode pour bénéficier au mieux
de notre bibliothèque conformationelle serait de directement inclure notre méthode
de génération des récepteurs flexibles dans le logiciel de docking. Un algorithme
moderne pourrait ainsi faire varier la conformation initiale du récepteur à partir
des informations contenues dans la bibliothèque, pour obtenir des résultats plus
représentatifs de la diversité conformationelle intrinsèque du récepteur.
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Appendix A
Docking code
Generation of receptors from the peak finder algorithm
Modiﬁcation of the TcAChE stracture to generate the receptors is done using python
modules in PyMOL.
In particular, we took advantage of the set_chi function and of the ‘rotamers.py‘
module written by Dan Kulp (Dunbrack and Cohen, 1997). Starting from the struc-
ture of native TcAChE (1ea5) we modiﬁed side chains of a set of chosen residues
following the (χ1, χ2) values extracted from molecular dynamics simulations as ex-
plained above. The code (reported in appendix 1) works in slightly different ways
for the two methods of extractions of dihedrals.
For the method of histogram peak finding, we need to calculate all of the possible
combinations for the (χ1, χ2) pairs for each residue of interest. This means that the
total number of output structures is determined by the equation
Nreceptors =
n∏
i=1
Xi (A.1)
where Xi is the number of possible peaks per residue. It is evident that the number
of output structures becomes exponentially large with each residue added . If we
consider an average of five conformation peaks per residue, the modification of only
three residues dihedrals would lead to 125 output structures, 625 output structures
for four residues and so forth.
Each output structure is generated by modifying in sequence all the chosen
residues and storing them in a separate pdb file. It is important to check at this point
if the newly created structure contains some clashes between the rotated side chains
and the rest of the protein. This is due to the fact that each conformational region
in the (χ1, χ2), even if in reality it is spread over some tens of degrees, is represented
by a single value for each dihedral angle, loosing all the information on the possible
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adjustments the residue can make. Idealization of the structures in the docking
library is performed in two steps. At ﬁrst, a clash checking function, written using
the function pymol.cmd.distance, excludes all the structures with residues getting
closer then 1.5Å. If water molecules are included in the modeling, a second function
deletes all the ones that are too close to a residue, normally at a distance lower
than 2Å. These distances are smaller than what could be accepted in a structure,
but they allow making a first selection of very problematic conformations. Output
structures passing the first clash filter are then processed with a crystallography
tool, phenix.geometry_minimization (Adams et al., 2010), to idealize the regions
where contacts are likely to occur.
r e i n i t i a l i z e
python
import numpy as np
import pymol
import rotamers
def loadData ( f i l ename ) :
ch i= [ ]
chi1 , ch i2 = np . l oadtx t ( f i l ename , d e l im i t e r=(" , " ) , u s e c o l s =(0 ,1) ,
unpack = True )
for i in range (0 , len ( ch i1 ) ) :
tmpList =[ ]
tmpList . append ( ch i1 [ i ] )
tmpList . append ( ch i2 [ i ] )
ch i . append ( tmpList )
return ch i
pymol . cmd . load ( " start_model . pdb" )
pymol . cmd . s e l e c t ( " views " , s e l e c t i o n = " r e s ␣331␣ or ␣ r e s ␣279␣ or ␣ r e s ␣330␣␣
or ␣ r e s ␣84" )
ch i84 = loadData ( " trp84 . dat" )
ch i279 = loadData ( " trp279 . dat" )
ch i330 = loadData ( "phe330 . dat" )
ch i331 = loadData ( "phe331 . dat" )
p r i o r i t y = 1
for i in ch i84 :
rotamers . set_rotamer ( " r e s ␣84" , i [ 0 ] , i [ 1 ] )
for j in ch i279 :
rotamers . set_rotamer ( " r e s ␣279" , j [ 0 ] , j [ 1 ] )
for k in ch i331 :
rotamers . set_rotamer ( " r e s ␣331" , k [ 0 ] , k [ 1 ] )
for l in ch i330 :
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rotamers . set_rotamer ( " r e s ␣330" , l [ 0 ] , l [ 1 ] )
pymol . cmd . s e l e c t ( " toSave" , s e l e c t i o n = " chain ␣A" )
pymol . cmd . s e l e c t ( " r e f e r e n c e " , s e l e c t i o n = " r e s ␣1−600␣
and␣not␣view" )
pymol . cmd . s e l e c t ( "NewRef" , s e l e c t i o n = " r e f e r e n c e ␣and␣
not␣ views ␣and␣not␣ neighbor ␣ views " )
ClashControl = pymol . cmd . d i s t anc e ( "Clash" , " views " , "
NewRef" , " 1 . 5 " , "0" )
#
#
#Check i f t h e r e are no c l a s h e s and con t r o l s a l l water
mo lecu les
#to d e l e t e the ones t ha t are too c l o s e to the p ro t e in
i f ClashControl == 0 :
for ind in range (2001 ,2740) :
waterMol = " resn ␣HOH␣and␣ r e s i ␣" + str ( ind )
pymol . cmd . s e l e c t ( "Water_model" , waterMol )
d i s t ance = pymol . cmd . d i s t ( "Contact" , "
Water_model" , " toSave " , " 2 .5 " , "0" )
i f d i s t ance != 0 :
pymol . cmd . remove ( "Water_model" )
pymol . cmd . d e l e t e ( "Contact" )
pymol . cmd . d e l e t e ( "Water_model" )
pymol . cmd . save ( "output"+str ( p r i o r i t y )+" . pdb" , "
toSave " ,1 )
p r i o r i t y += 1
pymol . cmd . d e l e t e ( " toSave" )
python end
qu i t
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Generation of receptors with the rejection sampling method
The method of rejection sampling is more ﬂexible, both from the conceptual point of
view and concerning the program structure. Its key feature is the ability to deﬁne a
level of completeness for the user, that allows to choose the desired number of output
structures. The program will generate as many dihedral sets as needed to satisfy the
request. Differently from the peak finder method, we do not need to modify the code
to include additional residues. We just need to supply a list of valid residue names
and IDs. Obviously, the more residues we want to include in the library generation,
the longer the calculation will take. The structure of the program allows to simplify
clash checking. In this case, after each residue is modified, if the conformation clashes
we simply reject it and start again the process from the beginning, generating a new
set of rotamers. As soon as a valid conformation is found, the program tries to apply
an analogous modification to the following residue in the input list. Each time all
of the residues have been properly modified, a structure is stored and the program
starts back with the next editing cycle.
Also, this second routine can handle water molecules, which allowed us to verify
the role played by solvent molecules that are highly conserved in AChE structures
on the reliability of docking experiments.
# −∗− coding : u t f−8 −∗−
"""
Created␣on␣Wed␣Jan␣23␣ 10 : 12 : 19 ␣2013
@author : ␣ g i an luca ␣ Santoni
A␣pymol␣ s c r i p t ␣ to ␣ generate ␣ docking ␣ r e c ep t o r s ␣ from␣Molecular ␣dynamics␣
s imu la t i on
ensemble .
Uses␣pymol␣ to ␣be␣ s imple ␣ in ␣MacOS. ␣Links ␣ are ␣a␣ b i t ␣weird ␣ there ␣ : )
I t ␣ supposes ␣you␣ a l ready ␣ ext rac t ed ␣ the ␣Chi1−Chi2␣ ensembles
Requires :
Numpy
Rotamers . py
"""
import __main__
import numpy as np
import pymol
import rotamers
import re
from math import ∗
’ ’ ’
Here␣ I ␣ d e f i n e ␣how␣many␣ d i h ed r a l s
any␣ r e s i due ␣has .
w i l l ␣be␣used␣ l a t e r ␣ to ␣ search ␣ f o r ␣ the ␣good␣ opt ions
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’ ’ ’
’ ’ ’
The␣ d i h ed r a l s ␣ d i c t i ona ry ␣ i s ␣used␣ as ␣a␣ r e f e r e n c e
to ␣know␣how␣many␣ s ide−chain ␣ ang l e s ␣ each
r e s i due ␣has .
Obviously , ␣ a l an ine ␣ i s ␣not␣ cons ide r ed .
’ ’ ’
d i h ed r a l s = {}
d ih ed r a l s [ ’ARG’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ] ,
[ ’ ch i3 ’ ] ,
[ ’ ch i4 ’ ]
]
d i h ed r a l s [ ’ASN ’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ]
]
d i h ed r a l s [ ’ASP ’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ]
]
d i h ed r a l s [ ’CYS ’ ]= [ [ ’ ch i1 ’ ]
]
d i h ed r a l s [ ’GLN’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ] ,
[ ’ ch i3 ’ ]
]
d i h ed r a l s [ ’GLU’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ] ,
[ ’ ch i3 ’ ]
]
d i h ed r a l s [ ’HIS ’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ]
]
d i h ed r a l s [ ’ ILE ’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ]
]
d i h ed r a l s [ ’LEU ’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ]
]
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d ih ed r a l s [ ’LYS ’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ] ,
[ ’ ch i3 ’ ] ,
[ ’ ch i4 ’ ]
]
d i h ed r a l s [ ’MET’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ] ,
[ ’ ch i3 ’ ]
]
d i h ed r a l s [ ’PHE’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ]
]
d i h ed r a l s [ ’PRO’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ]
]
d i h ed r a l s [ ’SER ’ ]= [ [ ’ ch i1 ’ ]
]
d i h ed r a l s [ ’THR’ ]= [ [ ’ ch i1 ’ ]
]
d i h ed r a l s [ ’TRP’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ]
]
d i h ed r a l s [ ’TYR’ ]= [ [ ’ ch i1 ’ ] ,
[ ’ ch i2 ’ ]
]
d i h ed r a l s [ ’VAL’ ]= [ [ ’ ch i1 ’ ]
]
def populateHistogram ( re s idue , dataPath ) :
’ ’ ’
␣␣␣␣ get ␣ r e s i due ␣name␣and␣ populates ␣an␣histogram
␣␣␣␣ o f ␣ d i h ed r a l s ␣ d i s t r i b u t i o n
␣␣␣␣ ’ ’ ’
r e sn = re s i due [ : 3 ]
i f len ( d i h ed r a l s [ r e sn ] ) ==1:
dens i ty = np . z e ro s ( (120 ) , dtype=int )
f i l eCh i 1 = open( dataPath+’ / ch i1 ’+r e s i due+’ . xvg ’ )
l i n e s 1 = f i l eCh i 1 . r e a d l i n e s ( )
f i l eCh i 1 . c l o s e ( )
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e l i f len ( d i h ed r a l s [ r e sn ] ) ==2:
dens i ty = np . z e ro s ( (120 ,120) )
f i l eCh i 1 = open( dataPath+’ / ch i1 ’+r e s i due+’ . xvg ’ )
f i l eCh i 2 = open( dataPath+’ / ch i2 ’+r e s i due+’ . xvg ’ )
l i n e s 1 = f i l eCh i 1 . r e a d l i n e s ( )
l i n e s 2 = f i l eCh i 2 . r e a d l i n e s ( )
f i l eCh i 1 . c l o s e ( )
f i l eCh i 2 . c l o s e ( )
e l i f len ( d i h ed r a l s [ r e sn ] ) ==3:
dens i ty = np . z e ro s ( (120 ,120 ,120) , dtype=int )
f i l eCh i 1 = open( dataPath+’ / ch i1 ’+r e s i due+’ . xvg ’ )
f i l eCh i 2 = open( dataPath+’ / ch i2 ’+r e s i due+’ . xvg ’ )
f i l eCh i 3 = open( dataPath+’ / ch i3 ’+r e s i due+’ . xvg ’ )
l i n e s 1 = f i l eCh i 1 . r e a d l i n e s ( )
l i n e s 2 = f i l eCh i 2 . r e a d l i n e s ( )
l i n e s 3 = f i l eCh i 3 . r e a d l i n e s ( )
f i l eCh i 1 . c l o s e ( )
f i l eCh i 2 . c l o s e ( )
f i l eCh i 3 . c l o s e ( )
e l i f len ( d i h ed r a l s [ r e sn ] ) ==4:
dens i ty = np . z e ro s ( (120 ,120 ,120 ,120) , dtype=int )
f i l eCh i 1 = open( dataPath+’ / ch i1 ’+r e s i due+’ . xvg ’ )
f i l eCh i 2 = open( dataPath+’ / ch i1 ’+r e s i due+’ . xvg ’ )
f i l eCh i 3 = open( dataPath+’ / ch i1 ’+r e s i due+’ . xvg ’ )
f i l eCh i 4 = open( dataPath+’ / ch i1 ’+r e s i due+’ . xvg ’ )
l i n e s 1 = f i l eCh i 1 . r e a d l i n e s ( )
l i n e s 2 = f i l eCh i 2 . r e a d l i n e s ( )
l i n e s 3 = f i l eCh i 3 . r e a d l i n e s ( )
l i n e s 4 = f i l eCh i 4 . r e a d l i n e s ( )
f i l eCh i 1 . c l o s e ( )
f i l eCh i 3 . c l o s e ( )
f i l eCh i 3 . c l o s e ( )
f i l eCh i 4 . c l o s e ( )
for x in l i n e s 1 :
r e f e r e n c e = x . s p l i t ( )
order = int ( r e f e r e n c e [ 0 ] )
ch i1 = f loat ( r e f e r e n c e [ 1 ] )
i f chi1 <0:
ch i1+=360
try :
Chi2 = l i n e s 2 [ order ] . s p l i t ( )
ch i2 = f loat ( Chi2 [ 1 ] )
i f chi2 <0:
ch i2+=360
try :
Chi3 = l i n e s 3 [ order ] . s p l i t ( )
ch i3 = f loat ( Chi3 [ 1 ] )
i f chi3 <0:
ch i3+=360
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try :
Chi4 = l i n e s 4 [ order ] . s p l i t ( )
ch i4 = f loat ( Chi4 [ 1 ] )
i f chi4 <0:
ch i4+=360
dens i ty [ f l o o r ( ch i1 /3) , f l o o r ( ch i2 /3) , f l o o r ( ch i3 /3) ,
f l o o r ( ch i4 /3) ]+=1
except :
d ens i ty [ f l o o r ( ch i1 /3) , f l o o r ( ch i2 /3) , f l o o r ( ch i3 /3)
]+=1
except :
d ens i ty [ f l o o r ( ch i1 /3) , f l o o r ( ch i2 /3) ]+=1
except :
d ens i ty [ f l o o r ( ch i1 /3) ]+=1
return dens i ty
def TEST( resn , da t a f o l d e r ) :
f i l e 1=open( da t a f o l d e r+"/ ch i1 "+resn+" . xvg" )
f i l e 2=open( da t a f o l d e r+"/ ch i2 "+resn+" . xvg" )
dens i ty = np . z e r o s ( (120 ,120) )
l i n e s 1 = f i l e 1 . r e a d l i n e s ( )
l i n e s 2 = f i l e 2 . r e a d l i n e s ( )
l im i t = len ( l i n e s 1 )
f i l e 1 . c l o s e ( )
f i l e 2 . c l o s e ( )
for x in range (0 , l im i t ) :
r e f e r e n c e = l i n e s 1 [ x ] . s p l i t ( )
order = int ( r e f e r e n c e [ 0 ] )
ch i1 = f loat ( r e f e r e n c e [ 1 ] )
i f chi1 <0:
ch i1+=360
Chi2 = l i n e s 2 [ x ] . s p l i t ( )
ch i2 = f loat ( Chi2 [ 1 ] )
i f chi2 <0:
ch i2+=360
dens i ty [ f l o o r ( ch i1 /3) , f l o o r ( ch i2 /3) ]+=1
return dens i ty
def randomHist ( pdf ) :
’ ’ ’
␣␣␣␣ p i ck s ␣a␣random␣ conformation
␣␣␣␣ ’ ’ ’
normPdf=pdf /pdf .sum( ) #normal ize
check = False
while check==False :
ch i1= np . random . rand int (0 , 120)
ch i2= np . random . rand int (0 , 120)
z = np . random . uniform (0 , 1 )
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i f z<normPdf [ chi1 , ch i2 ] :
check = True
return 3∗ chi1 , 3∗ ch i2
cyclesNumber = 300
dataF i l e = ’ c on f i g . txt ’
dataFolder = ’TcAChE_angles ’
c on f i g=open( da taF i l e )
r e s i du e s = con f i g . r e a d l i n e s ( )
c on f i g . c l o s e ( )
Datasets = {}
Angles = {}
#crea t i n g a d i c t i ona r y o f input r e s i du e s
#w i l l be popu la ted from input f i l e
for x in r e s i du e s :
r = x . r s t r i p ( ’ \n ’ )
Datasets [ r ]=TEST( r , dataFolder )
# Sta r t i n g the pymol par t
#loop over a l l t he l i n e s o f the his togram to genera te a new enzyme
conformer
#a l s o checks c l a s h at every mod i f i ca t i on
x=287
__main__. pymol_argv = [ ’ pymol ’ , ’−qc ’ ]
pymol . f i n i sh_launch ing ( )
pymol . cmd . set ( " suspend_update" , "1" )
pymol . cmd . load ( "waters_model . pdb" )
while x < cyclesNumber :
print x
Scor ing = True
for r e s in r e s i du e s :
r = r e s . r s t r i p ( ’ \n ’ )
re sn = int ( r [ 3 : ] ) +3
chi_A=randomHist ( Datasets [ r ] )
rotamers . set_rotamer ( " r e s ␣"+str ( re sn ) , chi_A [ 0 ] , chi_A [ 1 ] )
pymol . cmd . s e l e c t ( "Clash" , s e l e c t i o n =" r e s ␣"+str ( re sn ) )
pymol . cmd . s e l e c t ( "Ref" , s e l e c t i o n="waters_model␣and␣not␣ ( Clash␣
expand␣ 1 . 5 ) " )
d i s t ance = pymol . cmd . d i s t anc e ( "Check" , "Ref" , "Clash" , "2" )
i f d i s t anc e != 0 :
Scor ing = False
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break
i f Scor ing == True :
pymol . cmd . save ( "Output"+str ( x )+" . pdb" , "waters_model" , 1)
x+=1
pymol . cmd . d e l e t e ( "Check" )
pymol . cmd . qu i t ( )
Appendix B
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Reaction site-driven regioselective synthesis of AChE
inhibitorsQ1 †
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Ludovic Jean,*a Cyrille Sabot,*a Florian Nachone and Pierre-Yves RenardQ2 *a
The enzyme-directed synthesis is an emerging fragment-based lead discovery approach in which the bio-
logical target is able to assemble its own multidentate ligands from a pool of building blocks. Here, we
report for the ﬁrst time the use of the human acetylcholinesterase (AChE) as an enzyme for the design
and synthesis of new potent heterodimeric huprine-based inhibitors. Both the speciﬁc click chemistry site
within the protein and the regioselectivity of the Huisgen cycloaddition observed suggest promising
alternatives in the design of eﬃcient mono- and dimeric ligands of AChE. Finally, a detailed compu-
tational modelling of the click reaction was conducted to further understand the origin of this TGS
selectivity.
Introduction
The target-guided synthesis (TGS) is a relatively unexplored but
promising approach for lead discovery. More precisely, an
enzyme acts as a template to autoassemble its own multi-
dentate inhibitors from a pool of building blocks bearing
complementary reacting fragments.1 This in situ ligation of
building blocks is often achieved through the reliable alkyne–
azide Huisgen cycloaddition (called “click chemistry”)2 to yield
the corresponding 1,2,3-triazole-containing inhibitors. In
addition, acetylcholinesterase that plays a key role in the treat-
ment of Alzheimer’s disease (AD)3 was the first enzyme used to
validate the in situ click chemistry approach. It is well-known
that the active site of AChE is composed of two distinct
binding sites, named the peripheral (1) and the acylation sites
(2), connected by a narrow hydrophobic channel, the AChE
gorge (3) (Fig. 1A). Taking advantage of the enzyme structure,
Sharpless and Kolb4 reported the capacity of mouse AChE
(m-AChE) to catalyse exclusively the formation of highly potent
syn-triazole heterodimeric inhibitors such as (±)-TZ2PIQA5
and (±)-TZ2PIQA6 (Fig. 1B). More precisely, the syn-triazole
formation occurred from a mixture of tacrine azide (catalytic
site binder) and phenyl tetrahydroisoquinoline alkyne (peri-
pheral site binder) building blocks, in a particularly favourable
constricted region composed of side chains of Tyr124, Phe297,
Tyr337, and Phe338 at the bottom of the gorge (vide infra).5
The observed syn-regioselectivity was attributed to the parallel
orientation of both azide and alkyne reactive groups that
pointed toward the catalytic pocket.
Following these interesting results, the in situ click chem-
istry was performed in other constricted active sites of
enzymes (HIV protease,6 carbonic anhydrase,7 or the transcrip-
tional repressor EthR8) or at a presumably more flexible
Fig. 1 (A) Description of the active site of m-AChE: (1) peripheral anionic site;
(2) acylation site; (3) hydrophobic channel. (B) Hits that emerged from in situ
click chemistry experiments described by Sharpless and Kolb.4
†Electronic supplementary information (ESI) available. See DOI:
10.1039/c3ob42109k
aNormandie Univ, COBRA, UMR 6014 & FR 3038, Univ Rouen, INSA Rouen, CNRS 1,
rue Tesnière 76821 Mont-Saint-Aignan, Cedex, France.
E-mail: pierre-yves.renard@univ-rouen.fr; Fax: (+) 33 2 35 52 29 71
bUniv Grenoble Alpes, IBS, F-38027 Grenoble, France
cCNRS, IBS, F-38027 Grenoble, France
dCEA, IBS, F-38027 Grenoble, France
eInstitut de Recherche Biomédicale des Armées BP73, F-91993 Brétigny-sur-Orge,
France
This journal is © The Royal Society of Chemistry 2013 Org. Biomol. Chem., 2013, 00, 1–6 | 1
1
5
10
15
20
25
30
35
40
45
50
55
1
5
10
15
20
25
30
35
40
45
50
55
environment such as the subunit interfaces of the nicotinic
acetylcholine receptor nAChR.9 To the best of our knowledge,
only one click chemistry site was reported for each enzyme
investigated to date, leading to one triazole regioisomer (either
syn or anti). Indeed, not only the overall spacing between the
two monomeric ligands but also the location of the triazole
ring construction within the enzyme proved to be of crucial
importance for the success of the in situ click chemistry
approach.2b Consequently, in order to extend the scope of the
TGS, we questioned whether the identification of a new reaction
site within a protein would be possible. This should oﬀer new
opportunities in the rational design of new enzyme inhibitors
by using various building block structures.
Thus, in this study we explored a novel AChE reaction site
suitable for TGS, involving the use of bulky active site ligands
such as huprine building blocks. Preliminary work from our
laboratory suggests that the huprine moiety would be a suit-
able catalytic site binder for in situ click chemistry.10 Huprine
derivatives, developed by Camps et al., are the best AChE
active-site ligands reported to date, especially huprines X
and Y that exhibit high aﬃnity towards AChE’s acylation site
(IC50 = 0.75 nM and 0.78 nM respectively, 270-fold more potent
than tacrine),11 and can be readily functionalized at position 9
or 12.12 Moreover, we selected the phenyl tetrahydroisoquino-
line scaﬀold that already proved to be a convenient peripheral
site binder in TGS.4 Not to mention the currently growing
interest in developing multi-target-directed drugs and particu-
larly new potent dual-binding site AChE inhibitors able to
exert a dual action,13 i.e. interacting simultaneously with the
AChE active site (inhibition of cholinesterasic activity) and the
peripheral site (inhibition of AChE-mediated Aβ deposition).14
From this investigation, the following important outcomes
may be expected: (1) the design and synthesis of new potent
dual-binding site inhibitors directed for the first time by the
flexible recombinant human rh-AChE;15 (2) a better under-
standing of the relationship between the location of the click
chemistry within the enzyme and the observed regioselectivity;
and (3) a deeper insight into the fundamentals that govern the
TGS strategy.
Results and discussion
(±)-12-HUPZ2,16 functionalized by an amino ethyl azide group
at position 12 on the quinoline ring, and (±)-PIQ-A6 (n = 6),17
bearing an alkyne group, were incubated in the presence of
the model enzyme m-AChE (Table 1, entry 1). Interestingly, no
trace of (±)-12-HUPZ2PIQ-A6 was observed using HPLC
coupled with ESI/MS detection, whereas the incubation under
similar conditions of (±)-PIQ-A6 and TZ2, the latter sharing
important structural similarities with (±)-12-HUPZ2, aﬀorded
the corresponding dimeric inhibitor syn-(±)-TZ2PIQ-A6
(Fig. 1B) as reported by Sharpless and Kolb.4 Huprine and
tacrine share similar binding zones within the active site of
the enzyme, but the additional carbobicyclic ring system in the
huprine scaﬀold hinders the access to the esteratic site, which
would prevent the formation of the triazole of (±)-12-HUPZ2-
PIQ-A6 in this sequestered enzyme site. Moreover, the moder-
ate IC50 value of (±)-12-HUPZ2PIQ-A6 (i.e. 7.0 nM) is in
agreement with our previous studies showing that functionali-
zation of huprines at the quinoline moiety (position 12)
resulted in a significant decrease of their inhibitory potency.
Indeed, the free amino group on the quinoline ring is involved
in key hydrogen bonds with the nearby structural water mole-
cule12d ( Q4Fig. 2).
This preliminary result emphasizes the importance of
finding alternative reaction sites within an enzyme, especially
to widen the scope of bivalent inhibitors designed via in situ
click chemistry. Furthermore, we recently reported that suit-
able modifications at position 9 of the huprine derivative leave
the water network unchanged, and could increase their aﬃnity
toward AChE. Interestingly, our previous docking studies
suggested that the ligation to a peripheral site binder could be
carried out at position 9.10 Consequently, the enzymatic tri-
azole synthesis could be envisioned in the a priori less favorable
mid-gorge of m-AChE, i.e. closer to the peripheral anionic site.
Yet, the higher degree of enzyme flexibility expected at this
location may disadvantage the click chemistry process.
Thus, huprines bearing alkyl azide (m = 2 and 4), and
phenyl tetrahydroisoquinolines decorated with alkyl acetylene
Table 1 m-AChE-directed synthesis of huprine-based heterodimers
Entry Ligand m n Click in situ IC50
a (nM)
1 (±)-12-HUPZ2PIQ-A6 n.a.b 6 — 7.0 ± 1.0
2 (±)-9-HUPZ4PIQ-A1 4 1 — 1.5 ± 0.3
3 (±)-9-HUPZ4PIQ-A2 4 2 antic 0.4 ± 0.1
4 (±)-9-HUPZ4PIQ-A3 4 3 syn/antid 1.2 ± 0.3
5 (±)-9-HUPZ4PIQ-A4 4 4 — 3.1 ± 0.6
6 (±)-9-HUPZ2PIQ-A4 2 4 — 13.0 ± 2.5
a Corresponding to the anti isomer. bNot applicable. cDetected after a
two-day incubation period. dDetected after a seven-day incubation
period.
Fig. 2 (±)-Huprine X, Y.
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of varying chain lengths (n = 1–4), were incubated in the pres-
ence of m-AChE. Control experiments were also performed
without an enzyme (or with BSA protein). The reaction
mixtures were next analysed by RP-HPLC through electrospray
ionisation mass spectrometry in the positive selected ion
monitoring mode (SIM) (Fig. 3), and compared to authentic
samples obtained by thermal or copper-catalysed 1,3-dipolar
cycloaddition.18
From ten heterodimers that could theoretically be formed
in situ (Table 1, entries 2–6), only the anti-9-HUPZ4PIQ-A2 and
the regioisomeric mixture of syn- and anti-9-HUPZ4PIQ-A3
(≈ 1 : 2) were observed (Table 1, entries 3 and 4). These results
show that the acetylene moiety of the peripheral site ligand
(±)-PIQ-A2, with a two carbon-atom chain length, would be
located at an optimal distance from the azide unit of (±)-9-
HUPZ4 to adopt a specific conformation leading to a unique
regioisomer (i.e. anti). However, the presence of an additional
methylene unit in (±)-PIQ-A3 would enable the alkyne chain to
fold, and lead to the subsequent syn-triazole isomer as well.
Interestingly, no trace of (±)-9-HUPZ2PIQ-A4 was formed (entry
6), even though it has the same overall spacing between the
peripheral and catalytic site binders as (±)-9-HUPZ4PIQ-A2. In
this case, the triazole unit would be unfavourably located at
the bottleneck of the active site gorge.
It is noteworthy that this study, together with Sharpless and
Kolb’s results, shows that AChE is able to template either the
anti isomer of (±)-9-HUPZ4PIQ-A2 (entry 3) or the syn isomer of
(±)-TZ2PIQ-A6, depending on the location of the click chem-
istry within the active site of the enzyme. Indeed, as depicted
in Fig. 4, these dual-binding site inhibitors are templated at
two clearly distinct sites of m-AChE, located on either side of
the enzyme bottleneck. syn-(±)-TZ2PIQ-A6 is assembled in the
constricted region located in proximity to the acylation site of
the enzyme, resulting from reacting functionalities extended
in a parallel orientation. anti-(±)-9-HUPZ4PIQ-A2 is ligated
closer to the rim of the gorge, an unprecedented reaction site
of AChE, from complementary functional groups lying in an
antiparallel orientation.19
We next examined whether these promising results could
be extrapolated to the more flexible rh-AChE. In fact, the symp-
tomatic approach to treat neurological disorders such as AD
consists of controlling the enzymatic activity of human AChE.
It is noteworthy that switching from m- to rh-AChE template is
not a trivial task as both enzymes have marked diﬀerences in
dynamic properties despite fully conserved active site resi-
dues.15b The same series of binary mixtures was incubated in
the presence of rh-AChE to direct the synthesis of hetero-
dimeric huprine-based inhibitors (Table 2). Gratifyingly, in situ
click chemistry was observed and similar results were obtained
with the clinically relevant enzyme. Note that longer reaction
times were necessary before detecting the triazole-adducts
(±)-9-HUPZ4PIQ-A2 and (±)-9-HUPZ4PIQ-A3, probably due to
the greater flexibility of the rh-AChE active site compared with
the m-AChE one.
Consequently, these in situ click chemistry results high-
lighted that the functionalization of the huprine scaﬀold at
position 9 was an appropriate strategy to access the peripheral
anionic site of AChE (Table 2, entry 1 vs. 3 and 4). As expected,
the overall chain length between the catalytic and the peri-
pheral site ligand (entries 2 and 5 vs. 3 and 4), as well as the
location of the triazole ring into the gorge, should be con-
sidered (entry 3 vs. 6). The latter information would be particu-
larly valuable to build eﬃcient triazole-containing dimeric and
Fig. 4 Superimposition of in situ auto-assembled ligand syn-(±)-TZ2PIQ-A6
(in red) and anti-(±)-9-HUPZ4PIQ-A2 (in blue) docked in the active site of
m-AChE (pdb code 1Q83). The triazole unit of each ligand is colored in orange.
Table 2 rh-AChE-directed synthesis of huprine-based heterodimers
Entry Ligand m n Click in situ IC50
a (nM)
1 (±)-12-HUPZ2PIQ-A6 n.a.b 6 — 6.1 ± 0.8
2 (±)-9-HUPZ4PIQ-A1 4 1 — 3.3 ± 0.2
3 (±)-9-HUPZ4PIQ-A2 4 2 antic 0.6 ± 0.1
4 (±)-9-HUPZ4PIQ-A3 4 3 syn/antid 0.6 ± 0.1
5 (±)-9-HUPZ4PIQ-A4 4 4 — 0.8 ± 0.1
6 (±)-9-HUPZ2PIQ-A4 2 4 — 5.3 ± 0.3
a Corresponding to the anti isomer. bNot applicable. cDetected after a
nine-day incubation period. dDetected after a thirteen-day incubation
period.
Fig. 3 LCMS/SIM traces of (±)-9-HUPZ4PIQ-A2: (A) a mixture of anti and syn-
(±)-9-HUPZ4PIQ-A2 obtained under the thermal Huisgen process; (B) anti-(±)-9-
HUPZ4PIQ-A2 formed by catalytic CuAAC; (C) trace of the blank experiment
without m-AChE; and (D) trace of the click experiment with m-AChE.
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monomeric inhibitors. Indeed, the present TGS approach con-
firmed our previous observations10 showing that ligands
bearing a triazole unit at four carbon atoms away from the
huprine scaﬀold, such as compounds 3 and 4, were much
more potent than their two carbon atom chain length ana-
logue 1 or 2, due to better accommodation midway in the
active site gorge, and notably favourable interactions of the
triazole with Tyr341 and the main chain of Phe295 (Fig. 5).20
Compound 4 constitutes one of the best rh-AChE active-site
ligands reported to date (IC50 = 0.43 nM).
In order to investigate the potential reasons for the regio-
selective formation of the anti-(±)-9-HUPZ4PIQ-A2 (i.e. the role
of the residues in close proximity to the reaction site, the reac-
tion barriers and the total energy of the protein–substrate
complex), additional theoretical studies were undertaken. To
this aim, the structures of protein–ligand complexes for syn-
and anti-molecules were obtained by docking and MD equili-
bration. The structure of the complexes was used as the basis
to model the click reaction between substrates, using the com-
bined quantum mechanics/molecular mechanics approach
(QM/MM). A detailed computational procedure is given in
ESI.†
First, pre-reactive complexes of syn-(±)-9-HUPZ4PIQ-A2 and
anti-(±)-9-HUPZ4PIQ-A2 in the active site of rh-AChE were ana-
lysed (Fig. 6). The huprine moiety is firmly maintained by aro-
matic stacking in between Trp86 and Tyr337, while the azido
group is confined in an aromatic pocket formed by Phe295,
Phe297, Tyr337 and Phe338.
The tetrahydroisoquinoline substrate is bound to the
peripheral site, stacking parallel to Trp286 with additional
T-stacking involving its phenyl ring and Tyr341. In the pre-syn
complex, the alkynyl group lies away from Trp286 (4.6 Å) paral-
lel to the azido group and makes favorable pi–pi interaction with
Tyr341 (3.4 Å). By contrast, the alkynyl group lies orthogonally
to the azido group in the pre-anti complex, at closer distance
from Trp286 than Tyr341 (3.4 Å vs. 4.0 Å). However, no clear
conclusion could be drawn at this stage from this preliminary
analysis.
Consequently, reaction barriers for syn and anti substrates
in the protein environment were next investigated from a
quantum chemistry viewpoint by fully optimizing the corres-
ponding transition states, and were found to be 16.3 kcal
mol−1 and 20.5 kcal mol−1, respectively. These values (both
accessible at ambient temperature) suggest a slight but not
definitive kinetic preference for the syn product. It can be
noticed that Senapati and co-workers21 reported a similar
diﬀerence (4 kcal mol−1) between the activation barriers in
favour of the experimentally non-observed product. The strong
catalytic role of the enzyme can also be enlightened by remark-
ing that the activation energies calculated using the same com-
putational protocol for the formation of the heterodimeric
inhibitors without AChE are about twice (35 kcal mol−1) the
ones calculated in the presence of the enzyme.
From a thermodynamic point of view, a direct comparison
of the total energies of protein–substrate complexes shows that
the anti-complex is more stable than the syn-complex by
173 kcal mol−1 at the MM level and 144 kcal mol−1 at the
QM/MM level. This means that once the system is trapped in
the anti conformation, it cannot be converted to the syn
isomer. Thus, the selective formation of anti-9-HUPZ4PIQ-A2
is mainly the result of accumulation of protein–substrate com-
plexes and interactions in the anti configuration. It should
be mentioned that similar findings were reported earlier by
Senapati and co-workers21 on the selective formation of the
observed product in m-AChE. It thus seems reasonable to con-
clude that the physicochemical factors driving the selectivity of
the process in rh-AChE are the same as those in m-AChE.
Finally, the total energy diﬀerence (i.e. 144 kcal mol−1)
between syn and anti products can be decomposed into three
contributions: substrate and protein internal energy diﬀer-
ences and binding interaction (protein–substrate) diﬀerences
between both conformations. It was found that 9.6 kcal mol−1
is brought about by the stabilization of the anti-substrate with
respect to the syn-substrate, 17.3 kcal mol−1 is due to a higher
binding interaction energy of the anti-isomer with the protein
and the larger contribution of 117.5 kcal mol−1 comes from
Fig. 6 Pre-reactive complexes of syn-(±)-9-HUPZ4PIQ-A2 and anti-(±)-9-
HUPZ4PIQ-A2 in the active site of rh-AChE. The main chain of active site resi-
dues is represented as grey sticks, with oxygen in red and nitrogen in blue.
Atoms of the reactive azido and ethyne groups are represented as spheres.
Fig. 5 X-ray crystal structure of the 4-m-AChE complex (pdb code 4A16) and
comparative IC50 values of huprines bearing a triazole unit separated by a two-
and four-carbon chain length.
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the protein internal energy diﬀerence between both confor-
mations. Interestingly, these three contributions have cumulat-
ive eﬀects, favouring the formation of the anti-complex. The
main contribution comes clearly from the protein internal
energy diﬀerences, and thus highlights the induced fit contri-
bution to the triazole formation. These results, which are in
agreement with experiments, also highlight the relevance of
such a QM/MM approach.
Conclusions
Herein, we have reported the first use of human AChE as the
template for in situ synthesis of subnanomolar dual binding
site inhibitors. To achieve this outcome, the identification of a
novel click chemistry site within the AChE gorge that enables
the use of bulky huprine building blocks as an acylation site
binder was required. Whilst the syn-triazole isomer was pre-
viously reported by Sharpless and Kolb to be preferentially
formed in the sequestered region within the AChE gorge, inter-
estingly, we observed a reversal of regioselectivity moving the
reaction toward the upper part of the gorge, in the mid-gorge
site of AChE. This selectivity is thermodynamically driven and
is principally related to the protein internal energy diﬀerence
between both conformations, and shows for the first time that
an enzyme could govern the absolute regioselectivity of the
Huisgen reaction (either syn or anti isomer), depending on the
reaction site selected and the overall spacing between the two
monomeric ligands.
Importantly, this study shows that the TGS, sustained by
docking experiments, is a flexible tool capable of highlighting
diﬀerent click chemistry sites within an enzyme, depending on
the combination of building blocks selected. Consequently,
the identification of a broader diversity of inhibitors may be
expected.
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a b s t r a c t
A series of new uncharged functional acetylcholinesterase (AChE) reactivators including heterodimers of
tetrahydroacridine with 3-hydroxy-2-pyridine aldoximes and amidoximes has been synthesized. These
novel molecules display in vitro reactivation potencies towards VX-, tabun- and paraoxon-inhibited
human AChE that are superior to those of the mono- and bis-pyridinium aldoximes currently used
against nerve agent and pesticide poisoning. Furthermore, these uncharged compounds exhibit a
broader reactivity spectrum compared to currently approved remediation drugs.
 2014 Published by Elsevier Masson SAS.
1. Introduction
Organophosphorus compounds (OP) include the extremely
toxic chemical warfare agents (CWA) (sarin, soman, cyclosarin,
tabun, methylphosphonothioate VX) and pesticides (paraoxon,
parathion, tetraethyl pyrophosphate (TEPP)) (Fig. 1). Their acute
toxicity results from the irreversible inhibition of acetylcholines-
terase (AChE) through phosphylation of its catalytic serine [1].
Accumulation of neurotransmitter acetylcholine (ACh) at cholin-
ergic synapses ensues, leading to nervous and respiratory failures.
Depending on the class of OP and on the administrated dose, death
can occur within minutes [2].
Due to the similarity between the chemical precursors of CWA
and pesticides, and to the relatively simple chemistry involved in
their synthesis, efforts to control the proliferation of these agents
have proved of limited success [3]. Illustrative examples include the
terrorist attack in the Tokyo subway in 1995, the bombing of Kurd
civilians during the IraqeIran war in 1988, and that of civilians in
Syria, as reported in August 2013. Additionally, despite the inter-
national efforts aimed at regulating and lessening the use of these
environmentally toxic compounds, ca. 100 different OP are still
used intensively as pest control agents, with only anecdotal
monitoring. This results in about 3,000,000 acute intoxications per
year, 200,000 of which lead to death [4,5]. Therefore, the devel-
opment of effective measures to counteract OP poisoning remains a
challenging issue to protect and treat both civilian and military
populations [6].
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The current treatment against OP poisoning consists in the
administration of a combination of atropine (antimuscarinic agent)
and diazepam (anticonvulsant drug), to limit convulsions, and of a
standard pyridinium oxime (pralidoxime, trimedoxime, HI-6, obi-
doxime, and HLö-7, Fig. 2) to reactivate AChE. Oximes exert their
action on OP-inhibited AChE by attacking the phosphorus atom of
the phosphylated serine, yielding to the removal of the phospho-
nate and recovery of the enzyme’s catalytic activity. To this end,
pyridinium oximes must display high nucleophilicity, which is
generally attained by the formation of an oximate anion at physi-
ological pH. As of today, however, not a single oxime has proven
equally effective against all types of OP-inhibited AChE, and most
are ineffective for the reactivation of tabun-inhibited hAChE [6].
Another weakness of currently approved pyridinium aldoximes
is their difﬁculty in crossing the bloodebrain barrier (BBB) owing to
the permanent charge carried by the oximate [7]. For example, it
was estimated using in vivo rat brain microdialysis coupled with
HPLC/UV, that the BBB penetration of the most commonly used
oxime, 2-PAM, is only 10% [8]. Therefore, oximes reactivating AChE
in the peripheral nervous system are not effective in the brain and,
consequently, do not protect against the neurological effects of OP-
exposure.
To overcome this obstacle, we recently reported the synthesis
of a series of uncharged oxime-based compounds, both able to
cross the BBB and to reactivate OP-inhibited AChE in the CNS [6].
Monoisonitrosoacetone (MINA) and diacetylmonooxime (DAM)
respectively bearing the a-ketoaldoxime and ketoxime moieties
(Fig. 3) were also reported to cross the BBB, yet their in vitro
reactivation potency towards OP-inhibited AChE was lower than
that exhibited by 2-PAM [9]. Connection of an a-ketoaldoxime
function to a piperidine-derived peripheral site ligand (PSL)
allowed increasing the afﬁnity for AChE, resulting in higher reac-
tivation rates of sarin- and VX- inhibited AChE. Yet, these com-
pounds were still less efﬁcient than currently used pyridinium
oximes towards the latter, and totally inefﬁcient towards tabun-
inhibited AChE [10]. Hydroxyimino acetamides 1aeb showed
in vitro reactivation efﬁcacy superior to MINA and DAM, but
remained less effective than 2-PAM, except for cyclosarin [11].
Likewise, amidine-oxime reactivators 2a,b were less potent than
2-PAM in reactivating AChE in vitro [12]. Low reactivation potency
of these new uncharged reactivators is likely due to their higher
pKa, which results in inefﬁcient deprotonation at physiological pH
and thus, in a reduced nucleophilicity (for instance, for MINA,
pKa ¼ 8.3) [13].
Recently we found that 3-hydroxy-2-pyridine aldoximes 3 and
amidoxime 4 (Fig. 4) exhibited high reactivation ﬁrst order rate
constant towards VX-inhibited hAChE (kr ¼ 0.5 ! 0.1 min
"1 and
0.08!0.1min"1, respectively) [14,15], i.e.values either similarorone
order of magnitude larger than that displayed by 2-PAM
(kr ¼ 0.06 ! 0.01 min
"1). Owing to the lower afﬁnity of 3 and 4 for
VX-hAChE (second order reactivation rate constants kr2 ¼ kr/KD are
0.015 and 0.0026 mM"1 min"1 for 3 and 4, respectively, to compare
to 0.28 mM"1 min"1 for 2-PAM), much higher concentrations are
however required to reach the desirable reactivation of the enzyme.
We have shown that connection of 3-hydroxy-2-
pyridinaldoxime reactivators with a PSL ligand, such as phenyl-
tetrahydroisoquinoline (PIQ) [16], results in a dramatically
improved afﬁnity for the enzyme and, consequently, in increased
Fig. 1. Structures of organophosphorus CWA and pesticides.
Fig. 2. Structures of developed pyridinium aldoxime reactivators.
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reactivation potency towards OP-inhibited hAChE [17]. Recently,
similar beneﬁcial effects have been reported for tryptoline-3-
hydroxypyridine-2-aldoxime hybrids for the reactivation of OP-
inhibited h-BChE [17c]. PIQ-functionalized 3-hydroxy-2-pyridine
aldoximes indeed displayed reactivation potency either equalling
or exceeding those of HI-6 and obidoxime. For example, 5awas 2.3
and 2.8 times more efﬁcient than obidoxime and HI-6, respectively,
and 5 times more potent than trimedoxime, the best known reac-
tivator of tabun-inhibited hAChE (kr2 ¼ 3.4 mM
!1 min!1 for 5a, as
compared to 0.7 mM!1 min!1 for trimedoxime).
One of the important drawbacks when using pyridinium
aldoximes (especially for pyridinium-4-aldoximes) is that the
Fig. 3. Neutral reactivators: a-ketoaldoximes, ketoxime, hydroxyimino acetamides, and amidine-oximes.
Fig. 4. 3-hydroxy-2-pyridine aldoxime, 3-hydroxy-2-pyridine amidoxime, and phenyl-tetrahydroisoquinoline-3-hydroxy-2-pyridine aldoxime AChE reactivators.
Fig. 5. Structures of novel uncharged AChE hybrid reactivators investigated.
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reactivation products, phosphyloximes, can themselves display
high afﬁnity for the enzyme, and thus prolong AChE inhibition
(recapture phenomenon) [18]. In the case of oximes 3, 5a, 5b, as
well as in that of amidoxime 4, the presence of the 3-OH group in a-
position of the oxime/amidoxime moiety allows subsequent
intramolecular cyclisation, resulting in isoxasole formation and
thus in the bypass of this possible complication [14,15].
In the following, we describe the rational design, synthesis and
in vitro evaluation of a new class of uncharged reactivator mole-
cules. Their design is based on a 1,2,3,4-tetrahydroacridine (tacrine)
substructure, able to bind to the peripheral site of AChE [19,20],
coupled with various linkers to either 3-hydroxy-2-pyridine
aldoxime or 3-hydroxy-2-pyridine amidoxime (Fig. 5).
2. Results and discussion
2.1. Rational design of bifunctional reactivator molecules
Acetylcholinesterase (AChE) features an active site buried at the
bottom of a deep and narrow gorge [21]. At the entrance of the
latter, a peripheral binding site serves as a transient binding loca-
tion for substrates and products en route to/from the active site
[22], but also as an anchor point for ligands [23]. Bifunctional in-
hibitors have been developed that display higher afﬁnity, and
which are based on two moieties binding at either site that are
connected by a ﬂexible linker [19,20,24]. By analogy, we designed
bifunctional reactivators that comprise a peripheral site ligand
(PSL) connected to a reactivator function by a covalent linker
(Fig. 6). In addition to increasing the afﬁnity of the reactivator for
the enzyme, the use of a PSL further allows preventing unproduc-
tive binding to the active site as it was, for example, observed with
2-PAM [25].
In practice, we used as a starting model the X-ray crystal
structure of Torpedo californica (Tc)AChE in complex with a bis-
tacrine inhibitor [19], which allowed predicting how the tacrine
moiety would bind to the peripheral site. Obviously, the length
of the linker had to be optimized so that the oxime moiety
could approach the enzyme’s phosphylated serine without un-
binding from the peripheral site. In silico optimization of the
linker-length was performed to maximize the reactivation po-
tency of the bifunctional reactivators, and is described in Sec-
tion 3.
3. Synthesis of the hybrid molecules
3.1. Synthesis of 1,2,3,4-tetrahydro-9-aminoacridine a-
hydroxypyridine amidoximes
The 4-substituted a-hydroxypyridine amidoxime 6 was syn-
thesized starting from commercially available 3-hydroxy-2-cyano-
pyridine 16 (Scheme 1). The introduction of the ortho-directing N-
(diethylamino)carbamate group (both as ortho directing group for
the metallation, and as further phenol protecting group) was ach-
ieved in standard conditions allowing to obtain compound 17 with
a good yield (95%). Subsequent ortho-lithiation and substitution
with iodine gave the key building block 18. The Sonogashira
coupling with alkyne 19 [26] proceeded cleanly and allowed pro-
ducing the hybrid compound 20 with 87% yield. Reduction of the
alkyne 20 in the presence of Pd/C yielded the corresponding
saturated compound 21. Attempts to selectively deprotect the N-
(diethylamino)carbamate group of 21 in either acidic or basic
conditions proved unsuccessful, due to the competing hydrolysis or
degradation of the cyano group. After a set of screening conditions,
this critical reaction was successfully achieved upon the treatment
of 21with a large excess (30 equiv.) of hydroxylamine. Under these
conditions, the N-(diethylamino)carbamate was removed in a one-
pot process, and the cyano group was concomitantly converted to
the desired amidoxime 6. Thus, the ﬁnal hybrid molecule 6 was
synthesized in a convergent 5-steps protocol with 13% overall yield.
The synthesis of a-hydroxyamidoxime tetrahydroacridine con-
jugate 7 is shown in Scheme 2. It differs from that of conjugate 6 in
that the substitution on the pyridine ring was performed using the
optimized modular approach described previously for the Sono-
gashira coupling of bromopyridine 22 [27] with alkyne 19 (Scheme
2). Indeed, this coupling worked nicely and gave 23 in excellent
yield (86%). The one-pot alkyne reduction and O-debenzylation
proceeded cleanly to give nitrile 24, which was directly reacted
Fig. 6. General structure of targeted hetero-bifunctional reactivators.
Scheme 1. Synthesis of amidoxime 6.
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with excess of hydroxylamine hydrochloride to give expected
amidoxime 7 with 45% overall yield over the 3 steps.
Docking studies (unpublished results) suggested that the pres-
ence of a tertiary amine in the linker could increase the afﬁnity of
the molecule for AChE -and thus presumably enhance its reac-
tivation efﬁcacy -owing to the amine protonation at physiological
pH that would allow cation-p interactionwith the tyrosine residues
in AChE gorge [28]. To verify this hypothesis, we therefore prepared
hybrids 8 and 9. The synthesis of these a-hydroxypyridine ami-
doxime hybrids connected with tetrahydroacridine byNeMe linker
was based on the reductive amination of aldehyde 25 (obtained by
ortho-lithiation and subsequent formylation of 17) with amines 26
and 27 [29] (Scheme 3). The treatment of 28 and 29 with excess
hydroxylamine gave a-hydroxypyridine amidoximes 8 and 9 in 13%
and 19% overall yields, respectively, over the 3 steps syntheses.
3.2. Synthesis of 1,2,3,4-tetrahydro-9-aminoacridine a-
hydroxypyridine aldoximes
For the synthesis of a-hydroxypyridine oxime hybrids, we ﬁrst
started with the synthesis of 3-hydroxypyridine aldoxime with the
linker in position 4, using the common intermediate 21. For these
molecules, we privileged the one-pot carbamate group removal and
methanolysis of cyano- function to give methyl ester 30 with a
reasonable yield of 42% (Scheme 4). Next, 30 was converted to 31
via a three-step [17] sequence that included: (a) TBDMS protection
of phenol function; (b) reduction of methyl ester to aldehyde with
DIBAL-H; (c) and subsequent deprotection of the silyl-oxy function
using TBAF (33% over three steps). Reaction of the resulting alde-
hyde 31 with NH2OH resulted in the formation of the desired
pyridinaldoxime 10, with 7% overall yield.
Scheme 2. Synthesis of amidoxime 7.
Scheme 3. Synthesis of amidoximes 8 and 9.
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The 5- and 6-substituted a-hydroxypyridine oximes analogues
11e13 were obtained using the modular synthetic approach, con-
sisting in the Sonogashira coupling reaction of 6-bromopyridine 32
[17] or 5-bromopyridine 33 [30] with alkynes 19 or 34 [31],
respectively, followed by reduction of the alkyne and ﬁnally O-
debenzylation. The subsequent three-step transformation of
methyl ester to aldehyde, ensued by reaction with hydroxylamine
(Scheme 5), yielded the desired a-hydroxypyridine oximes 11e13
in 15, 28 and 18% yields.
3.3. Synthesis of 1,2,3,4-tetrahydro-9-thioacridine a-
hydroxypyridine aldoxime
In order to tune the afﬁnity of hybrid reactivator for hAChE, the
structure of the PSL was changed by the substitution of NH at po-
sition 9 of 1,2,3,4-tetrahydroacridine with a sulphur atom. In short,
conjugate 14 bearing 1,2,3,4-tetrahydro-9-thioacridine as PSL was
synthesized according to Scheme 6 by alkylating 1,2,3,4-
tetrahydro-9-thioacridine 44 [32] with 45 to give 46, which was
then used for Sonogashira coupling reaction with 47 to provide
compound 48. Contrary to 35e37, the attempts to reduce the triple
bond of 48 using Pd/C or Pd(OH)2/C failed, possibly due to the
poisoning of catalyst by the reactionwith thioether groups. The use
of only 1.5 equiv of PtO2 yet resulted in successful hydrogenation,
allowing to obtain compound 49with 64% yield. The further three-
step sequence comprising protection of the phenol group, reduc-
tion of methyl ester with DIBAL-H into aldehyde, and the following
deprotection using TBAF generated the desired aldehyde 50, with
42% yield. Finally, reaction of 50 with NH2OH resulted in the for-
mation of pyridinaldoxime 14, with 6% overall yield.
4. Docking and molecular dynamics simulations
Ternary complexes between VX-inhibited hAChE and 3-
hydroxypyridine aldoxime with 2, 3, 4 (compound 12) or 5 (com-
pound 11) carbons linker were investigated by molecular docking
and molecular dynamics simulations (see Supporting Information).
Flexible docking experiments were undertaken, in which the side
chains of active site gorge residues key to the binding of the reac-
tivators were allowed to wander from their native position (see
Scheme 4. Synthesis of oxime 10.
Scheme 5. Synthesis of oximes 11, 12, and 13.
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Supporting Information). In all four docking experiments, a
conformational change was observed in the side chain of
peripheral-site Trp286 (Fig. 7), faithfully reproducing the crystal-
lographic observation from the bis-tacrine/TcAChE complex (PDB
code 2CEK) [19]. This conformational change results in a pep
sandwiching of the tacrine moiety between the aromatic side
chains of Tyr72 and Trp286. The scoring function of the docking
algorithm yielded similar binding energies for the 4 molecules of
about e 9 kcal/mol, indicating that the linker is sufﬁciently long to
prevent unproductive binding of the reactivators in the gorge of the
inhibited enzyme.
The structures resulting from the 4 independent dockings were
then subjected to molecular dynamics (MD) simulations for 5 ns at
a temperature of 300 K. For each, the distance between the
aldoxime oxygen and the VX-AChE phosphorus atom was moni-
tored along the simulation trajectory and the distributions of dis-
tances were analyzed (Fig. 8). The shorter the distance, the higher
the probability to form a covalent bond between the reactivator
oxygen and the phosphorus atom, that is, the more likely should
reactivation occur at a fast rate. Molecule 12 brings the aldoxime
oxygen closer to the phosphorus atom and more frequently (Fig. 8),
suggesting that a 4-carbon linker between the PSL and the aldox-
ime is optimum for reactivation.
5. In vitro reactivation of VX-, tabun and POX-inhibited
hAChE
The abilities of amidoximes 6e9, as well as of aldoximes 10e14
to reactivate in vitro VX-, tabun- and ethyl-paraoxon inhibited
hAChE were investigated by spectrophotometry using the Ellman’s
reaction. Reactivation kinetics were compared to those of known
reactivators, including 2-PAM, obidoxime, HLö-7, trimedoxime
(TMB4) and HI-6. 6-Substituted a-hydroxypyridine amidoxime 7
and 4-substituted a-hydroxypyridine oxime 10 were both totally
inefﬁcient in reactivating either VX-inhibited hAChE or tabun-
inhibited hAChE. (Table 1)
In contrast, 4-substituted tetrahydroacridine a-hydroxypyridine
amidoximes 6 (C5 alkyl linker), 8 and 9 (NeMe linkers) displayed
improved afﬁnity and higher reactivation efﬁciencies (kr2) towards
VX-inhibited hAChE than both 2-PAM and trimedoxime.While they
remained less efﬁcient than obidoxime, HLö-7, and HI-6 in reac-
tivating VX-inhibited hAChE, it is noteworthy that these com-
pounds are the ﬁrst amidoxime-based reactivators that are efﬁcient
towards VX-inhibited hAChE. Quite remarkably, aldoximes 11 and
12 substituted in position 6 of the pyridine ring by the C5 and C4
alkyl linker proved more efﬁcient in reactivating VX-inhibited
hAChE than 2-PAM, obidoxime, trimedoxime, and HI-6. Although
oximes 11 and 12 do not surpass the reactivating efﬁciency of HLö-
7, nor that of our previously described compound 5a, they repre-
sent an interesting new starting point for further improvement. It
must be stressed, in particular, that since they neither bear a per-
manent charge nor a tertiary amine, they should be able to cross the
BBB quite efﬁciently.
Also noteworthy is the fact that oxime 12 is able to reactivate
tabun-inhibited hAChE (Table 2), an OP complex known to be
reluctant to reactivation due to its weak electrophilicity and to the
steric hindrance imposed on the phosphorus atom in the tabun-
hAChE adduct. In fact, compound 12 exhibited higher in vitro
reactivation potency than all quaternary pyridinium aldoximes
described to date. Despite a lower reactivation rate constant (kr)
compared to obidoxime and trimedoxime, compound 12was 4-fold
more efﬁcient than trimedoxime, the best pyridinium aldoxime
reactivator of tabun-inhibited hAChE. Again, this increase in
Scheme 6. Synthesis of oxime 14.
Fig. 7. Docked conformation of molecule 12 (yellow) at the peripheral site of VX-
hAChE. The docked conformations of the ﬂexible residues are shown in cyan and the
native conformations (pdb code 1b41) in blue. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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efﬁciency is likely to be ascribed to its signiﬁcantly greater afﬁnity
towards the tabun-hAChE conjugate (KD). The better reactivity of
compound 12 on both VX- and tabun-inhibited hAChE, as
compared to compound 11, suggest that a 4-carbon linker is opti-
mum for both a good binding to the inhibited enzyme and an ac-
curate orientation of the oxime function needed for displacing of
the phosphyl or phosphoramidyl moiety.
As mentioned already, most organophosphate intoxication re-
sults from pesticide poisoning, which involves the formation of a
diethylphosphoryl conjugate of hAChE. Testing molecules for their
ability to reactivate ethylparaoxon-inhibited hAChE, therefore, al-
lows evaluating them for their general efﬁcacy against pesticide
poisoning. Interestingly, compounds 11 and 12 proved more efﬁ-
cient than obidoxime and HLö-7 towards paraoxon-inhibited
hAChE, (Table 3). Much like the trend observed in the case of VX,
decreasing the linker length from 5 to 4 carbons led to a 1.5-fold
increase in kr.
We note that compounds 7, 10, 11 and 12 are also able to inhibit
native hAChE, with IC50 similar to tacrine and tacrine-pyridyl het-
erodimer 51 (Table 4). While these inhibitory properties could be
envisaged as a drawback of our strategy aiming at increasing the
efﬁcacy of reactivators by increasing their afﬁnities for the target
enzyme, we argue conversely. Indeed, it remains to be proven that
signiﬁcant reversible inhibition of AChE at a concentration similar
to that used to reactivate of OP-inhibited AChE is really problematic
in vivo. Also, it was shown that reversible inhibitors have a pro-
tective effect on AChE, preventing its phosphylation by transiently
occupying the active site [35].
Interestingly, 4-substituted pyridine aldoxime 10 showed no
reactivation of VX-, tabun- and paraoxon-inhibited hAChE and a
higher inhibition compared to tacrine. This is in strong contrast
with 6-substituted compound 11 and suggests that 4-substitution
of pyridine ring favours the binding of tacrine moiety to the
Fig. 8. Distribution of distances between the aldoxime oxygen and the VX phosphorus analyzed along the simulation trajectory for the four different linker lengths (KM 2: eCH2e
CH2e; KM 3: eCH2eCH2-CH2e, KM 4: eCH2eCH2eCH2eCH2e, 12; KM 5: eCH2eCH2eCH2eCH2eCH2e, 11).
Table 1
In vitro reactivation of VX-hAChE.
Reactivator kr (min
!1) KD (mM) kr2 (mM
!1 min!1)b
2-PAM 0.06 ! 0.01 215 ! 75 0.28
Obidoxime 0.60 ! 0.05 54 ! 12 11
HLö-7 0.49a 7.8a 63a
Trimedoxime ndc ndc 0.50 ! 0.02c
HI-6 0.44 ! 0.15 50 ! 26 9
6 ndc ndc 0.65c
8 0.0094 ! 0.0004 15 ! 2 0.6
9 0.032 ! 0.001 30 ! 3 1.1
11 0.56 ! 0.12 41 ! 11 13
12 0.72 ! 0.07 31 ! 6 22
13 ndd (kobs ¼ 0.0038 ! 0.00006 min
!1 at 1 mM)
14 ndd (kobs ¼ 0.0076 ! 0.0005 min
!1 at 200 mM)
a From the ref. [33].
b kr2 ¼ kr/KD.
c If [reactivator] # KD, then there is a linear dependence between kobs and
[reactivator]: kobs ¼ (kr/KD) [reactivator]. In this case, kr and KD cannot be deter-
mined, but kr2 ¼ kr/KD is the slope of the line.
d Not determined if kobs is <0.01 min
!1 at practical concentration.
Table 2
In vitro reactivation of tabun-hAChE.
Reactivator kr (min
!1) KD (mM) kr2 (mM
!1 min!1)a
Obidoxime 0.04 ! 0.006 250 ! 110 0.16
HLö-7 0.020 ! 0.0007 106 ! 15 0.2
Trimedoxime 0.085 ! 0.005 145 ! 25 0.7
8 Less than 10% reactivation at 100 mM in 2 h
9
11 0.0075 ! 0.0005 30 ! 6 0.27
12 0.021 ! 0.001 7.1 ! 1.5 3
a kr2 ¼ kr/KD.
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catalytic site of the enzyme, rather than at its peripheral site. The
substitution of tacrine with thiotacrine as PSL resulted in three
order of magnitude lower inhibition of native hAChE by model
compound 52 and 14, as compared to compounds 51 and 11,
respectively. However, oxime 14 exhibited very poor reactivation of
VX-hAChE, demonstrating that the key to the improvement of the
reactivation potency is ﬁnding the optimal balance between afﬁnity
of the bifunctional reactivator for the enzyme and positioning of
the oxime function relative to the phosphorus atom of the OP-
hAChE adduct.
6. Conclusion
We have described the synthesis and the in vitro biological
properties of a series of novel, promising, non-permanently
charged AChE reactivators, including differently substituted
tacrine a-hydroxypyridine oximes and amidoximes. We demon-
strated that the amidoxime function can be used as a reactivator
function, and allows producing hybrid molecules that equal or
surpass currently approved mono- and bis-pyridinium oximes,
both in terms of reactivation efﬁciency and broadness of their ac-
tivity spectrum. While it remains to be evaluated if the molecules
are centrally active, or require further modiﬁcations to be so, this
new family of oximes holds great promise for the medical treat-
ment of OP-poisoning.
7. Experimental part
7.1. General materials and methods
All reactions were carried out in a ﬂame dried glassware under
an argon atmosphere with dry solvents, under anhydrous
conditions unless otherwise indicated. The chemicals used in the
synthesis and solvents were purchased from Aldrich, Acros, Alfa-
Aesar or ABCR and used without further puriﬁcation. Thin layer
chromatographies (TLC) were carried out using Merck silica gel
plates (silica gel 60 F254). TLC plates were visualized using UV light
(254 nm), followed by detection with cerium sulphate and ninhy-
drin. The column chromatographies were performed using Merck
silica gel 60 (0.063e0.200mm, 70e230mesh, ASTM) according to a
standard procedure. Analytical HPLC chromatography (purity
>95%) were performed using SPD-20A Shimadzu apparatus
equipped with a Zorbax 300SB-C18 column, using a mixture of
acetonitrile and water as eluent (0.1% TFA). 1H NMR and 13C NMR
spectra were recorded on Brucker DPX300, DPX400 and DPX500.
Chemical shifts (d) are quoted in parts permillion and are calibrated
relative to solvent residual peaks. Multiplicities are reported as
follows: s ¼ singlet, d ¼ doublet, t ¼ triplet, m ¼ multiplet,
q ¼ quartet, qui ¼ quintet. Coupling constant are reported in Hertz.
Mass spectra were recorded on an MS/MS high resolution Micro-
mass ZABSpecTOF spectrometer.
7.2. General procedures and analytical data of key compounds 35,
36, 38, 39, 41, 42, 11, and 12
General procedure 1 for the Sonogashira coupling reaction
(synthesis of compounds 20, 23, 35, 36, and 37). The ﬂask con-
taining solution of iodo- or bromopyridine (1 equiv) in THF/Et3N
was evacuated and ﬁlled with Ar three times before the addition of
catalysts Pd(PPh3)4 (0.1 equiv) and CuI (0.2 equiv). After degazation
with Ar the mixture was stirred at the room temperature for 5 min,
then the degazed solution of alkyne (1.1 equiv) was added and the
reaction mixture was stirred during 20 h at the room temperature.
After concentration at reduced pressure the residue was puriﬁed by
the column chromatography.
General procedure 2 for N-(diethylamino)carbamate group
removal and nitrile conversion to amidoxime (synthesis of com-
pounds 6, 8, and 9). The solution of 21, 28 or 29 (1 equiv),
NH2OH.HCl (30 equiv), and pyridine (30 equiv) in 2 mL of ethanol
was reﬂuxed during 14 h. The solvent was removed in vacuo, the
residue was subjected to preparative HPLC chromatography.
General procedure 3 for the one-pot alkyne reduction and O-
debenzylation (synthesis of compounds 24, 38, 39, and 40). To the
degazed solution of alkyne (1 equiv) in ethyl acetate or methanol
Pearlman’s catalyst Pd(OH)2/C (20%, moisture 50%, 0.3 equiv) was
added. After the degazation the solution was bubbled with H2. The
reaction mixture was stirred at RT under H2 (1 atm) during 24 h.
Table 3
In vitro reactivation of paraoxon-hAChE.
Reactivator kr (min
!1) KD (mM) kr2 (mM
!1 min!1)b
Obidoxime 0.81a 32.2a 20a
HLö-7 0.63 " 0.04 210 " 31 3
Trimedoxime 0.34 " 0.02a 47.8 " 6.9a 17a
8 Less than 10% reactivation at 100 mM in 2 h
9 ndd (kobs ¼ 0.0043 " 0.0004 min
!1 at 100 mM)
11 0.0228 " 0.0006 1.1 " 0.1 20.9
12 0.111 " 0.002 3.6 " 0.2 31
cNot determined if kobs is <0.01 min
!1 at practical concentration.
a From the ref. [34].
b kr2 ¼ kr/KD.
Table 4
Inhibition of hAChE.
Compound IC50 (mM) Compound IC50 (mM)
Tacrine 0.20 " 0.02 (Human erythrocyte AChE)a 12 1.40 " 0.03 (hAChE)
0.15 " 0.01 (hAChE) 13 0.163 (hAChE)
7 0.26 " 0.01 (hAChE) 130 " 15 (hAChE)
10 0.077 " 0.003 (hAChE) 14 307 (hAChE)
11 0.26 " 0.01 (hAChE)
a From ref. [36].
M. Kliachyna et al. / European Journal of Medicinal Chemistry 78 (2014) 455e467 463
The solution was ﬁltered through celite, the solvent was evapo-
rated, and the product was dried in vacuo.
General procedure 4 for the three-step transformation of the
methyl ester into aldehyde (synthesis of compounds 31, 41, 42, 43
and 50). The solution of methyl ester 30, 38, 39, 40 or 49 (1 equiv),
imidazole (4.15 equiv), and TBDMSCl (2.4 equiv) in dry DMF was
stirred at the room temperature under argon during 2 h. Ethyl ac-
etate was added, and the organic phase was washed with water 3
times, dried over Na2SO4 and concentrated in vacuum. After drying
in vacuum the compound obtained was subjected without puriﬁ-
cation to the following reduction of methyl ester with DIBAL-H. To
the solution of the compound obtained (1 equiv) in dry CH2Cl2
at !78 !C DIBAL-H (1 M solution in CH2Cl2, 2 equiv) was added
dropwise. The reaction mixture was stirred at  78 !C for 12 min,
then it was quenched with MeOH, and the cooling bath was
removed.When themixturewas warmed to the room temperature,
the organic phase was washed with aqueous solution of NaOH
(1M), dried over Na2SO4 and concentrated under reduced pressure.
After drying in vacuum the product obtained was subjected to the
following reaction with TBAF. To the solution of the compound
obtained (1 equiv) in dry THF at 0 !C TBAF (1 M solution in THF,
1.1 equiv) was added, and the reaction mixture was stirred at this
temperature for 1 h. After removal of the solvent under reduced
pressure the residue was puriﬁed by the column chromatography
(silica gel).
General procedure 5 for synthesis of oximes 10e14. The solution
of aldehyde 31, 41, 42, 43 or 50 (1 equiv), NH2OH.HCl (1.5 equiv),
and CH3COONa (1.5 equiv) in dry ethanol was stirred during 8 h.
After concentration under reduced pressure the crude product was
puriﬁed by the column chromatography or preparative HPLC.
7.2.1. Methyl 3-(benzyloxy)-6-{5-[(1,2,3,4-tetrahydroacridin-9-yl)
amino]pent-1-yn-1-yl}pyridine-2-carboxylate (35)
Compound 35 was obtained accordingly to the general proce-
dure 1 for Sonogashira coupling using 32 (0.147 g, 0.46 mmol,
1 equiv), 19 (0.132 g, 0.5 mmol, 1.1 equiv), Pd(PPh3)4 (0.041 g,
0.046 mmol, 0.1 equiv), CuI (0.017 g, 0.09 mmol, 0.2 equiv), Et3N
(3 mL), and THF (6 mL). The crude product was puriﬁed by the
column chromatography (silica gel, gradient from ethyl acetate to
ethyl acetate/MeOH ¼ 8/2, Rf ¼ 0.24). Yield 180 mg, 78%.
1H NMR
(300 MHz, CDSl3, d): 1.76e1.84 (4H, m), 1.87e1.97 (2H, qui,
J ¼ 6.7 Hz), 2.49 (2H, t, J ¼ 6.7 Hz), 2.64 (2H, m), 3.03 (2H, m), 3.67
(2H, t, J¼ 6.9 Hz), 3.88 (3H, s, CH3O), 5.14 (2H, s, PhCH2O), 7.18e7.38
(8H, m, ArH), 7.48 (1H, t, J ¼ 7.6 Hz), 7.90e7.93 (2H, m). 13C NMR
(100MHz, CDCl3, d): 17.29; 22.79; 23.13; 25.05; 29.98; 33.79; 48.42;
52.88; 71.10; 80.64; 88.84; 120.24; 121.96; 122.93; 124.19; 127.12;
128.37; 128.47; 128.63; 128.75; 128.83; 128.95; 130.11; 132.24;
132.34; 135.23; 135.66; 146.91; 150.97; 153.20; 158.23; 164.99.
7.2.2. Methyl 3-hydroxy-6-{5-[(1,2,3,4-tetrahydroacridin-9-yl)
amino]pentyl}pyridine-2-carboxylate (38)
Compound 38 was obtained accordingly to the general proce-
dure 3 for the reduction of the triple bond and O-debenzylation
using 35 (0.180 g, 0.35 mmol), Pd(OH)2/C (20%, 0.075 g, 0.11 mmol,
0.3 equiv), and 2.5 mL of MeOH. Yield 0.140 g, 94%. Rf ¼ 0.34
(CH2Cl2/MeOH¼ 10/1).
1HNMR (300MHz, CDCl3, d): 1.40e1.50 (2H,
m), 1.67e1.78 (4H, m), 1.87e1.92 (4H, m), 2.63 (2H, m), 2.78 (2H, t,
J ¼ 7.9 Hz), 3.11 (2H, m), 3.56 (2H, t, J ¼ 7.2 Hz), 4.00 (3H, s, CH3O),
7.23 (1H, d, J ¼ 8.6 Hz), 7.28 (1H, d, J ¼ 8.6 Hz), 7.31e7.36 (1H, m),
7.54e7.59 (1H, m), 7.95 (1H, d, J ¼ 8 Hz), 8.05 (1H, d, J ¼ 8.6 Hz). 13C
NMR (100 MHz, CDCl3, d): 20.87; 22.11; 23.78; 26.38; 28.60; 29.62;
31.09; 37.02; 48.61; 53.55; 110.88; 115.99; 121.66; 124.19; 125.49;
127.88; 129.65; 132.63; 139.27; 152.03; 153.45; 155.55. HRMS (ESI,
m/z): calcd. for C25H30N3O3 [M þ H]
þ, 420.22871; found,
420.22836.
7.2.3. 3-Hydroxy-6-{5-[(1,2,3,4-tetrahydroacridin-9-yl)amino]
pentyl}pyridine-2-carbaldehyde (41)
Compound 41was obtained by the general procedure 4 from 38
with yield 37% (over three steps). Rf ¼ 0.23 (ethyl acetate/
MeOH ¼ 10/3). 1H NMR (400 MHz, CDCl3, d): 1.40e1.48 (2H, m),
1.67e1.79 (4H, m), 1.85e1.90 (4H, m), 2.64 (2H, m), 2.76 (2H, t,
J ¼ 7.7 Hz), 3.05 (2H, m), 3.52 (2H, t, J ¼ 7.3 Hz), 7.23 (1H, d,
J ¼ 8.7 Hz), 7.25 (1H, d, J ¼ 8.7 Hz), 7.29e7.33 (1H, m, ArH), 7.51e
7.55 (1H, m, ArH), 7.92e7.95 (2H, m), 9.99 (1H, s, CHO). 13C NMR
(100MHz, CDCl3, d): 22.73; 23.11; 24.88; 26.70; 29.48; 31.76; 33.48;
37.28; 49.45; 115.48; 123.10; 124.02; 126.64; 127.99; 129.01;
129.88; 131.06; 135.95; 151.45; 154.66; 157.23; 157.88; 198.83.
HRMS (ESI, m/z): calcd. for [M þ H]þ, C24H28N3O2, 390.21815;
found, 390.21892.
7.2.4. 2-[(1E)-(hydroxyimino)methyl]-6-{5-[(1,2,3,4-
tetrahydroacridin-9-yl)amino]pentyl}pyridin-3-ol (11)
Compound 11 was obtained accordingly to the general proce-
dure 5 using 41 (0.050 g, 0.13 mmol, 1 equiv), NH2OH.HCl (0.013 g,
0.19 mmol, 1.5 equiv), CH3COONa (0.016 g, 0.19 mmol, 1.5 equiv),
and 1.2 mL of ethanol. After evaporation of the solvent and puriﬁ-
cation by column chromatography (ethyl acetate/MeOH ¼ 8/2)
product was obtained with yield 55%. Rf ¼ 0.44 (ethyl acetate/
MeOH ¼ 2/1). 1H NMR (400 MHz, CD3OD, d): 1.37e1.44 (2H, m,
CH2), 1.68e1.76 (2H, qui, J ¼ 7.4 Hz, CH2), 1.77e1.85 (2H, qui,
J ¼ 7.4 Hz, CH2), 1.90e1.94 (4H, qui, J ¼ 3.3 Hz, CH2), 2.63 (2H, m,
CH2), 2.70 (2H, t, J ¼ 7.4 Hz, CH2), 3.00 (2H, m, CH2), 3.87 (2H, t,
J ¼ 6.9 Hz, CH2), 7.08 (1H, d, J ¼ 8.4 Hz, ArH), 7.20 (1H, d, J ¼ 8.4 Hz,
ArH), 7.50e7.54 (1H, m, ArH), 7.76e7.81 (2H, m, ArH), 8.17 (1H, s,
N]CH), 8.30 (1H, d, J ¼ 8.7 Hz). 13C NMR (100 MHz, CD3OD, d):
22.31; 23.30; 25.25; 27.05; 30.30; 30.53; 30.91; 31.42; 37.56; 117.95;
121.70; 125.51; 126.08; 126.18; 133.42; 136.35; 152.90; 153.85;
154.49. MSm/z (ESI) calcd. for C24H29N4O2 [MþH]
þ, 405.22; found,
405.2.
7.2.5. Methyl 3-(benzyloxy)-6-{4-[(1,2,3,4-tetrahydroacridin-9-yl)
amino]but-1-yn-1-yl}pyridine-2-carboxylate (36)
Compound 36 was obtained accordingly to the general proce-
dure 1 for Sonogashira coupling reaction using 32 (0.292 g,
0.91 mmol, 1 equiv), 34 (0.250 g, 1 mmol, 1.1 equiv), Pd(PPh3)4
(0.081 g, 0.091mmol, 0.1 equiv), CuI (0.035 g, 0.18mmol, 0.2 equiv),
Et3N (6 mL), and THF (12 mL). The crude product was puriﬁed by
the column chromatography (silica gel, gradient from ethyl acetate/
MeOH ¼ 10/1 to ethyl acetate/MeOH ¼ 8/2), Rf ¼ 0.43 (ethyl ace-
tate/MeOH ¼ 4/1). Yield 0.440 g, 98%. 1H NMR (400 MHz, CDCl3, d):
1.82e1.89 (4H, m), 2.67 (2H, t, J ¼ 6.3 Hz), 2.79 (2H, t, J ¼ 5.9 Hz),
3.06 (2H, t, J ¼ 5.9 Hz), 3.70e3.75 (2H, dt, J ¼ 6.4 Hz), 3.95 (3H, s),
4.48 (1H, t, J ¼ 6.4 Hz, NH), 5.19 (2H, s, OCH2Ph), 7.25 (1H, d,
J ¼ 8.8 Hz), 7.28 (2H, d, J ¼ 8.8 Hz), 7.31e7.42 (6H, m, ArH), 7.52e
7.56 (1H, m), 7.97 (2H, t, ArH, J ¼ 8.3 Hz). 13C NMR (100 MHz, CDCl3,
d): 22.10; 22.59; 22.99; 24.93; 29.89; 33.29; 47.34; 52.93; 71.10;
77.43; 81.98; 86.71; 116.94; 120.15; 121.92; 123.00; 124.56; 127.14;
127.66; 128.51; 128.97; 129.30; 130.09; 134.74; 135.59; 140.67;
146.04; 151.08; 153.37; 157.78; 164.98. HRMS (ESI, m/z): calcd. for
C31H30N3O3 [M þ H]
þ, 492.22871; found, 492.22851.
7.2.6. Methyl 3-hydroxy-6-{4-[(1,2,3,4-tetrahydroacridin-9-yl)
amino]butyl}pyridine-2-carboxylate (39)
Compound 39 was obtained accordingly to the general proce-
dure 3 using 36 (0.43 g, 0.87 mmol), Pd(OH)2/C (20%, 0.184 g,
0.26 mmol, 0.3 equiv), and 3 mL of MeOH. Yield 0.34 g, 96%.
Rf ¼ 0.43 (CH2Cl2/MeOH ¼ 10/1).
1H NMR (300 MHz, CD3OD, d):
1.67e1.74 (4H, m), 1.87e1.91 (4H, m), 2.68 (2H, t, J ¼ 5.3 Hz), 2.72
(2H, t, J ¼ 7 Hz), 2.96 (2H, t, J ¼ 5.5 Hz), 3.62 (2H, t, J ¼ 6.7 Hz), 3.96
(3H, s, CH3O), 7.23 (1H, d, J ¼ 8.6 Hz), 7.27 (2H, d, J ¼ 8.6 Hz), 7.34e
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7.40 (1H, m), 7.57e7.62 (1H, m), 7.74 (1H, d, J ¼ 8.4 Hz), 8.10 (1H, d,
J ¼ 8.4 Hz). 13C NMR (100 MHz, CD3OD, d): 23.25; 23.87; 25.96;
28.22; 31.31; 32.84; 37.27; 53.34; 115.73; 120.15; 125.07; 125.29;
125.74; 128.52; 130.46; 130.65; 131.09; 145.48; 154.49; 154.54;
156.94; 158.65; 170.62. HRMS (ESI, m/z): calcd. for C24H28N3O3
[M þ H]þ, 406.21306; found, 406.21307.
7.2.7. 3-Hydroxy-6-{4-[(1,2,3,4-tetrahydroacridin-9-yl)amino]
butyl}pyridine-2-carbaldehyde (42)
Compound 42 was obtained from 39 accordingly to the general
procedure 4 after puriﬁcation by the column chromatography
(silica gel, ethyl acetate/MeOH ¼ 8/2) with yield 54% (over 3 steps).
Rf ¼ 0.21 (ethyl acetate/MeOH ¼ 7/3).
1H NMR (400 MHz, CDCl3, d):
1.66e1.75 (2H, m), 1.78e1.89 (6H, m), 2.67 (2H, m), 2.79 (2H, t,
J ¼ 7 Hz), 3.04 (2H, m), 3.52 (2H, t, J ¼ 7 Hz), 7.20 (1H, d, J ¼ 8.6 Hz),
7.24 (1H, d, J¼ 8.6 Hz), 7.31 (1H, td, J¼ 6.8 Hz, J¼ 1 Hz), 7.53 (1H, td,
J¼ 6.8 Hz, J¼ 1 Hz), 7.89e7.93 (2H, m), 9.98 (1H, s, CH]O). 13C NMR
(100MHz, CDCl3, d): 22.89; 23.20; 25.01; 26.96; 31.37; 33.92; 36.98;
49.32; 116.06; 120.29; 122.94; 123.95; 126.69; 128.68; 129.87;
136.00; 147.27; 150.99; 154.29; 157.29; 158.43; 198.74. HRMS (ESI,
m/z): calcd. for C23H26N3O2 [Mþ H]
þ, 376.20250; found, 376.20201.
7.2.8. 2-[1-(Hydroxyimino)methyl]-6-{4-[(1,2,3,4-
tetrahydroacridin-9-yl)amino]butyl}pyridin-3-ol (12)
Compound 12 was obtained accordingly to the general proce-
dure 5 using 42 (0.090 g, 0. 24 mmol, 1 equiv), NH2OH.HCl (0.025 g,
0.36 mmol, 1.5 equiv), CH3COONa (0.029 g, 0.36 mmol, 1.5 equiv),
and 2.5 mL of ethanol. Compound 12 was puriﬁed by the column
chromatography (silica gel, CH2Cl2/MeOH ¼ 8/2) with yield 55%.
Rf ¼ 0.6 (ethyl acetate/MeOH ¼ 2/1).
1H NMR (400 MHz, CD3OD, d):
1.80e1.83 (4H, m, CH2CH2CH2CH2), 1.90e1.95 (4H, m,
CH2CH2CH2CH2), 2.62 (2H, t, J ¼ 5.5 Hz, CH2), 2.71 (2H, t, J ¼ 6.4 Hz,
CH2), 2.98 (2H, m, CH2), 3.87 (2H, t, J ¼ 5.6 Hz, CH2), 7.04 (1H, d,
J ¼ 8.4 Hz, ArH), 7.09 (1H, d, J ¼ 8.4 Hz); 7.47e7.51 (1H, m, ArH),
7.71e7.79 (2H, m, ArH), 8.08 (1H, s, CH]N), 8.24 (1H, d, J ¼ 8.8 Hz).
13C NMR (100 MHz, CD3OD, d): 22.04; 23.09; 25.03; 27.55; 29.84;
30.60; 37.11; 113.35; 117.54; 121.08; 125.43; 125.83; 126.12; 126.19;
133.51; 136.24; 140.59; 152.44; 152.75; 153.65; 154.12; 157.25.
HRMS (ESI,m/z): calcd. for C23H27N4O2 [M þ H]
þ 391.21340; found,
391.21337.
7.3. Biological essays
7.3.1. IC50 measurements
Recombinant hAChE was produced and puriﬁed as previously
described (see reference: http://www.ncbi.nlm.nih.gov/pubmed/
18975951). Oximes were dissolved in MeOH to make 5- or 10-
mM stock solution. Recombinant hAChE activity was measured
spectrophotometrically (absorbance at 412 nm) in the presence of
various concentrations of oximes in 1 mL Ellman’s buffer (phos-
phate 0.1 M, pH 7.4, 0.1% BSA, 5% MeOH, 0.5 mM DTNB, 25 "C).
Measurements were performed at least in duplicate for each con-
centration tested. The concentration of oxime producing 50% of
enzyme inhibition was determined by non-linear ﬁtting using
ProFit (Quantumsoft) using the standard IC50 equation: %
Activity ¼ 100*IC50/(IC50 þ [Ox]).
7.3.2. Inhibition of hAChE by OPs
VX, tabun were from DGA maîtrise NRBC (Vert le Petit, France).
Paraoxon-ethyl was purchased from SigmaeAldrich. Stock solution
of VX and tabun were 5 mM in isopropanol. The inhibition of
120 mM hAChE is realized with a 5-fold excess of OPs and was
performed in tris buffer (20 mM, pH 7.4, 0.1% BSA) at 25 "C. After a
20-min incubation, inhibited hAChE was desalted on PD-10 column
(GE Healthcare).
7.3.3. Reactivation of hAChE inhibited by OPs
Hlö-7 was from DGA maîtrise NRBC (Vert le Petit, France), HI-6
from Pharmacie Centrale des Armées (Orléans, France) and obi-
doxime was from CRSSA (Lyon, France; synthesized by Bernard
Desiré). OP-inhibited hAChE was incubated at 37 "C with at least 4
concentrations of oxime in phosphate buffer (0.1 M, pH 7.4, 0.1%
BSA). The ﬁnal concentration of MeOH in the incubation mix was
below 2% and had no inﬂuence on the enzyme stability. At time
intervals ranging from 1 to 10 min depending on the reactivation
rate, 10-mL aliquots of each solutions containing the different con-
centrations of oxime were transferred to cuvettes containing 1 mM
acetylthiocholine in 1 mL Ellman’s buffer (phosphate 0.1 M, pH 7.4,
0.1% BSA, 0.5 mM DTNB, 25 "C) for measurement of hAChE activity.
The enzyme activity in the control (uninhibited enzyme þ oxime)
remained constant during the experiment. Oximolysis was
undetectable.
The percentage of reactivated enzyme (%Ereact) was calculated as
the ratio of the recovered enzyme activity and activity in the con-
trol. The apparent reactivation rate kobs for each oxime concentra-
tion, the dissociation constant KD of inhibited enzymeeoxime
complex (EePOx) and the maximal reactivation rate constant kr,
were calculated by non-linear ﬁt with ProFit (Quantumsoft) using
the standard oxime concentration-dependent reactivation equa-
tion derived from the following scheme:
E # P þ Ox%
KD
E # POx !kr E þ POx
%Ereact ¼ 100$
 
1# ekobs$t
!
and kobs ¼
kr ½Ox&
KD þ ½Ox&
Detailed reactivator concentrations used for each set of experi-
ments are given in the Supplementary Information.
7.4. Molecular modelling
Flexible dockings have been performed using autodock vina
[37] and by preparing the system in PyMOL (Schrödinger) using the
plug-in developed by Daniel Seeliger (http://wwwuser.gwdg.de/
wdseelig/adplugin.html). VX-hAChE was constructed from the
apo form (pdb code 4EY4) by homology to the mAChE-VX structure
(pdb code 2Y2U), keeping in the active site all the usually conserved
water molecules. Residues in the gorge (Tyr72, Asp74, Trp86,
Tyr124, Ser125, Trp286, Tyr337, Phe338, Tyr341) have been chosen
as ﬂexible, along with the ethyl group of VX. A docking box of
60 ' 60 ' 60 Å was chosen, centered at the bottom of the gorge
between Tyr124 and Trp86. Ligands were built and optimized from
SMILEs string using Phenix elbow [38]. The default parameter set of
Autodock vina was used to generate 9 docking poses per molecule.
Molecular dynamics simulations were carried out using
GROMACS 4.5.6 [39] and the Amber99sb forceﬁeld [40]. The to-
pological description of each KM molecule was built using acpype
and the general amber forcefield [41]. The hAChE-VX complex in
the conformation obtained from ﬂexible dockings together with
crystal water molecules and the different KM molecules, was
immersed in a periodic water box of cubic shape with a minimal
distance of 10 A to any edge and periodic boundary conditions. The
box was solvated using the TIP3P solvation model and chloride and
sodium counter ions were added to neutralize the simulation sys-
tem. After energy minimization using a 500-step steepest decent
method, the system was subjected to equilibration at 1 bar for 50 ps
under the conditions of position restraints for heavy atoms. The
solvent, the counter ions, and the protein were coupled separately
to a temperature bath at 300 K. The LennardeJones interactions
were cutoff at 1.4 nm. The long-range electrostatic interactions
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were handled using particle-mesh Ewald method for determining
long-range electrostatics (9 A cutoff). Temperature was set to 300 K
and was kept constant using a Berendsen thermostat [42] (with a
coupling time constant of 0.1 ps). Pressure with a reference value of
1 bar was controlled by a Berendsen barostat (with a coupling time
constant of 1 ps and a compressibility of 4.5 105 bar). Full MD
simulationwas performed for 5 ns at 300 K, using 2 fs timesteps. All
bond lengths were constrained using the LINCS algorithm allowing
an integration step of 2 fs [43]. Coordinates were saved every 250
steps (every 0.5 ps).
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ABSTRACT: Tri-o-cresyl-phosphate (TOCP) is a common
additive in jet engine lubricants and hydraulic ﬂuids suspected
to have a role in aerotoxic syndrome in humans. TOCP is
metabolized to cresyl saligenin phosphate (CBDP), a potent
irreversible inhibitor of butyrylcholinesterase (BChE), a natural
bioscavenger present in the bloodstream, and acetylcholinesterase
(AChE), the oﬀ-switch at cholinergic synapses. Mechanistic
details of cholinesterase (ChE) inhibition have, however,
remained elusive. Also, the inhibition of AChE by CBDP is
unexpected, from a structural standpoint, i.e., considering the
narrowness of AChE active site and the bulkiness of CBDP. In the following, we report on kinetic X-ray crystallography
experiments that provided 2.7−3.3 Å snapshots of the reaction of CBDP with mouse AChE and human BChE. The series of
crystallographic snapshots reveals that AChE and BChE react with the opposite enantiomers and that an induced-ﬁt
rearrangement of Phe297 enlarges the active site of AChE upon CBDP binding. Mass spectrometry analysis of aging in either
H2
16O or H2
18O furthermore allowed us to identify the inhibition steps, in which water molecules are involved, thus providing
insights into the mechanistic details of inhibition. X-ray crystallography and mass spectrometry show the formation of an aged
end product formed in both AChE and BChE that cannot be reactivated by current oxime-based therapeutics. Our study thus
shows that only prophylactic and symptomatic treatments are viable to counter the inhibition of AChE and BChE by CBDP.
■ INTRODUCTION
Tri-o-cresyl phosphate (TOCP), a toxic isomer of tricresyl
phosphate (TCP), is suspected to play an important role in
aerotoxic syndrome. TCP is added to commercial jet engine
lubricants for its antiwear and ﬂame-retardant properties.1−3
When oil seals in jet-airplanes leak, the cabin bleed-air becomes
contaminated with TOCP. TOCP is inhaled and metabolized
by liver microsomal cytochrome P450 and serum albumin into
2-(o-cresyl)-4H-1,3,2-benzodioxaphosphoran-2-one (CBDP),
also called cresyl saligenin phosphate.4−6
CBDP is a bicyclic organophosphorus compound (OP),
which irreversibly inhibits both human acetylcholinesterase
(hAChE; EC 3.1.1.7) and butyrylcholinesterase (hBChE; EC
3.1.1.8).7 hAChE is the enzyme responsible for the termination
of nerve-impulse transmission at cholinergic synapses, and as
such, it is the primary target of chemically synthesized OPs.
hBChE is a structurally and functionally homologous enzyme
that is present in the bloodstream (50 nM, in humans) and acts
as a stoichiometric bioscavenger of OPs. 8 Irreversible
inhibition of hAChE and hBChE by OPs generally proceeds
in two steps; phosphylation of the catalytic serine with
concomitant release of a leaving group, followed by deal-
kylation of the OP-enzyme adduct, a process also called aging.
It is noteworthy that medical countermeasures to reactivate
cholinesterases are only eﬃcient against nonaged enzymes:9
aged ChEs can indeed no longer be reactivated by oximes used
as antidotes against OP poisoning.
hAChE and hBChE diﬀer mostly by the amino acid
distribution in their active site gorges, the former containing
more aromatic residues than the latter. In particular, the
replacement of two phenylalanine residues in the acyl-binding
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pocket of hAChE, by a leucine and a valine in BChE, results in
an enlargement of the pocket, thereby allowing accommodation
of bulkier substrates and inhibitors and expanding the substrate
speciﬁcity of hBChE as compared to that of hAChE.10
Accordingly, hAChE and hBChE have repeatedly been reported
to preferentially react with diﬀerent OP stereoisomers.11
The ensemble of neurological symptoms associated with
aerotoxic syndrome includes memory impairment and uncon-
trollable shaking.12,13 It has been shown that CBDP inhibits
esterase enzymes, notably the neuropathy target esterase14,15
but also hBChE and hAChE.7,16−18 In addition, other serine
esterases are likely inhibited by CBDP and tyrosine residues in
several proteins have been shown to be reactive toward CBDP.
Inhibition of such proteins may participate in the pathogenesis
of aerotoxic syndrome.
We earlier investigated the inhibition mechanisms of hAChE
and hBChE by CBDP using a combination of kinetic
measurements, mass spectrometry, and X-ray crystallography.7
As shown in Scheme 1, the inhibition of hBChE by CBDP
occurs in three steps.
CBDP ﬁrst forms a phosphorylserine conjugate of hBChE,
with saligenin and o-cresyl as substituents (oCSP-hBChE). The
ﬁrst aging reaction corresponds to the release of the saligenin
moiety, and results in the o-cresyl-phospho-BChE adduct
(oCP-hBChE). A second aging reaction then occurs that allows
the release of the o-cresyl moiety and yields phospho-hBChE,
whose structure we reported already.7 We also showed that the
bimolecular rate constant of CBDP for hBChE is at least 10-
fold higher than that for hAChE. CBDP is, in fact, one of the
most potent BChE inhibitors reported to date (1.5 × 108
M−1·min−1), suggesting that hBChE eﬃciently scavenges
CBDP in the bloodstream. The reactivity of CBDP toward
hAChE is in the same range as that exhibited by paraoxon,
tabun, or soman (106−107 M−1·min−1). It remains unclear,
however, if hAChE and hBChE inhibition by CBDP proceeds
in the same fashion, and whether the same intermediate states
form.
Here, we provide a detailed description of mouse (m) AChE
and human (h) BChE inhibition by CBDP, based on
crystallographic snapshots of inhibition intermediate states
and on mass spectrometry analyses. We show that mAChE
inhibition by CBDP occurs in two steps and involves a transient
enlargement of the acyl-binding pocket to allow accommoda-
tion of the bulky CBDP adduct. The resulting o-cresyl-
phospho-mAChE is a stable OP-aged adduct that does not
evolve further. In contrast, the o-cresyl-phospho-hBChE adduct
represents an unstable, strained conformer of hBChE that
undergoes a second aging reaction yielding a phospho-serine-
hBChE adduct. CBDP inhibition of mAChE and hBChE
involves a diﬀerent stereoisomer of CBDP, occurs through
diﬀerent pathways, and yields a diﬀerent end-conjugate.
■ EXPERIMENTAL PROCEDURES
Caution: CBDP is a highly toxic organophosphorus compound.
Handling requires suitable personal protection, training, and facilities.
These requirements are the same as those for other poisonous
organophosphorus compounds.
Chemicals. CBDP was synthesized by Starks Associates Buﬀalo,
NY, and provided by Dr. D. Lenz (USAMRICD, Aberdeen PG, MD)
and Dr. Wolf Dettbarn (Vanderbilt University, Nashville, TN). A 0.1
M stock solution of CBDP in acetonitrile was stored at −20 °C and
diluted in water on the day of the mass spectrometry or
crystallography experiment. Pepsin (from porcine stomach mucosa)
was purchased from Sigma (a member of the Sigma-Aldrich group, St.
Louis, MO). 18O-Water (99% 18O) was purchased from ISOTEC (a
member of the Sigma-Aldrich group). Chemical structures and
reaction schemes were illustrated using the program ChemDraw
(CambridgeSoft).
Production of Recombinant ChEs. Recombinant hBChE
(L530stop) is a truncated monomer containing residues 1 to 529
but missing 45 C-terminal residues that include the tetramerization
domain. Four of the nine carbohydrate attachment sites were deleted
by site-directed mutagenesis. Mutagenesis of N486 resulted in
glycosylation of N485, an asparagine that is not glycosylated in native
hBChE so that the recombinant hBChE contains six N-linked
glycans.19 The recombinant hBChE gene was expressed in Chinese
hamster ovary (CHO) cells, secreted into serum-free culture medium,
and puriﬁed by aﬃnity and ion-exchange chromatographies as
described previously.19
The synthetic gene (GeneArt) coding for a truncated mutant of
mAChE (L544Stop) was inserted into a pGS vector carrying the
glutamine synthetase gene marker and expressed in Chinese hamster
ovary (CHO)-K1 cells. The cells were maintained in serum-free
Ultraculture Medium (BioWhittaker, Walkersville, MD) and trans-
fected using DNA−calcium phosphate coprecipitation. Transfected
clones were selected by incubation in media containing methionine
sulfoximine. The mouse enzyme, secreted into the culture medium,
was puriﬁed by aﬃnity chromatography and ion-exchange chromatog-
raphy using a protocol identical to that described for the recombinant
human enzyme.20 The enzyme was concentrated to 14 mg/mL using a
Centricon-30 ultraﬁltration microconcentrator (30000 MW cutoﬀ,
Amicon, Millipore, Billerica, MA) in 10 mM MES buﬀer at pH 6.5.
Crystallization of hBChE and Generation of CBDP-hBChE
Conjugates. hBChE was concentrated to 9 mg/mL and crystallized
using the hanging drop vapor-diﬀusion method as described
previously.19 Two diﬀerent conjugates were obtained by soaking
native crystals for either 2 min or 12 h at 4 °C in a mother liquor
solution (0.1 M MES at pH 6.5 and 2.1 M ammonium sulfate)
containing 1 mM CBDP. Crystals were then soaked for a few seconds
in a cryoprotectant solution (0.1 M MES buﬀer at pH 6.5, 2.3 M
ammonium sulfate, and 20% glycerol) before being ﬂash-cooled in
liquid nitrogen for data collection.
Crystallization of mAChE and Generation of CBDP-mAChE
Conjugates. mAChE, concentrated to 14 mg/mL, was crystallized
using the hanging drop vapor-diﬀusion method as described
previously.21 Two diﬀerent conjugates were obtained by soaking
native mAChE crystals for either 30 min or 12 h at 4 °C in a mother
Scheme 1. Reaction of CBDP with hBChE
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liquor solution (0.1 M Tris HCl buﬀer at pH 7.4 and 1.6 M
ammonium sulfate) containing 1 mM CBDP. Crystals were soaked for
a few seconds in a cryoprotective solution (0.1 M Tris HCl buﬀer at
pH 7.4, 1.8 M ammonium sulfate, and 18% glycerol) and ﬂash-cooled
in liquid nitrogen.
X-ray Data Collection and Processing, Structure Determi-
nation, and Reﬁnement. Diﬀraction data were collected on the
ID14-eh4 beamline22 at the European Synchrotron Radiation Facility
(ESRF, Grenoble, France) with an ADSC Quantum Q315r detector.
The beam was characterized by a wavelength of 0.9765 Å, and the
crystals were held at 100 K during data collection. All data sets were
processed with XDS,23 intensities of integrated reﬂections were scaled
using XSCALE, and structure factors were calculated using
XDSCONV. The structures were solved by molecular replacement
with the program MOLREP24 of the CCP4 suite25 using the
recombinant hBChE structure (PDB entry 1P0I) and mAChE (PDB
entry 4A16) as starting models. For all diﬀraction data sets, the initial
models were reﬁned as follows: a rigid-body reﬁnement, carried out
with REFMAC5,26 was followed by iterative cycles of model building
with Coot27 and restrained TLS reﬁnement was carried out with
Phenix.28 The bound ligands and their descriptions were built using
the Dundee PRODRG2.5 server including energy minimization using
GROMOS96.1 force ﬁeld calculations. Successive alternation of
reﬁnement cycles and manual model building were performed until
Rcryst and Rf ree did not decrease any further.
In addition, for mAChE, a reﬁnement strategy involving TLS,
Ramachandran, secondary structure restraints, and occupancy
optimization was performed using Phenix. In the course of the
reﬁnement of oCSP-mAChE, it appeared that Phe297 adopts two
alternative conformations and that occupancies of saligenin of oCSP-
mAChE were partial. Therefore, the occupancies of Phe297 and
saligenin in oCSP-mAChE were reﬁned with Phenix as follows: B-
factors and occupancy of Phe297 and saligenin were initially set to 30
Å2 and 0.5, respectively. Then, coordinates and B-factors were reﬁned
resulting in a B-factor about 50 Å2 for Ser198. To account for the
higher disorder of oCSP, its B-factor was manually adjusted to the B-
factor of Ser198 plus 20% (60 Å2). Next, occupancies were reﬁned,
grouping the alternative conformation of Phe297 with saligenin. The
resulting occupancies were rounded to the next digit, and a ﬁnal
reﬁnement cycle of coordinate and B-factor was performed. Protein
structures were illustrated using the program PyMOL (Schrödinger,
LLC).
Mass Spectrometry of CBDP-mAChE and CBDP-hBChE after
Reaction in H2
18O. mAChE or hBChE (3.2 μM) was irreversibly
inhibited by reaction with CBDP (93 μM) either in H2
18O (93%
enriched) or H2
16O and 10 mM ammonium bicarbonate (pH 8) at 22
°C for 1 or 40 h. At the end of the inhibition period, there was no
activity remaining for either mAChE or hBChE. Before proteolysis,
water from both the H2
18O and H2
16O samples was removed by
evaporation in a Savant SpeedVac (Thermo Fisher Scientiﬁc,
Waltham, MA). The samples were then redissolved in H2
16O to a
ﬁnal concentration of 3.2 μM. Removal of the 18O water simpliﬁed the
mass spectra by preventing 18O atoms from being incorporated into
the carboxyl termini of the peptides during proteolysis. Proteolysis was
performed by adding pepsin (5 mg/mL in 5% formic acid) to each
tube to obtain a ﬁnal cholinesterase to pepsin ratio of 1:2 (w/w) and a
ﬁnal pH of 2.5. Mixtures were incubated at 37 °C for 2 h. Aliquots of
each digest were diluted 1 to 10 in 50% acetonitrile and 0.3%
triﬂuoroacetic acid (TFA), spotted directly onto MALDI sample
plates, and air-dried. Dried spots were overlaid with a 2,5-dihydroxy
benzoic acid matrix (Acros Organics a part of the Thermo Fisher
Scientiﬁc group, Geel, Belgium). Samples were analyzed in a MALDI
TOF/TOF 4800 mass spectrometer (Applied Biosystems, Foster City,
CA) in negative reﬂector mode with delayed extraction (625 ns) and a
laser intensity of 5500 V.
Molecular Dynamics Simulations of oCP-mAChE. A monomer
from the oCSP-mAChE X-ray structure was used as the initial model
for molecular dynamics simulations. All crystallographic water
molecules were conserved. Both alternate conformations of Phe297
being present in the experimental structure, we retained only the non-
native one. The saligenin group located in the acyl-binding pocket was
manually removed from the initial model in order to generate the
oCP-mAChE conjugate. We developed a full force ﬁeld (FF) for the o-
CP serine. The modiﬁed serine was built using Chimera29 with
geometry optimization at the Molecular Mechanics level. RESP
charges of the modiﬁed residue were calculated using the REDS
server30 following the recommended procedure, including a Quantum
Mechanics optimization of the fragments achieved with the
Gaussian09 package at the HF/6-31G* theoretical level. The new
FF was included in the amber99sb FF.31 When parameters (bond
distances, angles, and dihedral) were not available in amber99sb, they
were assigned from the General Amber Force Field32 using
Antechamber.33 Molecular dynamics simulations were carried out
using the GROMACS 4.5.4 package.34 The protein system was
immersed in a 10-Å layer truncated cubic periodic water box using the
TIP3P solvation model.35 Charge equilibration was made by adding 9
Na+ ions. A 2-fs time step was used in all the simulations, and long-
range electrostatic interactions were treated with the particle-mesh
Ewald (PME) procedure36 using a cubic B-spline interpolation and a
10−5 tolerance for the direct-space and with a 12-Å nonbonded cutoﬀ.
A 300 K temperature coupling scheme using a separated Berendsen
thermostat for solvent and protein was applied. Pressure was kept
constant at 1 bar by a Berendsen barostat considering a compressibility
of 4.5 × 10−5. Molecular dynamics was preceded by an energy
minimization (500 cycles of Steepest Descent) and a 50 ps position-
restrained MD-simulated soak. Six full MD simulations diﬀering only
by the seed used to generate initial velocities were performed for 10 ns
at 300 K under these conditions. The resulting trajectories were
visualized using VMD37 and analyzed using the tools provided in the
GROMACS package.
■ RESULTS
Crystallographic Structures of o-Cresyl-phospho-
hBChE (oCP-hBChE) and Phospho-hBChE. The oCP-
hBChE adduct was generated by soaking a hBChE crystal for
2 min in a mother liquor solution containing 1 mM CBDP. The
crystal was then ﬂash-cooled to 100 K, and diﬀraction data were
collected to a resolution of 2.7 Å (Table 1).
The initial Fourier-diﬀerence electron density map (Fo − Fc)
featured a strong positive peak (10.4 σ) at covalent bonding
distance from catalytic Ser198Oγ (not shown), allowing to
assign the position of the phosphorus atom of the CBDP
adduct. The saligenin substituent was not present despite the
short soaking time. Rather, the ligand was modeled as an o-
cresyl phosphate, with its o-cresyl moiety bound in the acyl-
binding pocket (Figure 1A); this binding scenario implies that
the P(R) enantiomer of CBDP initially bound to the enzyme.
In the reﬁned model, the covalent bonds oCP600P-Ser198Oγ,
Ser198Oγ-Ser198Cβ, and Ser198Cβ-Ser198Cα are elongated
and characterized by distances of 2.0, 1.7, and 1.65 Å,
respectively. These values can be compared to predicted values
of 1.60, 1.45, and 1.55 Å (calculated ab initio using Gaussian09)
and to observed values of 1.85, 1.45, and 1.55 Å, in the
previously determined crystal structure of phospho-hBChE, the
end product of the hBChE inhibition by CBDP (Figure 1B;
pdb ID 2y1k). Restraining the length of these bonds to their
ideal values led to the appearance, in the resulting Fourier-
diﬀerence map, of a large negative peak (>5 σ) between the
phosphorus atom and Ser198Oγ, and of equivalent positive
peaks on the opposite side of the phosphorus atom and
Ser198Oγ. We interpret this observation as an indication of
strain in the 3 consecutive bonds between the phosphorus atom
and the serine main chain, which we propose to stem from the
steric exclusion of the o-cresyl group by Trp231 (closest
distance between non-hydrogen atoms: 3.5 Å). The entire
phosphoryl group is pushed-up the active site gorge by 1.3 Å
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and twisted counter-clockwise around the Ser198Oγ-P bond
when compared to its conformation in the phospho-BChE
structure (Figure 2, panel A). This results in the absence of
hydrogen-bonding interaction between the phosphoryl oxygen
(O3P) of oCP600 and Ala199N in the oxyanion hole, again in
contrast to what is observed in the phospho-hBChE structure
(4.5 Å interatomic distance vs 2.7 Å in the oCP- and phospho-
hBChE structures, respectively). Likewise, the hydrogen bond
interaction between O1P of oCP and His438Nε2 and
Ser198Oγ are both weakened (3.3 Å and 3.2 Å, respectively)
relative to phospho-hBChE (2.9 Å and 3.0 Å; Figure 1B).
Altogether, these observations indicate that the oCP-hBChE
adduct is not as stable as a canonical aged-BChE-OP conjugate,
which the phospho-hBChE structure resembles more.
Crystallographic Structure of o-Cresyl Saligenin
Phospho-mAChE (oCSP-mAChE). The oCSP-mAChE ad-
duct was trapped by ﬂash cooling a mAChE crystal that had
been soaked for 30 min in a mother liquor solution containing
1 mM CBDP. The structure was solved at 2.95 Å resolution
(Table 1). In this space group, the asymmetric unit contains
two mAChE biological dimers that are related by noncrystallo-
graphic symmetry, and in each, monomers associate through a
four helix-bundle.38 In each dimer, one monomer features a
solvent accessible peripheral site, while the peripheral site of the
other is occupied by the Cys257-Cys272 loop from another
monomer in the asymmetric unit tetramer. The o-cresyl and
saligenin substituents are located in the choline- and acyl-
binding pockets, respectively, indicating a preferential binding
of the P(S) enantiomer of CBDP in mAChE (Figure 1C). This
is in contrast with hBChE, in which it is the P(R) enantiomer
that preferentially binds and where the o-cresyl substituent is
located in the acyl-binding pocket (Figure 1A). In the acyl-
binding pocket of oCSP-mAChE, Phe297 adopts an alternate
conformation with a χ1 rotation of about 145° (around the Cα-
Cβ bond), as required for the accommodation of saligenin
(Figure 1C). We used the direct correlation between the
alternate conformation of Phe297 and the presence of the
saligenin moiety in the acyl-binding site to evaluate the partial
occupancy of saligenin in the oCSP-mAChE structure (see the
Experimental Procedures section for details). The fraction of
bound CBDP retaining saligenin ranges from 0.4 to 0.5,
depending on which of the four monomers is inspected.
Overall, the geometry of catalytic-Ser203 in oCSP-mAChE is
not distorted compared to catalytic-Ser198 in oCP-hBChE
(Figure 2, compare the slate colored structures in panels A and
B). The reﬁned length of the covalent oCSP600P-Ser203Oγ
bond is 1.7 Å in the mAChE structure, compared to a predicted
value of 1.59 Å (as calculated ab initio). Finally, the catalytic
His447Nε2 forms a H-bond with Ser203Oγ (2.8 Å) but does
not interact with O2P of the cresyl substituent (Figure 1C).
Crystallographic Structure of o-Cresyl-phospho-
mAChE (oCP-mAChE). The oCP-mAChE adduct was
obtained by extending the soaking time to 12 h before ﬂash
cooling the crystal. The resolution of this structure is relatively
low (3.35 Å) in comparison to that of the analogous oCP-
hBChE structure (Table 1). It is unclear whether it is the
relatively long soaking time or the eﬀect of enzymatically
produced saligenin that aﬀected the crystal quality and the
resolution of the diﬀraction data. Electron density maps were
yet of good quality and thus allowed the unambiguous
modeling of the o-cresyl moiety into a strong peak of positive
Fo − Fc electron density (10 σ) in the vicinity of the catalytic-
serine hydroxyl group (Figure 1D). No electron density is
observed in the acyl-binding pocket, indicating that the
saligenin moiety has exited the active site (Figure 1D).
Accordingly, Phe297 fully occupies its native position as
indicated by the electron density maps and further conﬁrmed
by the occupancy reﬁnement of its side chain. The o-cresyl
moiety is stabilized in the choline-binding pocket by a
perpendicular pi-stacking interaction with the aromatic rings
of Trp86. No H-bond interaction is noticeable between the o-
cresyl O2 atom and His447Nε2, the later being hydrogen-
bonded to Ser203Oγ (2.9 Å). With the o-cresyl substituent in
the choline-binding pocket, the oCP-mAChE adduct appears to
be the mirror image of the oCP-hBChE adduct in which the
substituent is found in the acyl-binding pocket (Figure 1A and
D). X-ray data collected after soaking periods ≥12 h repeatedly
yielded an oCP-mAChE adduct and not a phosphoserine
adduct as observed in hBChE.
Mass Spectrometry Analysis. The repeatedly unproduc-
tive attempts to obtain the structure of a phospho-mAChE
adduct suggested that CBDP inhibition of mAChE occurs in
two steps, i.e. phosphorylation of the enzyme and a canonical
aging reaction. From our crystallographic data alone, however,
we could not determine whether the observation of an o-cresyl
phosphoserine adduct as the end-product of mAChE inhibition
by CBDP was a crystallographic artifact or, rather, a sign for
CBDP inhibition of AChE and BChE occurring through
diﬀerent pathways.
In order to ascertain the number of steps involved in the in
vitro mAChE inhibition by CBDP, MALDI-TOF mass-
spectrometry of proteolyzed, CBDP-inhibited mAChE was
Table 1. Crystallographic and Reﬁnement Statistics
oCP-BChE oCSP-AChE oCP-AChE
PDB entry code 4bbz 4bc0 4bc1
space group I422 P212121 P212121
unit cell (Å)
a 154.7 135.5 136.9
b 154.7 173.3 174.0
c 127.0 224.9 225.6
resolution (Å) 54.7−2.7 48.3−2.95 48.6−3.35
completeness (%)a 98.1 (99.0) 99.7 (99.4) 96.6 (98.6)
Rsym (%)
a 7.1 (46.5) 8.1 (52.8) 7.5 (58.4)
I/σ(I)a 28.1 (5.2) 17.1 (3.1) 16.2 (2.8)
unique reﬂectionsa 21 049 111 473 75 488
redundancya 10.1 (9.2) 4.4 (4.5) 3.6 (3.4)
Wilson B factor (Å2) 53.4 63.9 94.92
Rfact (%) 16.6 18.6 16.2
Rf ree (%) 22.5 23.8 20.7
non-hydrogen atoms 4547 17994 17432
protein 4222 16 899 16 806
ligands 186 260 215
solvent 139 835 411
RMS bond length (Å) 0.008 0.009 0.009
RMS bond angles (deg) 1.269 1.368 1.482
Ramachandran
favored (%) 94 92 94
allowed (%) 6 7.8 5.7
outliers (%) 0 1.2 0.3
average B factor (Å2) 41.3 46.8 47.2
protein 40 46.9 47.1
ligands 74.1 91.2 92.7
solvent 36.2 31.5 28.3
aValues in parentheses refer to the highest resolution shell.
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used, as previously described for hBChE.7 We investigated the
involvement of water molecules in the various steps of mAChE
inhibition by CBDP by performing the inhibition in either
H2
16O or in H2
18O, which allowed us to characterize the step at
which water is incorporated into the enzyme adducts. As a
control, the same analyses were performed on CBDP-inhibited
hBChE. Inhibition yields reached 100%, for both mAChE and
hBChE, as evidenced by the absence of catalytic activity at the
end of the reaction period and by the absence of unlabeled
active-site peptides in the mass spectra.
From the hBChE-CBDP reaction, both o-cresyl phosphate
(oCP) and phosphate adducts on the active-site peptic-peptide
were detected.18 Post source decay fragmentation conﬁrmed
that these adducts were on the active-site serine. Figure 3,
panels A and B, show mass spectra (in negative mode) for o-
cresyl phosphate adducts at 877 amu (for the peptic peptide
FGESAGAA) and at 964 amu (for the miscleavage peptide
FGESAGAAS). These adducts are formed following the release
of saligenin from the initial CBDP-hBChE reaction product.
The masses of these adducts are not aﬀected by the presence of
H2
18O indicating that no oxygen atoms from water are
incorporated into the phosphorus moiety upon the release of
saligenin. Figure 3, panels A and B, also show mass spectra
(negative mode) for phosphate adducts. In H2
16O, the
phosphate adduct appears at 874 amu (for peptide
FGESAGAAS). In H2
18O, the 874 amu mass is shifted to 876
amu indicating the incorporation of an oxygen atom from water
into the phosphate adduct upon the hydrolytic release of the o-
cresyl moiety.
From the mAChE-CBDP reaction, only an o-cresyl-
phosphate adduct was detected (Figure 3, panels C−D). No
evidence for the phosphate adduct was obtained after the 1 h
reaction period used for this experiment, nor was the phosphate
adduct detected when the reaction was allowed to proceed for
40 h. Post-source decay fragmentation showed that the o-cresyl
phosphate adduct was located on the active site serine. In mass
spectra (negative mode) for both the H2
16O and H2
18O
samples, masses for the oCP adducts appeared at 877 amu (for
peptide FGESAGAA) and 964 amu (for peptide FGESAGAAS)
indicating that no oxygen atom from water is incorporated into
the adduct upon release of saligenin.
Molecular Dynamics Simulations. Phe297 is in an
alternate conformation in the oCSP-mAChE adduct and
moved back to its native position during aging as seen in the
crystallographic structure of the oCP-mAChE adduct. We
Figure 1. Sequential crystallographic snapshots of mAChE and BChE inhibition by CBDP. For BChE (upper panels), a soaking time of 2 min
yielded an o-cresyl-phospho-BChE conjugate (A, current work). A soaking time of 12 h yielded the ﬁnal phospho-BChE conjugate7 (B). For mAChE
(lower panels), soaking times of 30 min and 12 h yielded the o-cresyl saligenin phospho-AChE conjugate (C) and the o-cresyl-phospho-AChE
conjugate (D), respectively. Key residues are represented as sticks with carbon atoms in green, nitrogen atoms in blue, phosphorus in orange, and
oxygen atoms in red. Atoms and bonds of the adducts are represented as ball and sticks, respectively. Hydrogen bonds are represented by red dashes
with distances in Å. A dashed ellipse in panel C highlights the native (magenta) and an alternate (green) position of Phe297. The electron density
2Fo − Fc is represented by a blue mesh contoured at 1.0 σ.
Figure 2. (A) Superimposition of oCP-BChE (slate) and phospho-
BChE (green) structures. (B) Superimposition of oCSP-AChE (slate)
and oCP-AChE (green) structures. Key residues are represented as
sticks. Atoms and bonds of the adducts are represented as ball and
sticks, respectively.
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carried out molecular dynamics (MD) simulations in order to
address whether the observed conformational change is part of
equilibrium dynamics preexisting to ligand binding or a ﬁt
induced by ligand binding.39 An initial model was created based
on the oCSP-mAChE crystallographic structure, i.e., with the
side chain of Phe297 in the alternate conformation but not with
the saligenin substituent. In none of the six 10-ns MD
simulations was a reversal of Phe297 to its native conformation
observed.
■ DISCUSSION
Previously, we showed that hBChE inhibition by CBDP
proceeds through a three-step reaction mechanism.18 First,
the catalytic serine is organophosphorylated to form the ring-
opened CBDP-hBChE adduct. A dealkylation step then occurs
viz. the ﬁrst aging reaction, which results in the loss of the
saligenin moiety. Last, the oCP-hBChE adduct undergoes
hydrolysis with the concomitant departure of the o-cresyl
moiety yielding the ﬁnal phosphoserine hBChE adduct
(Scheme 1).7 That the latter is the end product of hBChE
inhibition by CBDP was known from its X-ray structure at 2.7
Å resolution as well as from previous mass spectrometry
experiments. It remained unclear, however, how these steps
proceed at the atomic level of resolution. Also, it was unknown
if mAChE follows the same inhibition pathway as hBChE and/
or displays the same enantiomer selectivity.
In the current study, a combination of X-ray crystallography
and mass-spectrometry was used to speciﬁcally address the
above-mentioned unresolved issues. Atomic-resolution crystal-
lographic snapshots of hBChE and mAChE were taken at
diﬀerent time points during their reaction with CBDP.
Together with adduct masses obtained from the mass spectra,
they allow one to develop detailed mechanistic models for the
CBDP inhibitions of mAChE and hBChE, respectively.
Inhibition of mAChE by CBDP. In this study, mAChE was
employed instead of hAChE because our preparation of the
latter only crystallizes in the presence of the gorge-capping
peptide fasciculin. Such capping prevents inhibitors from
entering the active site precluding the use of soaking techniques
to introduce inhibitors. mAChE is yet a reliable model for
hAChE in that nearly all of the residues lining the active site
gorge of mAChE and hAChE are identical. Noteworthy,
Cheung et al. very recently reported a truncated form of
hAChE able to crystallize without fasciculin and suitable for
soaking techniques.40 Use of this new form of hAChE will be
preferred for future crystallographic studies.
After soaking a crystal of mAChE for 30 min in a CBDP
containing solution, the initial ring-opened oCSP-AChE adduct
could be trapped by ﬂash cooling (Figure 1C). The o-cresyl and
saligenin moieties are located in the choline- and the acyl-
binding pockets, respectively. This positioning indicates that
crystalline mAChE preferentially binds and reacts with the P(S)
enantiomer of CBDP.
Figure 1C also shows that the acyl-binding pocket is only
partially occupied by saligenin. The partial occupancy (0.4−
0.5) indicates that about half of the crystalline oCSP adducts
have released saligenin after a 30 min soak (note that the o-
cresyl site is fully occupied). Thus, the half-life for the ﬁrst
aging reaction is about 30 min in crystallo. Extending the
soaking time to 12 h or more results in the complete
elimination of saligenin and in the formation of an oCP-AChE
conjugate (Figure 1D).
Mass spectral analysis after proteolysis, combined with the
crystal structures, shows that mAChE inhibition by CBDP
occurs in two steps, viz. organophosphorylation and deal-
kylation of saligenin in the acyl-binding pocket, yielding a ﬁnal
o-cresyl-phosphoserine adduct (Scheme 2). The fact that no
water was incorporated in the o-cresyl-phosphoserine mAChE
adduct indeed excludes the possibility that saligenin was
released through its hydrolysis. Dealkylation is an unusual
reaction for a substituent located in the acyl-binding pocket: the
two residues known to catalyze dealkylation of OPs adducts,
His447 and Glu202, are indeed part of the choline-binding
pocket, on the opposite site of the active site gorge. No unusual
strain is observed in the o-CSP adduct, which eliminates this
source of enthalpy as the driving force for the dealkylation
reaction. This implies that another driving force must be
involved. A possibility is that the hydroxyl group of saligenin
stabilizes a water molecule that could in turn react with the
benzylic carbocation, thereby promoting the dealkylation
reaction. The return to its native conformation of the Phe297
side chain, which was displaced from the acyl-binding pocket by
the saligenin substituent, could constitute an additional driving
force for the dealkylation.
Both the 40-h mass spectrometry and the 12-h crystallo-
graphic data indicate that the oCP adduct is the end product of
mAChE inhibition by CBDP, in contrast to hBChE where the
oCP adduct reacts further to yield a phosphoserine adduct
(Figure 1B).7 This diﬀerence is most likely to ascribe to the
Figure 3. Reaction of hBChE and mAChE with CBDP in the presence
of O16-water (A and C) and O18-water (B and D). The 874−877 amu
region and 964 amu region of pepsin-digested 1-h CBDP-inhibited
ChEs are shown. All spectra were taken in negative mode. The
sequence of the phosphopeptide of mass 874 is FGES*AGAAS with
PO4 on serine. The sequences of the o-cresyl phosphate adducts of
mass 877 and 964 are FGES*AGAA and FGES*AGAAS, where the
asterisk indicates the labeled serine.
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symmetric conﬁguration of the o-cresyl substituent in mAChE
and hBChE. In hBChE, the o-cresyl substituent is in the acyl-
binding pocket; thus, the choline-binding pocket remains free
for a water to approach the phosphorus atom, resulting in oCP
adduct hydrolysis. Conversely in mAChE, hydrolysis does not
occur because the o-cresyl substituent is located in the choline-
binding pocket, meaning that the water would have to attack
from the crowded acyl-binding pocket. While dearylation of the
oCP-mAChE adduct could theoretically have occurred,
considering that the o-cresyl substituent is located in proximity
to His447/Glu202, our data unequivocally show that it does
not. In this context, it is noteworthy mentioning that one of the
strategies envisaged to counteract OP-intoxication is to
realkykate aged phosphylconjugates;41 by showing that
dearylation does not occur on the time scale of our experiments
(tens of hours), our data thus suggest that arylation may be
more promising than realkylation.
In mAChE, organophosphorylation correlates with a rotation
of the Phe297 side chain (Figure 1C), which enlarges the acyl-
binding pocket and is thus required to accommodate the
saligenin moiety. An identical conformational change was
observed in the crystal structures of fenamiphos-inhibited
mAChE in complex with the ortho-7 reactivator (pdb accession
code 2wu4)42 as well as in a TcAChE/Bis(5)-tacrine complex
(pdb accession code 2cmf).43 In the ortho-7 complex, one
pyridinium ring of ortho-7 pushes the isopropylamino
substituent of fenamiphos toward the acyl-loop 285−298 and
leads to its rearrangement. In the TcAChE complex, non-
covalent binding of the tacrine produces drastic rearrangements
in the active site gorge, including a rotation of Phe290 (Phe297
in mAChE), that are induced by a tilt of Tyr121.43 Since
molecular dynamics simulations of native TcAChE did not
reveal alternate Phe290 conformations,44 the rotation seen in
the TcAChE/Bis(5)-tacrine complex must be induced by the
ligand rather than being selected by the ligand among
preexisting native conformations. By extrapolation, the rotation
of Phe297 observed in mAChE is also most likely the
consequence of an induced ﬁt mechanism, meaning that the
conformational change is induced by ligand binding, rather than
being part of preexisting equilibrium ﬂuctuations. Although the
acyl-loop determines the speciﬁcity of hAChE for the natural
substrate acetylcholine,45,46 the acyl-loop remains ﬂexible
enough to accommodate bulkier ligands at the cost of an
induced ﬁt rearrangement. This rearrangement is reversed once
Scheme 2. Detailed Chemical Mechanism for CBDP Inhibition of mAChE and hBChE
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the acyl-binding pocket becomes unoccupied, as after the aging
of oCSP-mAChE. The conformational change was not
reproduced in six 10 ns molecular dynamics simulations,
indicating that the crystallographically observed conformational
change is not a simple side chain ﬂip but rather requires a larger
rearrangement of the acyl-loop region that is not observed on
the time scale of the simulations. These larger rearrangements
of the acyl-loop are probably part of the proposed induced-ﬁt
mechanism.
Inhibition of hBChE by CBDP. The ﬁrst species observed
in the reaction of CBDP with hBChE is oCP-hBChE (Figure
1A), which corresponds to the second intermediate in the
reaction mechanism (see Scheme 1). oCP-hBChE is created by
the loss of saligenin from the initial intermediate, the ring-
opened CBDP adduct. The latter could not be trapped, even by
reducing soaking times to as short as 30 s, indicating that this
adduct decays faster than it forms.
The o-cresyl moiety is located in the acyl-binding pocket of
the oCP-hBChE adduct, which indicates that the saligenin
moiety was bound in the choline-binding pocket prior to the
ﬁrst aging step and suggests a preferential reaction of the P(R)
enantiomer of CBDP with crystalline hBChE. MD and QM/
MM studies of hBChE reacting with CBDP, as well as titration
experiments, support the proposed stereoselectivity (Lushche-
kina et al., unpublished results). Mass spectrometry showed
that no oxygen atom from water is incorporated into the oCP-
adduct, inferring that the release of saligenin likely stems from a
His438/Glu197-catalyzed dealkylation.7 This conclusion is in
agreement with the proposal that aging of OP-hBChE proceeds
through O-dealkylation of substituents bound in the choline-
binding pocket.47 However, an oxygen atom from water is
incorporated during the second aging reaction. This observa-
tion supports the hypothesis of a nucleophilic attack, by a water
molecule, on the phosphorus atom of oCP, resulting in the
release of the o-cresyl moiety and the formation of the
phospho-BChE adduct.7
From a mechanistic point of view, the most probable
scenario is that this water attacks from the open face opposite
the cresyl−O-P bond, vicinal to Glu197 (refer to Figure 1A),
leading to the formation of a bipyramidal transition state and its
subsequent collapse, with the release of o-cresyl (Scheme 2).
The other possibility is that water approaches from the side
opposite to the Ser198Oγ-P bond. However, we conjecture this
scenario is unlikely considering the steric hindrance imposed by
the presence of the o-cresyl moiety in the acyl-binding pocket.
Also, a water attack from that side should lead to the scission of
the Ser198Oγ-P bond and, therefore, to the release of the entire
o-cresyl phosphate group, not just the o-cresyl moiety. Yet,
neither was a native active site peptide identiﬁed in our mass
spectrometry study, nor was self-reactivation observed in our
previous kinetics studies. Thus, the attack of water is proposed
to occur from the open face opposite the cresyl−O-P bond,
vicinal to Glu197. A similar mechanism was proposed for the
aging reaction of an analogue of the nerve agent tabun.48
A structural comparison between the oCP- and the phospho-
hBChE adducts shows a release of the strain imposed on the
enzyme, when o-cresyl is released and the phospho-conjugate is
formed (Figures 2A). We conjecture that the release of this
strain contributes to the driving force responsible for the
scission of the P−O bond linking the o-cresyl to the
phosphorus. It should be noted that unlike in mAChE, no
side chain undergoes major conformational changes upon the
binding of CBDP in hBChE.
■ CONCLUSIONS
The combination of crystallographic snapshots with mass
spectrometric analysis shows that the inhibition of mAChE and
hBChE by CBDP involves the binding of opposite enantiomers.
Therefore, two diﬀerent reaction pathways are undertaken by
mAChE and hBChE for inhibition and aging. hBChE
undergoes a three-step reaction process including (i) the
organophosphorylation of the catalytic serine to form a CBDP
ring-opened adduct, (ii) a dealkylation resulting in the loss of
the saligenin substituent from the choline-binding pocket, and
(iii) a nucleophilic hydrolysis of the o-cresyl substituent in the
acyl-binding pocket, yielding a ﬁnal phosphoserine-hBChE
conjugate. In contrast, the inhibition of mAChE is a two-step
reaction, resulting from of organophosphorylation and
subsequent dealkylation, leading to the release of saligenin
and the formation of the o-cresyl-phosphoserine mAChE
adduct. Additionally, the crystallographic snapshots of the
mAChE inhibition intermediates illustrate how a bulky
inhibitor like CBDP is able to ﬁt into the active site of
mAChE through an induced ﬁt rearrangement. It is worth
noting that for both mAChE and hBChE, the ﬁnal enzyme
conjugate is aged, meaning that it cannot be reactivated by
oximes.47 In other words, there is currently no eﬀective
therapeutics to reactivate inhibited AChE in the case of severe
TOCP intoxication.
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Resumé de la thèse en français
L’acétylcholinestérase (AChE), une des enzymes les plus rapides dans la nature, est la
cible d’un large nombre de toxiques, dont notamment les neurotoxiques organophosphorés.
La première partie de ce manuscrit de thèse décrit le développement raisonné d’un nou-
veau réactivateur, qui présente des propriétés de réactivation supérieures aux molécules
actuellement sur le marché. Les interactions entre cette molécule, KM297, et l’AChE ont
été étudiées par dynamique moléculaire, docking et cristallographie aux rayons X. La con-
naissance des modes de liaison du KM297 dans l’AChE native ou inhibé par un OP ont
permis de développer la molécule JDS207, qui se lie de façon exclusive au site périphérique
de l’AChE. La deuxième partie de la thèse est dédiée à l’analyse des simulations de la
AChE par dynamique moléculaire. On observe que la combinaison de multiples trajec-
toires générées avec des paramètres de vélocité initiale différents est une méthode fiable
pour caractériser les conformations atteintes par les chaînes latérales des acides aminés. En
comparant la distribution des rotamères pour l’AChE humaine et celle du poisson Torpedo
californica, on montre que des différences importantes existent entre les enzymes des deux
espèces. A partir de ces informations sur les conformations de résidus clés du site actif,
une méthode a été développée pour générer des récepteurs utilisable pour des calcules de
docking flexible, de façon à prendre en compte la dynamique propre à chaque résidu de
l’enzyme. Cette méthode a été validé en comparent les résultats obtenues à des structures
cristallographiques connues.
Resumé de la thèse en anglais
Acetylcholinesterase (AChE), one of nature fastest enzyme, is the target of multiple toxics,
including organophosphate nerve agents (OP). In the first part of this thesis I present the
structure-based development of a new uncharged reactivator, which showed characteristics
better than any molecule commercially available to date. The molecule has been rationally
designed to present both affinity to the inhibited enzyme and good reactivation capabili-
ties. The interactions between the lead molecule KM297 and AChE has been characterized
by means of flexible docking, molecular dynamics simulations and X-ray protein crystal-
lography. The deeper understanding of its binding modes to both native and OP-inhibited
AChE has helped in developing a derivative, JDS207, whose binding mode at the peripheral
site of AChE is optimized. This derivative has also been studied by flexible docking and X-
ray crystallography. The design of this family of reactivators taught us that a deep insight
of the AChE dynamics is necessary to optimize ligands. The second part of the thesis is
devoted to the analysis of molecular dynamics simulations of AChE. At first, we assessed
that combining multiple short simulations is a fast and reliable method to characterize
the dynamics of the amino-acids side-chains. By comparing dynamics of the side-chains
from hAChE and TcAChE, we confirm that some key dynamical differences exist between
the two enzyme. The knowledge of the rotamers issued of MD simulation has lead us to
develop a new method to generate flexible receptors for docking, which is specific to each
single residue in the enzyme. This method has been validated by comparing its output
structures with the ones found on the PDB database.
